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Abstract
Development of Dynamic Bayesian Network for the Anal-
ysis of High-Dimensional Biomedical Data
Inferring gene regulatory networks (GRNs) from time-course expression data is a ma-
jor challenge in Bioinformatics. Advances in microarray technology have given rise
to cheap and easy production of high-dimensional biological datasets, however, accu-
rate analysis and prediction have been hampered by the curse of dimensionality prob-
lem whereby the number of features exponentially larger than the number of samples.
Therefore, the need for the development of better statistical and predictive methods is
continually on the increase.
The main aim of this thesis is to develop dynamic Bayesian network (DBN) methods
for analysis and prediction temporal biomedical data. A two stage computational bio-
network discovery approach is proposed. In the ovarian cancer case study, 39 out of
592 metabolomic features were selected by the Least Angle Shrinkage and Subset Op-
erator (LASSO) with highest accuracy of 93% and 21 chemical compounds identified.
The proposed approach is further improved by the application of swarm optimisation
methods for parameter optimization. The improved method was applied to colorec-
tal cancer diagnosis with 1.8% improvement in total accuracy, which was achieved
with much less feature subsets of clinical importance than thousands of features when
compared to previous studies.
In order to address the modelling inefficiencies in inferring GRNs from time-course
data, two nonlinear hybrid algorithms were proposed using support vector regression
with DBN, and recurrent neural network with DBN. Experiments showed that the
proposed method was better at predicting nonlinearities in GRNs than previous meth-
ods. Stratified analysis using Ovarian cancer time-course data further showed that the
expression levels Prostrate differentiation factor and BTG family member 2 genes,
ii
were significantly increased by the cisplatin and oxaliplatin platinum drugs; while ex-
pression levels of Polo-like kinase and Cyclin B1 genes, were both decreased by the
platinum drugs. The methods and results obtained may be useful in the designing of
drugs and vaccines.
iii
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Chapter 1
Introduction
1.1 Motivation
Advances over the past few decades has resulted in increase in availability of both
static and temporal high-dimensional biomedical data. The sequencing of the human
genome has also increased research interest in developing novel methods for biomed-
ical data analysis since its sequencing more than a decade ago [7], [8]. The discovery
of more than three billion base pairs in the human genome project was undoubtedly re-
markable. The success of the project heavily relied on computational methods which
makes the field of computational biology very essential for future biological discover-
ies.
The completion of the human genome project gave rise to a new era known as post-
genome era and advances in technology has resulted in the generation of vast amounts
of data. A considerable amount of effort is required to discover knowledge from these
data that may be of clinical benefit. Manual analysis in wet laboratories can no longer
cope with the complexity of problems associated with the huge amount data and com-
putational and statistical data mining approaches are inevitable.
1
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The inevitability of computational methods for knowledge discovery in the vast amount
of biomedical data since the post-genome era gave rise to the field of study known to-
day as Bioinformatics. Bioinformatics is an interdisciplinary research field concerned
mainly with the development of methods and software for mining and understanding
of biological data. It integrates mathematics, statistics, computer science and biotech-
nology that aid in molecular sequence analysis, structural analysis and functional anal-
ysis of biomedical data.
These methods can be broadly divided into two. Methods for static analysis and
methods for temporal or time-course analysis. Static data have been analysed us-
ing computational methods such as Boolean Networks and Artificial Neural Networks
[9] but there is a lack of efficient methods for the analysis and visualization of high-
dimensional temporal biomedical data such as Protein-Protein Interaction (PPI) net-
works [10]. Modelling and making predictions over time in non-linear complex sys-
tems involve the use of temporal (dynamic) data and not static data [11]. Various
methods have been used to model the stochastic nature of such temporal data such as
Hidden Markov Models (HMM), Kalman Filter Models (KFM) and DBN [12]. HMM
and KFM are however not suitable for representing temporal data with two or more
state variables, and large qualitative discrete variables, respectively [13].
A major problem of HMM and the motivation for choosing DBN is computational
complexity. For example in an HMM where each state generates an observation with
Xt ∈ 1, ...,K representing the hidden state at time t and yt representing the observa-
tion, inference takes O(T K2) time for T sequence length and K number of states.
For a factorial HMM with D chains each with K values, computing the probability
P(Xt |Xt−1) needs O(K2D) parameters to specify however, a DBN needs O(DK2) pa-
rameters to specify. For an HMM, the exact inference computational complexity is
O(T K2D) whereas a DBN is O(T DKD+1) which is exponentially less than that of the
HMM [13].
2
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DBN represents temporal probability distribution over semi-infinite collections of ran-
dom variables have widely gained recent attention [14]. However, optimisation of
inference algorithms in DBN to handle high-dimensional correlated data using ma-
chine learning techniques have not been fully explored. Another motivation is that
DBN-based methods for inferring the structure of the relationships among high qual-
ity selected biomarkers using high-dimensional datasets have not been explored as
current methods focused on classification and feature selection performances without
considering possible temporal relationships across selected biomarkers. Also, existing
DBN methods assume that the relationships between features in time-course gene ex-
pression data are linear. This strong assumption may not always be true as biological
networks are inherently nonlinear.
Time-course data refers to data from evolution of measurements over time from bi-
ological experiments. This differs from time-series data which refers to that from a
sequence ordered in time. For instance time-course data could be from experimental
measurements taken at different times such as 1hr, 3hrs, 9hrs and 24hrs as the ex-
periment progresses while time series data is in an ordered pattern such as in speech
recognition and signal processing. There is therefore need to develop a hybrid DBN
that combines nonlinear predictive algorithms within a DBN. The parameters of the
predictive algorithm could further be optimised using parameter optimisation algo-
rithms for improved accuracy. This would lead to novel optimised hybrid DBN-based
algorithms that would more accurately model and infer gene regulatory networks from
time-course gene expression data. These developed algorithms could aid in the diag-
nosis of diseases such as cancer as the network of the disease metastasis could be more
accurately inferred.
3
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1.2 Contributions of the PhD Study
This thesis aims at developing and improving Dynamic Bayesian Network (DBN)
for temporal prediction of biomedical data using optimisation and machine learning
methods. DBN model was preferred as HMMs are more complex and are not suitable
for representing temporal data with two or more variables and Kalman filters cannot
be used to represent large qualitative discrete variables.
The contributions made are in line with the stated aim of the thesis.
• Development of a two-stage DBN-based bio-network discovery approach for
analysing and inferring temporal associations of biomedical data.
Accurate modelling of temporal relationships between biomarkers is important
in disease prognosis and drug discovery. Existing methods focused only on
classification performance of selected biomarkers but did not consider possible
temporal relationships among feature subsets. At the first stage of the approach,
feature selection is carried out using five different selection algorithms which
are Random Forest Recursive Feature Elimination (RF-RFE), Least Absolute
Shrinkage and Selection Operator (LASSO) and Linear, Polynomial and Radial
Basis Function kernels of the Support Vector Machine Recursive Feature Elim-
ination (SVMRFE) algorithm. Performance of the selected biomarkers were
evaluated using machine learning criteria such as Sensitivity, Specificity, Accu-
racy, False Positive Rate and Matthews Correlation Coefficient. At the second
stage, the temporal relationships of features with the best overall performance
from the first stage are inferred using Dynamic Bayesian Network. The rel-
evance of the feature interactions and inferred network model is verified from
literature for each of the use cases studied. Two case studies that were developed
and published to address this objective are: ovarian cancer [3] and hypertension
[4]. This objective is also addressed in chapter 5.
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• Development of optimised two-stage approach using swarm optimisation for
parameter optimisation
This study aimed to address the problem of inaccuracies in selection of key
biomarkers of potential relevance to drug discovery by using optimization algo-
rithms to fine-tune the parameters of feature selection algorithms for improved
accuracy. Two key case studies were investigated:
A) Diagnosis of Colorectal Cancer. In this study, significant pathways in col-
orectal cancer metastasis were discovered using the proposed two-stage DBN-
based optimization approach. Previous modelling techniques from literature
adopted less accurate filter methods of feature selection and methods of param-
eter optimization for improved accuracy were not proposed nor implemented.
Furthermore, temporal relationships among potential biomarkers which might
reveal significant pathways in the spread of the disease were not considered.
This study aimed to address the aforementioned problems by adopting three
kinds of more efficient SVMRFE feature selection algorithm. The algorithms
were further optimized using particle swarm optimization and five differential
optimization algorithms. The best performing features from the algorithm were
modelled using DBN. The resulting inferred network, verified from published
literature, showed that Alpha-2-HS-glycoprotein was highly associated with
Fibrinogen alpha chain which had been shown to be a possible biomarker for
colorectal cancer. This is addressed in chapter 6 and published in IET Systems
Biology [15].
B) Diagnosis of Hepatocellular Carcinoma (liver cancer)
In this study, five Differential Evolution (DE) algorithms were used to optimize
the parameters of three SVMRFE algorithms. To minimize the average error
rate and increase accuracy, the algorithms: DE/rand/1, DE/best/1, DE/rand-to-
best/1, DE/best/2 and DE/rand/2, were run for 30 independent times with each
run done for 40,000 fitness evaluations. The Wilcoxon rank sum test was used
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to evaluate algorithmic performance under the null hypothesis that the perfor-
mance of the reference algorithm, DE/rand/1, is the same as the other DE al-
gorithms using 95 percent confidence interval. The results obtained showed
that features selected by DE/best/2-optimized SVMRFE radial kernel algorithm
outperformed the others. The DBN inferred network analysis from the features
showed that the SPINT2 gene may inhibit HGF activator which prevents the for-
mation of active hepatocyte growth factor which are the chief functional cells of
the liver. The methods and results of this study were published in IEEE [16].
• Development and implementation of optimized Recurrent Neural Network Dy-
namic Bayesian Network (RNN-DBN) algorithm for accurate inference of Gene
Regulatory Networks (GRNs).
The study aimed to address the problem of linearity assumed by most tempo-
ral inference methods and inefficiencies of parametric methods such as the S-
systems model. After analytical reviews of different recurrent neural network
models, the Elman Recurrent Neural Network was chosen due to its simple
feedback connections which makes it powerful for nonlinear mapping. The pa-
rameters of the RNN were further optimized using particle swarm optimization
(PSO) and comprehensive learning particle swarm optimization (CLPSO) algo-
rithms. Results from the area under the precision recall (AUPR) curve using
benchmark Drosophila Melanogaster dataset showed that the algorithm outper-
formed existing G1DBN algorithm which had been know to outperform three
other algorithms: the LASSO, the ARACNE and the CLR algorithms. The
developed algorithm was further used to model time-course human ovarian car-
cinoma cell dataset. Five key hub genes with four outgoing edges each were dis-
covered. These are flap structure-specific endonuclease 1, kinesin family mem-
ber 11, CDC6 cell division cycle 6 homolog (S. cerevisiae), histone 1, H2bd
and TRAF family member-associated NFIB activator. This study is presented in
chapter 7 and published in IEEE [5].
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• Development and implementation of optimized Support Vector Regression Dy-
namic Bayesian Network (SVR-DBN)
This study aims to further address the assumption of linearity by many gene reg-
ulatory network inference models proposed in literature. The study improves on
DBN for modelling GRNs by using a more efficient non-linear support vector re-
gression (SVR) algorithm. The SVR-DBN algorithm is further improved by the
use of particle swarm optimization to fine-tune the parameters of the SVR. The
robustness of the algorithm was tested on eight popular benchmark Dialogue
for Reverse Engineering Assessments and Methods (DREAM) datasets and two
real world datasets of Drosophila Melanogaster and Escherichia Coli. The re-
sults based on computed area under the precision recall curve (AUPR) and area
under the receiver operating characteristics curve (AUROC) showed that the al-
gorithm outperformed the existing G1DBN algorithm on all ten datasets. This
study is presented in chapter 7 and published in IEEE [6].
The open-source R language for statistical computing was the programming language
used for the whole of this PhD study [17]. Visualisation of inferred networks of
biomedical data used was done with open-source visualisation software called Cy-
toscape [18].
1.3 Structure of the PhD Thesis
The remainder of the PhD thesis is structured as follows:
Chapter 2 discusses the background theory in computation methods used. It discusses
machine learning methods such as the support vector machine (SVM), random forest
and recurrent neural networks. It also discusses the support vector machine recursive
feature elimination SVMRFE and shows how it integrates with optimization algo-
rithms and how the linear, radial and polynomial kernels perform with varying sizes
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of datasets. Bayesian networks and dynamic Bayesian networks are explained. The
assumptions surrounding DBN modelling based on vector autoregressive models are
explained. Furthermore, optimisation algorithms used in this thesis are also discussed.
Chapter 3 reviews literature in reverse engineering in Bioinformatics. Top-down and
bottom-up methods are explained and how they are important to causal relationships.
The generic framework of reverse engineering is reviewed and presented. Literature
around modelling uncertainty using a Bayesian Network and the limitations of using
a Bayesian Network are presented. Literature about temporal modelling is discussed.
The limitations of other methods such as the Hidden Markov Model and Kalman Filter
Models are explored and how dynamic Bayesian network is better than other methods.
The chapter also explores some machine learning concepts in Bioinformatics and ends
by explaining the gap in literature around inferring temporal relationships of high
quality selected features and the problem with DBN representation that assume linear
relationships among features.
Chapter 4 describes some of the datasets used in this study as contained within this
thesis. It describes ovarian cancer metabolite dataset from [19] which contained a total
of 592 metabolomic features from 72 observations. It discusses the hypertension gene
expression dataset from [20] which contained a total of 22184 gene expression profiles
and 159 observations. The chapter further describes colorectal cancer protein profiles
datasets from [21] which had a total of 16331 spectral feature and 112 observations.
Time-course ovarian cancer dataset from [22] which had 12625 genes is discussed
and how 34 genes used were selected. Benchmark reverse engineering datasets which
include both simulated and real datasets are also described.
Chapter 5 looks at the development of the two-stage approach for inferring the dynam-
ics an temporal relationships in biomedical data. Feature selection methods used at the
first stage include random forest recursive feature elimination, least absolute shrinkage
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and selection operator (LASSO) and support vector machine recursive feature elimina-
tion. Cross-validation results are presented and discussed. Two DBN methods used at
the second stage are compared. Two case studies of using ovarian cancer metabolites
and hypertension gene expression dataset are discussed.
Chapter 6 explores ways of improving the developed two-stage approach. The two-
stage approach relied on manual adjustment of parameter values such as the C and γ of
support vector machine. Parameter optimization methods are discussed. In particular,
two optimisation methods were adapted. These are the particle swarm optimisation
(PSO) and the Differential Evolution (DE) algorithm. Results showed improvements
over non-optimised approaches. The DBN was used to infer temporal relationships
between selected variables.
Chapter 7 discusses the development of two DBN-based algorithms. The develop-
ment was necessary as DBN methods previously adapted assumed linear relationship
among features which was not necessarily a true representation of biological systems.
Hybrid nonlinear approaches were therefore required. The recurrent neural network
dynamic Bayesian network (RNN-DBN) was developed. This was efficient but com-
putationally more intensive. To address that problem, the support vector regression
dynamic Bayesian network (SVR-DBN) algorithm was then developed. The algo-
rithms allowed for parameter optimisation which leads to more accurate inference.
Chapter 8 summarises and concludes the thesis. it discusses achievements and contri-
bution to literature as well as some future works.
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Background Theory in Computation
Methods
2.1 Introduction
The existence of things in the real world comprise of complex systems that evolve
over time and respond to external perturbations. For biological systems, there has to
be a way to capture these temporal evolution in order to infer progression of change in
states of a system across time points. For instance the life cycle of an organism or the
metastasis of a disease needs to be taken into account of. Machine learning techniques
such as Support Vector Machines (SVMs) have long been used in bioinformatics for
selecting features which may potentially be biomarkers for a disease. However, how
these features may possibly relate to each other if each observation is taken as a time
point has not been studied.
This is the idea behind the two-stage bio-network discovery approach introduced in
this thesis and successfully applied and published in various case studies [3],[23], [4]
using various datasets. Various datasets (described in chapter 4) of various dimensions
were explored because they all have different nature and come from different tissues
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and different genome platforms. This showed that the methods developed in this thesis
would be able to fit into all these different kinds of datasets and can handle both small
and high-dimensional datasets.
This chapter seeks to explore and define the background theory of the computational
methods used in this thesis.
2.2 Dynamic Bayesian Network (DBN)
Static Bayesian networks are graphical models that allow for the representation of
probabilistic dependencies between a given set of random variables in a concise way.
The random variables x = x1,x2, ...,xp are represented as a directed acyclic graph
(DAG). Real world entities are however made up of complex systems which change
over time. Dynamic Bayesian Networks extends static Bayesian network in its ability
to capture temporal informations which are useful in modelling feedback loops. As
this feedback loops are common in biological pathways, DBNs modelling is expected
to capture better representation of these pathways.
DBNs can be modelled from multivariate time series (MTS) based on vector auto-
regression (VAR). MTS is used to model interactions among a group of time series
variables. MTS are usually modelled as vector auto-regressive processes [24]. For a
vector auto-regressive process VAR of order p denoted as VAR(p), variables observed
at any time t ≥ p satisfy the equation:
X(t) = A1X(t−1)+ ...+AiX(t− i)+ ...+ApX(t− p)+B+ ε(t) (2.1)
where
• X(t) = (Xi(t)), i = 1, ...,k is the vector of k variables observed at time t;
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• Ai, i = 1, ..., p are matrices of coefficients of size k× k;
• B is a vector of size k which represent the baseline measurement for each vari-
able;
• ε(t) is a white noise vector of size k with zero mean (E(ε(t)) = 0) and time
invariant positive definite matrix (COV (ε(t)) = ∑)
In the above MTS representation, VAR of order p assumes a linear relationship be-
tween the k variables observed at t time points and k variables observed at previous
time points p. In the DBN, each variable is represented by several nodes across time
points. A DBN is obtained when an interaction graph is unfolded in time which en-
ables the accommodation of feedback loops. The acyclicity of the graph is required to
ensure a Bayesian network representation is maintained by setting the arc variables in
time. The arc is drawn between two successive time points in the resulting graph.
To enable a DBN to be represented as a VAR process, various assumptions are made
[1].
Assumption 1: The stochastic process X is assumed to be of first-order Markov chain.
This ensures that variable at time t depends on the past only through variables that
were observed at time t−1.
Assumption 2: The random variables X(t) = (X1(t), ...,Xi(t), ...,Xk(t)) observed at
time t, for all t > 0, are conditionally independent given the random variables X(t−1)
at the previous time t−1.
This implies that simultaneously observed variables at any time point are conditionally
independent given their immediate past variables. Hence a variable Xi at time t is better
explained by X(t− 1) than by any other variable X j at the same time point. This is
based on the assumption that time points are close enough.
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Assumptions 1 and 2 allows for a DBN with graph G to be modelled which will have
arc pointing from a variable observed at time t−1 to a variable observed at time t and
no arcs between variables observed simultaneously. A constant time delay for all the
interactions is assumed to restrict the number of parameters of the network. It may
be possible to include simultaneous interactions or a longer time delay e.g. from t to
t− 2 however, this will increase the number of parameters exponentially. This is left
as a future study.
Assumption 3: For any variable Xi, the temporal profile Xi(1), ...,Xi(n) cannot be
written as a linear combination of other profiles X j(1), ...,X j(n), where j 6= i.
The uniqueness of the graph G is guaranteed by this assumption when the k variables
are linearly independent. This means that the profiles cannot be linearly combined.
Assumptions 1, 2 and 3 guarantees that the probability distribution of the stochastic
process X can be represented as a DBN.
Theorem 1
The probability distribution of X can be represented as a dynamic Bayesian network
with directed acyclic graph G whenever assumptions 1, 2 and 3 are satisfied. The arcs
of G describe exactly the conditional dependencies between any pair of variables at
successive time points given any past variables [1].
Assumption 4: The process is homogeneous over time; all arcs and their directions
are time invariant.
This assumption allows for proper representation of a MTS using small number of
parameters. For each variable at a given time point, large number of repeated mea-
surements are needed for estimation. This kind of data is rarely available and in bioin-
formatics; most gene expression time series contain very few or no repeated measure-
ments [25].
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FIGURE 2.1: Dynamic Bayesian Network of a Regulation Motif [1]
Part A of Figure 2.1 shows a biological regulation motif with genes G1,G2 and G3.
Part B is the Gaussian variable representation Y i of the expression level of Gi for all
i ≥ 3. Part C shows the dynamic network equivalent of the regulation motif A where
the expression level of gene Gi at time t is represented by vertex X it .
If a VAR process of order 1 is assumed, a DBN can be represented as
Xt = MXt−1+B+ ε(t) (2.2)
where M is a k×k transition matrix which expresses dependence of Xt on Xt−1, ε(t) is
a vector white noise assumed to be multivariate normal with zero mean and covariance
matrix ∑. B is a k column vector representing baseline measurement for each variable.
The arc is set by defining the set of non-zero coefficients in matrix M such that if
the element ai j,i 6= j differs from zero, an arc will be included in the network from
Xi(t−1) to X j(t). Off diagonal elements in the covariance matrix ∑ can be set to zero
if the error term for each variable Xi is independent of other variables.
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M =

a11 a12 0
a21 0 0
0 a32 0
 (2.3)
Learning a DBN defining a VAR process is akin to identifying the non-zero coeffi-
cients of the auto-regressive matrix M. From theorem 1, a VAR process of order 1
denoted as VAR(1) whose error covariance matrix ∑ is diagonal can be represented as
a DBN whose non-zero elements of M identify the arcs to be included in the network.
2.3 Support Vector Machine
First introduced by Cortes and Vapnik in 1995 [26] the SVM is a supervised learning
method for classification and regression. For classification tasks the goal of the SVM
is to construct a hyperplane or a set of hyperplanes in a high-dimensional space to
be used for classification of a linearly separable dataset. The hyperplane with largest
distance to the training data is said to achieve good separation. The SVM can also
be used for non-linearly separable datasets which are common with high-dimensional
datasets.
For a two class classification problem with training vectors xi = i, ...l in a Euclidean
space, an indicator vector y can be defined such that
yi =

1 i f xi in class 1
−1 i f xi in class 2
(2.4)
The aim of the SVM therefore is to find a separating hyperplane which separates all
the data as shown in Figure 2.2.
The hyperplane wT x+b = 0 obeys the inequality constraints
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wT xi+b > 0 if yi = 1 (2.5)
wT xi+b > 0 if yi = 1 (2.6)
where the weight w and the bias b of the separating hyperplane need to be optimally
decided for good test set prediction. The most general hyperplane is the one that
maximizes the width of the hyperplane which is the distance of two parallel lines. The
distance between the lines wT xi + b = 1 and wT xi + b = −1 is maximised by 2/‖w‖
= 2/
√
wT w called the maximal margin. The SVM therefore aims to find w and b such
that the value of 2/‖w‖ is maximised.
Maximising a function however is equivalent to minimising its reciprocal and the in-
creasing function (the square root) is therefore removed [27] which results in:
min
w,b
{
1
2w
T w
subject to the constraints of Equation 2.5 and Equation 2.6. Combining the two in-
equalities and multiplying yi on both sides of Equation 2.5 and Equation 2.6 gives rise
to the quadratic programming problem
FIGURE 2.2: The SVM hyper-plane showing linearly separable data points.
16
Chapter 2 Background Theory in Computation Methods
min
w,b
{
1
2w
T w
subject to yi(wT xi + b) ≥ 1; i = 1, ..., l where l is the length of the training vectors.
For nonlinearly separable dataset, a nonlinear curve can be used to fit the data where
training errors are allowed in order not to have an infeasible optimisation problem. In
order to avoid many training errors, a penalty function C
l
∑
i=1
ζi is introduced where C
is the cost of constraint; a large value of C results in small penalty, and ζ is a positive
slack variable. This results in the standard SVM function
min
w,b,ζ
{
1
2w
T w+C
l
∑
i=1
ζi
subject to yi(wTφ(xi)+b)≥ 1−ζi, ζi ≥ 0, i = 1, ..., l where φ is a nonlinear function.
Solving the inner product of two vectors in high dimension presents a difficult problem
but can be handled effectively by kernels. When mapped to a high-dimensional feature
space, kernels return the value of the dot product between the images of two arguments
originally in an input space. x is mapped from an input space to a transformed feature
space φ(x) where data is separable. This results in a dual classifier in a transformed
feature space where φ(x) only occurs in pairs φ(x j)Tφ(xi).
Different kernels K result in different kinds of SVM. Three popular kernels are used
in this thesis:
The linear kernel:
K(xi,x j) = φ(xi).φ(x j) (2.7)
The Polynomial kernel:
K(xi,x j) = (xi.x j +1)d (2.8)
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where d is the dimension of the polynomial.
The Radial Basis Function kernel:
K(xi,x j) = exp−γ‖xi−x j‖
2
(2.9)
The SVM recursive feature elimination (SVM-RFE) uses the magnitude of the weight
of the SVM classifier to produce feature ranking by backward elimination [28] and
hence more accurate feature selection is performed because the algorithm interacts
with the classifier. The recursive feature elimination involves the following procedure:
1. Training the classifier.
2. Calculating the ranking criterion.
3. Removing the features with the smallest ranking criteria.
For regression tasks, the support vector machine for regression or the Support Vector
Regression (SVR) has the goal of finding a function f (x) that has the most ε deviation
from the actually obtained targets yi, where ε is the tolerance error. For the regression
model, only errors less than ε are acceptable and the SVR can be formulated with
different constraints as:
min
w,b,ζ ,ζˆi
{
1
2w
T w+C
l
∑
i=1
(ζi+ ζˆi)
subject to:
yi−wTφ(xi)−b≤ ε+ζi (2.10)
(wTφ(xi)+b)− yi ≤ ε+ ζˆi (2.11)
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ζi, ζˆi ≥ 0 (2.12)
where ζi, ζˆi are positive slack variable used to account for training errors. This ap-
proach is called the ε-Support Vector regression (or ε-SV regression) [29] and was
adapted in chapter 7 of this thesis because it is the most common approach and per-
forms well in high-dimensional dataset.
2.4 Random Forest
The random forest algorithm was developed by Leo Breiman [30] and Adele Cutler
[31] for tasks of classification and regression. It is an ensemble learning learning
algorithm that works by generating many decision trees using Breiman’s idea of bag-
ging in tandem with random selection of features introduced by Kam [32] and Ho
[33]. Many advances in the area of random forest has also come from Microsoft Re-
searchers Criminsi, shotton and Konukoglu [34] which extend the earlier work done
by Breiman.
The algorithm works by applying bagging to ensemble of decision trees. For a training
set X = x1, ...,xn with responses Y = y1, ...,yn, a bootstrap sample of the training set
is repeatedly selected by bagging and decision trees are fit to them. For samples b =
1 through B, sample with replacement n training examples from X,Y which will be
called Xb,Yb. The random forest function can then be written as:
fˆ =
B
∑
b=1
1
B
fˆb(x′) (2.13)
where B is a free parameter that represents trees to be trained on different subsets of
the data and fˆb is the b’th tree. A regression or decision tree fb is trained on Xb,Yb.
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Predictions for unseen sample x′ can be made after training by averaging predictions
from all the individual regression trees on x′. In the case of decision trees for classi-
fication tasks, the majority vote is taken. Example if in four decision trees within the
forest, two belonged to class y1, one to class y2 and one to class y3, class y1 is chosen
since it score the majority vote. Increasing the number of trees decreases the variance
without increasing the bias. This makes the training and test error to remain constant
after fitting some number of trees. Cross-validation can be used to find the optimum
number of trees B. The authors in [35] also suggested that finding the optimal num-
ber of trees can also be achieved by observing out-of-bag error which is the mean
prediction error on each sample xi using trees that did not have xi in their bootstrap
sample.
2.5 Recurrent Neural Network (RNN)
The class of Artificial Neural Network where forward and feedback (recurrent) con-
nection between neurons exist is known as Recurrent Neural Neural Network. Re-
current Neural Network allow feedback connections unlike Multilayer Perceptron that
allow only feedforward connections between neurons across different layers. This
makes them powerful and have been used to infer gene regulatory network from gene
expression data [36]. Temporal dynamics of a system can be represented by an a RNN
and can be used to model and predict nonlinear and noisy time-course gene expression
than linear predictors. There are four main Recurrent Neural Network architectures
commonly used [37].
2.5.1 Input-Output Recurrent Model
In this architecture, an input is applied to k units of tapped-delay-line memory. A
single output is fed back to the inputs through another k units of tapped-delay-line
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memory. The inputs layer of the multilayer perceptron is then fed by the contents
of these tapped-delay-line memories. The result is a nonlinear autoregressive with
exogenous inputs (NARX) model whose dynamic behaviour can be represented by
Yn+1 = θ(Yn,Yn+1, ...,Yn−q+1;Un,Un+1, ...,Un−q+1) (2.14)
where θ is a nonlinear function of its arguments, Un is the input to the model and
Un,Un+1, ...,Un−q+1 represent the present and past values of the exogenous inputs.
Yn,Yn+1, ...,Yn−q+1 represents the delayed values of the output on which the model
output Yn+1 is regressed.
2.5.2 The Recurrent Multilayer Perceptron (RMLP)
The Recurrent Mutlilayer Perceptron architecture has one or more hidden layers with
each layer having a feedback and can be more effective than using only single hidden
layer. If vector XI,n denotes the output of the first hidden layer, XII,n denotes the
output of the second hidden layer and vector Xo,n denotes the overall output of the
output layer, then the system of coupled equations given as
XI,n+1 = θI(XI,n,Un)
XII,n+1 = θII(XII,n,XI,n+1)
...
Xo,n+1 = θo(Xo,n,XK,n+1)
(2.15)
represents the general dynamic behaviour of the RMLP to Un input vector of K hidden
layers. θI(., .), θII(., .) and θo(., .) represent the activation functions of the first hidden
layer, the second hidden layer and the output layer of the network respectively.
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2.5.3 Second-Order Network
Second-order network comprise of second-order neuron k that uses a single weight
wk ji to connect it to input nodes i and j. They are the result of multiplying first-order
networks where order refers to the way in which an induced local field of a neuron
is defined. Second-order network accepts time-ordered sequence of inputs and evolve
with dynamics defined by the pair of equations:
vk,n = bk +∑
i
∑
j
wki jXi,nu j,n (2.16)
Xk,n+1 = φ(vk,n)
1
1+ exp(−vk,n) (2.17)
where u j,n is the input applied to source node j, wki j is a weight of second-order
neuron k, vk,n is the induced local field of the hidden neuron k, bk is the associated
bias and xk,n is the output of neuron k.
2.5.4 State-Space Model and the Elman Network
In the state-space model, the state of the network is defined by the hidden neurons.
The output of the hidden layers is fed back into the input through a bank of unit-
time delays which determine the order of the model. If vector un denotes the input
vector and vector xn denotes the output of the hidden layer at time n, then the dynamic
behaviour of the model may be described by the pair of equations:
xn+1 = α(xn,un) (2.18)
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yn = βxn (2.19)
where α(.,.) is a nonlinear function characterising the hidden layer and β is the synap-
tic weight matrix of the output layer. In the Elman network [38] also known as the
simple recurrent network (SRN) which is derived from the state-space model, the out-
put layer maybe nonlinear and the bank of unit-time delays at the output is omitted.
The Elman network has an error derivative delayed by one time step back in the past
and can be used to model time-course biomedical data more intuitively. The Elman
network was adapted in chapter 7 of this thesis due to its state-space characteristic and
simplicity. It best fits within the DBN framework due to its Markovian properties of
modelling nonlinear relationships delayed by one time step in the past. As explained
in chapter 7, the algorithm developed by combining it within DBN (RNN-DBN) was
efficient at inferring gene regulatory network from time-course gene expression data.
2.6 Parameter Optimisation Algorithms
Optimisation algorithms generally try the find the minimum values of various math-
ematical functions. Parametric optimisation involves a search in the space spanned
by parameter variables of a defined objective function with the aim of minimising or
maximising the function. They are used to fine-tune parameter values of various clas-
sification or regression algorithms in scientific and engineering computations. They
include evolutionary computation methods which are biologically inspired computa-
tional techniques based on theories of natural selection, reproduction and survival of
the fittest. Some well-developed evolutionary computation methods include Genetic
Algorithm [39], Genetic Programming [40], Evolution Strategies [41] and Differential
Evolution (DE) [42]. Other optimisation algorithms are inspired by theories of collec-
tive intelligence such as Particle Swarm Optimisation (PSO) [43] where individuals
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in a group (swarm) rely on each other’s individual knowledge of a treasure’s where-
abouts in order to find that treasure. The two optimisation algorithms adapted in this
thesis are Differential Evolution (DE) and Particle Swarm Optimization (PSO). They
were used because at the time of this PhD study, PSO and DE were not much explored
in the DBN domain for biomarker discovery and were quite good in high-dimensional
data applications of this research.
2.6.1 Differential Evolution (DE) Algorithm
DE is a population-based meta-heuristic algorithm developed by Storm and Price [42]
in which an objective function is optimised by iteratively searching through and im-
proving candidate solutions. In DE, mutation step is applied before crossover by gen-
erating a trial vector and is not sampled earlier from a known distribution. The ro-
bustness of the algorithm has led to its application various industries such as mechan-
ical engineering [44] and pattern recognition algorithms [45]. The algorithm aims
at evolving a population X of D-dimensional parameter vectors known as individu-
als such that Xi,K = X1i,K, ...,X
D
i,K for i = 1, ...D [46]. The individuals are randomised
within the search space such that the entire search space is covered as much as possi-
ble by the initial population. The population is constrained within the minimum bound
Xmin = X1min, ...,X
D
min and maximum bound Xmax = X
1
max, ...,X
D
max such that the initial
value of the jth parameter in the ith individual at generation K = 0 is given by:
X ji,0 = X
j
min+ rand(0,1)× (X jmax−X jmin) j = 1,2, ...,D (2.20)
where rand(0,1) is a uniformly distributed random variable between 0 and 1. Mutation
takes place after initialisation to produce a mutant vector Vi,K with respect to each
individual target vector Xi,K at generation K. The mutant vector Vi,K = v1i,K,v
2
i,K, ...,v
D
i,K
can be generated by various variants of the DE algorithm [47]. Five main variants are:
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DE/rand/1
Vi,K = Xri1,K +F× (Xri2,K−Xri3,K) (2.21)
DE/best/1
Vi,K = Xbest,K +F× (Xri1,K−Xri2,K) (2.22)
DE/rand-to-best/1
Vi,K = Xri1,K +F× (Xbest,K−Xri3,K)+F× (Xri1,K−Xri2,K) (2.23)
DE/best/2
Vi,K = Xbest,K +F× (Xri1,K−Xri2,K)+F× (Xri3,K−Xri4,K) (2.24)
DE/rand/2
Vi,K = Xri1,K +F× (Xri2,K−Xri3,K)+F× (Xri4,K−Xri5,K) (2.25)
where F is a scaling factor, the indices ri1,r
i
2,r
i
3,r
i
4andr
i
5 are mutually exclusive inte-
gers in the range 1 to D.
2.7 Particle Swarm Optimisation (PSO) Algorithm
The PSO is a stochastic population-based optimisation method inspired by the social
behaviour of fish schooling and bird flocking which was developed by Kennedy and
Eberhart [43] with a simple concept for each individual to emulate the successes of
neighbouring individuals as well as its own success. This gives rise to discovery of op-
timal regions of a high-dimensional search space [46]. In the conventional paradigm
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of evolutionary computation, a swarm is similar to a population, and a particle is
similar to an individual. Since its inception, PSO has attracted a lot of research inter-
ests from DNA sequencing [48] to optimising path-following footsteps for humanoid
robots [49].
The PSO adjusts its particles in searching the space of an objective function. A parti-
cle’s position is changed by the addition of a velocity vi(t) to its current position such
that
xi(t+1) = xi(t)+ vi(t+1) (2.26)
where xi(t) represents the position of particle i in the search space at discrete t time
steps. The optimisation process is driven by the change of the velocity and represents
the experiential knowledge or cognitive process of each particle. A point in the D-
dimensional space is represented by each ith particle such that xi = (xi1,xi2, ...,xiD).
Different variants of the PSO exist such as the inertia weight PSO [50] and the com-
prehensive learning PSO (CLPSO) [51].
For velocity v of each particle i, the inertia weight PSO’s velocity updating equation
can be written as:
vid = w× vid + c1× rand()× (pid− xid)+ c2×Rand()× (pgd− xid) (2.27)
xid = xid + vid (2.28)
where w is the inertia weight, the best known location or experience point is recorded
as Pi = pi1, pi2, ..., piD and c1 and c2 are positive acceleration constants. g represents
the index of the best particle among all particles while Rand() and rand() are two
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random functions in the range of 0 to 1. In the CLPSO, a particle’s velocity is updated
by all other particles’ historical best information.
Input Biomedical Data
Generate initial 
population of 
optimization 
parameters
Train a model with 
training examples
Compute an objective 
function (such as MSE)
Vary parameters until 
lowest objective 
function
Output parameters 
corresponding to lowest 
objective function
FIGURE 2.3: Generic Computational Optimization Model adapted in this study
Figure 2.3 shows the block diagram of generic computational optimisation model
adapted in this study. It takes biomedical data as input, generates initial population
of optimisation parameters. For the SVM for instance, this would be the C and γ
parameters. The model is trained using the parameters while an objective function
such as mean squared error (MSE) is being computed. The process continues with
various optimisation parameters being varied within the optimization algorithm until
lowest objective function is reached. The output is a vector of optimised parameters
corresponding to the lowest objective function. More specific block diagrams of com-
putational models adapted in this study are shown in their respective chapters.
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2.8 Conclusion
This chapter introduced and explored the theory behind the computational methods
used in this thesis. It describes support vector machine, Random Forest and the Recur-
rent Neural Network (RNN) algorithms. The random forest can be used for both clas-
sification and regression tasks and was used for the task of classification and feature
selection using recursive feature elimination. The RNN was introduced as a method of
modelling the temporal dynamics of a system and four architectures discussed which
are the Input-Output Recurrent Model, State-Space Model and the Elman Network,
the Recurrent Multilayer Perceptron and the Second-Order Network. The State-Space
Model and the Elman Network was chosen and used to develop a novel Recurrent
Neural Network Dynamic Bayesian Network (RNN-DBN) algorithm for the infer-
ence on gene regulatory network from time-course gene expression data. The choice
was due to its simplicity, state-space and Markovian properties of modelling nonlinear
relationships delayed by one time step back in the past.
Various parameters of algorithms such as Support Vector Machine and Recurrent Neu-
ral Network need to optimised and fine-tuned for best performance. Parameter opti-
misation algorithms were introduced which include Particle Swarm Optimisation and
Differential Evolution algorithms. These two algorithms were adapted because at the
time of this study, they have not been much explored within the DBN domain and
were quite good in high-dimensional dataset case studies throughout this research.
Dynamic Bayesian Network (DBN) is described and the DBN describing a vector
autoregressive (VAR) process is explained along with the theorem and necessary as-
sumptions. Support Vector Machine is described along the three kernels used in this
thesis: the linear, the polynomial and the radial basis function kernels. The SVM was
both used for the tasks of classification and feature selection using the recursive fea-
ture elimination (RFE) algorithm by backward selection. The SVM was further used
for the task of regression in chapter 7 (using nonlinear radial basis function kernel
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within DBN) to develop novel Support Vector Regression Dynamic Bayesian Network
(SVR-DBN) inference algorithm for reverse engineering of gene regulatory network
from time-course gene expression data.
Understanding the state-of-the-art in reverse engineering of gene expression network
from time-course gene expression data is therefore important in appreciating how
DBN works and how it is applied for this task. This is discussed in chapter 3.
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3.1 Reverse Engineering in Bioinformatics
In protein synthesis, transcriptional regulation plays an important role in the response
of the proteins to various internal stimulus like development processes and external
stimulus from the environment [52]. Transcriptional regulations in the cell are re-
sponsible for partial and temporal levels of mRNA and the abundance of protein [53].
Regulatory activities between regulators such as transcription factor (TF) make up the
transcriptional regulatory network. The expression of the genes is determined by the
regulatory relationship’s activation and repression [54].
Microarrays are technologies used to measure the amount of production of mRNA dur-
ing transcription by hybridisation of an mRNA molecule to the source DNA template.
The matching of both known and unknown DNA samples in an orderly arrangement
constitutes an array and this array samples make up Microarray data. The expression
level of a gene is the amount of mRNA that is bound to each site on the array. The
microarray chip can identify spots with more intensity for a diseased tissue gene if in
the diseased condition, that gene is over expressed. [55] [56] .
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Identifying and understanding transcriptional regulatory networks is of great impor-
tance in discovering potential drug targets [57], [58]. In understanding these networks,
various reconstruction methods have been proposed which generally fall into top-
down and bottom-up methods. Top-down methods are those that identify the global
regulatory interactions in parallel and systematic way by first acquiring many regu-
latory interactions and then through additional experiments validating them. As an
example, identifying the interactions of protein-DNA is made possible by ChIP-Seq
technology. It combines chromatin immunoprecipitation (ChIP) with massively par-
allel DNA sequencing for the identification of DNA-associated protein binding sites
[59] [60], [61]. Bottom-up methods are gene knock-out experiments in which detailed
regulations between transcription factors and their individual targets are are first iden-
tified, and then all the regulations are summarised to form a regulatory network. After
knocking out some genes, the genetic relationship can then be detected as a result [62],
[63].
Reverse engineering is the term used to describe the inference or reconstruction gene
regulatory networks from gene expression data produced from microarray experiments
[64]. Reverse engineering of gene regulatory networks have recently become very
popular in computational biology and bioinformatics and numerous computational
methods have been studied. [65] reviewed how complex networks are being con-
structed from simple modular components. It also reviewed how stochastic and deter-
ministic modelling of the modules can provide more accurate in silico representation
of gene regulatory networks. [66] reviewed how Bayesian statistical methods can be
used to infer the network structure and estimate model parameters based on experi-
mental data. [67] and [68] developed in silico reverse engineering benchmark datasets
through community efforts of the Dialogue for Reverse Engineering Assessments and
Methods (DREAM) project. These datasets known as the DREAM datasets are used
to test new algorithms developed for reverse engineering of gene regulatory networks
from time-course gene expression data.
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[69] used the DREAM datasets to perform comprehensive assessment of various in-
ference methods on Staphylococcus aureus, Escherichia coli, in silico microarray
data and Saccharomyces cerevisiae. The authors discovered that no single inference
method performed optimally across all datasets. [70] developed a new algorithm for
inferring gene regulatory networks known as BAyesian Clustering Over Networks
(BACON). The algorithm uses integrated, probabilistic clustering to lessen the prob-
lems of under-determination and correlated variables within a fully Bayesian frame-
work. The authors of [71] suggest that morphogenesis may be reverse engineered to
uncover its interacting mechanical pathway and molecular circuitry.
[72] developed a new search heuristic known as Divided Neighbourhood Exploration
Search to be used with inference algorithms such as Bayesian Networks for improv-
ing inference in reverse engineering. The algorithm systematically moves through
the search space to find topologies representative of gene regulatory networks that
are more likely to explain microarray data. [73] used the DREAM datasets to iden-
tify a better prognostic model for prediction of survival in patients with metastatic
castration-resistant prostate cancer. The computational methods for inference of these
gene expression data are motivated by the availability of genome-wide profiling data.
Gene perturbations or expression profiles of time series show dynamics of genes and
imply the possibilities of causal relationships [74], [75].
3.1.1 The Generic Framework for Reverse Engineering in Bioin-
formatics
Since the advent of microarray technologies, there has been great amount of oppor-
tunities to elicit information and insights from genome-wide gene expression data by
measuring and monitoring their expression patterns [55]. Regulatory knowledge can
also be derived from experimental data using various strategies developed for inferring
regulatory architectures from their corresponding gene expression profiles [68], [69].
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The general framework for reverse engineering is illustrated in Figure 3.1A. The aim is
to identify and infer relationships between transcription factors and target genes from
their expression profiles. Regulators in the network are represented by the nodes and
regulatory interactions are represented by the edges. From part A of the Figure 3.1, the
network structures and parameters are reversely engineered from gene expression data
which may be perturbation experiments of gene knockouts or time series processes
from gene expression data. Models and reverse engineering algorithms are developed
to measure these structure and parameters such as causality and strength of the rela-
tionships. For example, in the inference algorithm, the strength could be measured as
p-values where lower values indicate greater strength of edges [1].
For genes G1 and G2, there are four levels of clarity for which four different questions
about regulatory parameters need to be answered as shwon in Figure 3.1B. Level I
seeks to determine whether there are regulatory interactions between G1 and G2 from
the regulatory matrix data. When a causal influence from G1 to G2 has been identified
at level I, level II determines the edge direction by determining which gene is the
FIGURE 3.1: Generic Framework of Reverse Engineering of Regulatory Networks.
Part (A) represents how gene expression profiles data are fed into a reverse engineer-
ing algorithm and the output is an inferred transcriptional regulatory network showing
activation and repression. At (B), the algorithm addresses the four levels of clarity
in the reverse engineering process. (C) shows regulatory pair and the regulatory sys-
tem that consists of both complicated regulations such as regulation from G1 to G2
conditioned upon G3 that has to be systematically modelled. [2]
33
Chapter 3 Literature Review
regulator. Concentrations of target genes may be increased or decreased in certain
conditions when transcription factors activate or repress the target gene. Level III
determines whether the information is about activation or repression. For example, if
M is the regulatory matrix, G1 activates G2 if M12 > 0 or M21 = 0 and G1 represses
G2 if M12 < 0 or M21 = 0. Level IV determines the regulatory strength between G1
and G2. For example M12 = 1.76 or M21 =−0.63 shows the regulatory strength of the
relationship between the genes. In part C of Figure 3.1, strength of the regulation can
be determined as strong or weak by assessing all the real numbers of the regulatory
strength. In the illustration, G2 is regulated by G1 and shows direct causality while
the right shows an indirect causality is shown from G3. When matrix M is very large,
there obviously needs to be systematic and computationally efficient way of modelling
these relationships [2].
One major difficulty associated with reverse engineering in bioinformatics is the curse
of dimensionality problem where p n i.e. number of genes (predictors) p in thou-
sands have been experimented with very few samples n [76]. Also the likelihood of
false positives is very high since the regulatory networks are usually sparse [77], [78],
[79], [80]. The dynamics of gene regulation as a result of its real environment also
contribute to the difficulty in inference. For instance the downstream target genes can
be affected by upstream regulation of a gene that encodes a transcription factor [81],
[82]. There is also a lot of mismatch and inconsistency between protein and mRNA
which affects the correctness of the regulation inference [83]. All these challenges
pose significant difficulty in using expression data to reconstruct regulatory relation-
ships.
In order to address these challenges in reverse engineering of gene regulatory networks
and its evaluation, in silico methods have been developed to discover substantial reg-
ulations and traditional methods have been used to validate them [84], [85], [86],
[87]. One of such is The Dialogue for Reverse Engineering Assessments and Methods
(DREAM) international competition which involves simulated generation of datasets
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to speed up modelling and evaluation of inferences in regulatory networks [88], [89].
After inference of the transcription networks using the simulated datasets, assessment
is done by comparing the inferred network with a benchmark network [90] such the
network of the fully sequenced Drosophila Melanogaster and measures such as sen-
sitivity, accuracy, specificity, Matthews Correlation Coefficient and F1-score are used
to evaluate the performance of the inference algorithm [84], [91]. The receiver operat-
ing characteristics (ROC) curve is usually plotted as sensitivity versus specificity and
the area under the curve (AUC) used as an indicative measure of performance where
higher number represents better performance [92].
3.1.2 Present Inference Methods
There are various existing methods for inferring gene regulatory networks which have
been categorised into differential equation methods and knowledge-based methods.
Other methods such Boolean Networks and Correlation-based methods exist but are
however beyond the scope of this study.
3.1.2.1 Differential Equation Methods
The formalisms of differential equations such as partial and ordinary differential equa-
tions have widely used to study dynamical systems in engineering and scientific re-
search. These powerful methods have been adapted to model and represent metabolic
processes and dynamics of gene regulation processes [93], [94]. Here ordinary dif-
ferential equation (ODE) is focused on as it can be used to simultaneously represent
differentiations in time and the dynamics of causal relationships using the earlier dis-
cussed four inference levels of Figure 3.1.
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In ODE, the rate of change of a gene expression’s component is represented as a
concentration of all the components, and within the ODE systems, the causal effects
of the genes are fixed [95], [96]. ODE can be mathematically formulated as
dX
dt
= θ(t,X) (3.1)
where X = X(t) = (X1(t), ...,Xn(t))T denotes the gene expression values of genes
1, ...,n at time point t, t ∈ [t0,T ],0 ≤ t0 ≤ T ≤ ∞. The function θ describes the re-
lationship between the first-order derivative of X and how genes are concentrated in
the regulatory system. The function could be linear or nonlinear and describes the
relationship between the rate of change in concentration of the genes and their causal
regulators. For a linear ODE model, the relationship could be written as
dXi
dt
= αi0+
n
∑
j=1
βi jX j(t), j = 1, ...,n (3.2)
where αi0 is the intercept and β = {βi j}i, j=1,...,n represents how the genes in the regu-
latory system affect the rate of change of expression of the t-th gene.
Reconstructing the regulatory network from data is then transformed as a problem of
parameter identification of the ODE system. To identify these parameters, likelihood
and least squares-based methods have been used in the past [97], [77]. These methods
are however not very effective for reverse engineering and an integrative pipeline ap-
proach was proposed [95], [96]. This method involves a two-step process where the
first step involves fitting the gene expression’s mean curves and estimating its deriva-
tive. At the second step, variable selection is carried out using regularization methods
such as LASSO [98] and the Smoothly Clipped Absolute Deviation (SCAD) [99] to
optimally shrink variables.
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Gene regulations in ODE model are modelled and represented by derivative equations
where the dependent variables which is the rate of change of one gene’s expression,
is quantified as a function of other related genes. The TFs regulate the transcrip-
tional processes of the genes in the regulatory system and the independent variables
are assumed to be made up of the TF proteins. This assumption enables the reverse
engineering of the regulatory network to become a problem of parameter inference of
some functions such as linear functions used to model gene expression data [95].
Due to the underlying differences in the statistical and mathematical perspectives of
inferring a GRN, ODE aids modelling of the regulatory system but not its inference
[100]. This is because functional relationships are assumed to be described by deriva-
tion equations then inference of the regulatory architectures is done by statistical meth-
ods such as variable selection and parameter estimation [95] and the time delays asso-
ciated with the self-degradation and activations can integrated into the system by the
introduction of respective self-degradation and activation terms into the differential
equations.
3.1.2.2 Knowledge-based Methods
Genuine and accurate transcriptional regulations are difficult to identify sorely by re-
liance on data-driven approaches and the efficiency of reverse engineering using only
gene expression data is hard to promise [101], [97], [102]. This makes integration of a
priori knowledge of regulations an important requirement in the development of more
useful and robust methods of inference. Key functional linkages and relationships
can be derived from documented regulations [103], [104], protein-protein interactions
[91], protein-DNA binding data from ChIP-Seq [105] and motifs from TF binding se-
quence [82]. Transcriptional regulatory networks can be identified by the integration
of these a priori knowledge with gene expression data.
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Integrating a priori knowledge reliably often leads to probabilistic ways of inference
such as Bayesian Network [106], [107]. Many techniques have been proposed to
calculate these probabilities. In the area of statistical physics an energy function ap-
proach was proposed by [108], [109] which involves introduction of prior knowledge
from multiple sources by expressing prior knowledge as a function of network energy.
Gibbs distribution is used to obtain the prior distribution over the network structures
[108]. The weights of the prior knowledge are represented by the parameters of the
Gibbs distribution. As a result, the Bayesian network integrates the prior knowledge
in order to learn the structure of the regulatory network. The authors of [108] and
[109] achieved higher inference performance using both real and simulated data.
[110] proposed a linear programming (LP) method based on ODE for integration of
prior knowledge in reverse engineering of GRNs. In the proposed method, the as-
sociation gap between network structure and gene expression data is minimised by
building an LP model and obtaining an integrated regulatory network by solving the
LP. The objective function of the LP is then to minimise the number of gene connec-
tions needed to have the sparseness of the inferred network with constraints being the
prior knowledge and the linear additive equations. The solution that gives the sparser
network with respect to the two constraints is chosen as the inferred network [110].
3.2 Modelling and Representing Uncertainty using Bayesian
Networks
In real world applications, time is of great importance as events in all fields of life hap-
pen in time. In medical diagnosis, the condition of a patient with HIV may be observed
to improve with time given that the patient is on regular dosage of some anti-retroviral
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drugs. Accurate representation of uncertainty is therefore crucial in biomedical appli-
cations. Before exploring what temporal events are and how they are modelled, static
modelling using Bayesian network is introduced with a few application examples.
A Bayesian Network (BN) is a Directed Acyclic Graph DAG having nodes that rep-
resent random variables which may be discrete or continuous [13],[111] which can be
a set of finite variables from x1, ...,xn, where x represents features to be modelled. A
set of directed links or arrows connect pairs of nodes in a graph G. If there is an arrow
from node x to node y, x is said to be the parent of y. Each node xi has a conditional
probability distribution P(xi|Parent(xi)) that qualifies the effect of the parent on the
node.
Px1, ...,xn =
n
∏
i=1
Pxi|parents(xi) (3.3)
Figure 3.2 shows a simple Bayesian network that illustrates the relationship between
a student’s intelligence, grade and the score in the Scholastic Assessment Test (SAT).
FIGURE 3.2: A Simple Bayesian Network showing how a students intelligence af-
fects grade and score in the Scholastic Assessment Test (SAT)
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Bayesian Networks have been applied to many real world applications such as mod-
elling cognitive behaviours [112], variable optimisation of medical images [113] and
various medical prognosis [114] and protein predictions [115]. The major advan-
tage of BN is that they contain no redundant values of probability and hence have
no chance of inconsistency [13], [116]. BN algorithms are more capable of handling
very noisy biological experimental data due to their probabilistic nature [117], [118].
They can more easily handle incomplete datasets since they probabilistically encode
correlations between input variables [119]. Another advantage of BN is that they al-
low construction of causal relationships and determination of influences in expression
data variables [119], [117] however, Bansal et al [120] argued that BNs strictly define
only probabilistic dependencies between variables and therefore causal links cannot
be assumed except if the causal Markov condition is true.
Despite the advantages of BNs, they can only be used to model static events and do
not take into account temporal event that happen over a period of time [121], [122]
and modelling cyclic phenomena such a feedback loops and cyclic regulations are
not possible with BNs [123]. These limitations are overcome by dynamic Bayesian
networks (DBNs) which are extensions of BNs that incorporate time dependencies
and have been proposed by various authors [124], [125], [126], [127], [128], [129].
3.3 Representing Uncertainty in time: The DBN
Temporal models are processes where there are replications over time. They are used
to represent uncertainty in events that happen over time. There are three main kinds
of temporal models commonly used. These are Hidden Markov Models, Kalman Fil-
ters and Dynamic Bayesian Networks (DBNs). In bioinformatics, DBNs are used to
model gene regulatory networks and infer temporal relationships between features at
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successive time points. A popular DBN framework used for inferring gene regula-
tory network is representing it as a vector autoregressive models of order 1 [130], [1],
[131], [25].
The temporal models are also referred to as state-space model which is a term used to
imply that the hidden state is a vector [132]. Temporal events can be seen as series
of snapshots or time slices containing a set of random variables. Time is usually
discretised using time granularity. This time is the interval at which measurements
can be obtained from a sensor [14]. In representing their probability distributions for
state-space models, the Markov assumption is usually made. The Markov assumption
states that the state of the next time point is independent of the past state given the
present state [133], [14], [134].
DBNs identify time-course regulatory influences in biomedical data on the framework
of BNs where time is modelled as a stochastic temporal process over time series set of
random variables.
Figure 3.4 shows graphical representation of a network containing cyclic regulations
with cycle X1→ X2→ X5→ X1. This kind of network cannot be modelled by a
BN however, a DBN models this cyclic regulation and feedback loop common in
biological systems by dividing the states of the variables by time points as shown on
the right. Assuming each time point were as a single variable, the simplest causal
network for a time series sequence of data would be modelled as a first order Markov
FIGURE 3.3: Graphical representation of a network with cyclic regulations.
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chain where the state of the next variable is dependent only on the state of the previous
variable [13].
FIGURE 3.4: A DBN with sequence of time points corresponding to first order
Markov chain
Figure 3.4 shows a DBN corresponding to a first order Markov chain where Xt+2
depends only on Xt+1 and Xt+1 depends only on Xt . Xt then depends only on Xt−1
and Xt−1 depends only on Xt−2. Dependencies over more than one time step between
variables cannot be represented by the Markov chain [135]. A way to however extend
the model is to assume that there are hidden discrete variable known as states on which
the observed variables depend on. This sequence of hidden states are known popularly
as Hidden Markov Models (HMMs).
A Hidden Markov Model is a temporal probabilistic model in which a single discrete
random variable is used to describe the state of a process and stochastic processes are
represented as Markov chains where the states are not directly observed [136].
Figure 3.5 shows a HMM representation where Z1,Z2, ...,Zn represent some hidden
discrete random variables and X1,X2, ...,Xn represent some observed random variables.
FIGURE 3.5: A HMM showing Hidden variables Z1,Z2, ...,Zn and observed variables
X1,X2, ...,Xn
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Hidden Markov Models have been used in many real world applications such as speech
recognition [137] and classifying speech response of the brain [138]. HMMs have
further been combined with Bayesian networks to address the problem of overfitting
and model regularization for speech recognition [139], [140]. HMMs have been used
to model surgical performance and expert surgical gesture by processing kinematics
data such as movement of surgical instruments in time [141]
Despite the application capabilities of HMM and it being the simplest form of DBN
[135], there are inherent problems which make its application limited in some complex
real world applications [142],[132], [143], [13]. First, the initial states in HMMs are
represented by only single discrete random variables and are not suitable for represent-
ing temporal uncertainties with two or more state variables [142]. Another problem
with HMMs is the computational complexity in tasks such as tracking objects in a
sequence of images. For instance, if there are 20 Boolean state variables in a network
each with three parents, the HMM will have 220 states and therefore 240, almost a
trillion, probabilities in the transition matrix. This large transition matrix makes the
inference of HMM more computationally expensive and the problem of learning such
large number of parameters makes it unsuitable for high-dimensional data such as
gene expression data and other large biomedical data. A corresponding DBN transi-
tion model for the same problem described above will have 20×23 = 160 probabilities
[13], [142] hence DBN is preferred over HMM for modelling temporal uncertainty in
bioinformatics.
Kalman filter models (KFMs) can be seen as HMMs with conditional linear Gaussian
distribution and also a simple form of DBN [144]. They are Bayes optimal minimum
mean-squared error estimator for linear systems with Gaussian noise [145]. Since
Kalman filters are recursive data processing algorithms for solving discrete linear fil-
tering problems, the estimates of the system variables are updated at each time step
using only the observations at that time without having to store all past observations
[145]. Kalman filters are powerful in solving localization estimation problems [146]
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and have been used for object tracking [147], robot control [148] and 3-D modelling
[149]. KFMs have also been applied in statistical neuroscience for spike sorting [150]
and modelling physiological tremor [151]. The assumption of a linear Gaussian model
is however too strong and an extended Kalman filter (EKF) was proposed to overcome
the problem of nonlinearities [152]. The EKF has been applied to neural networks
training and to data fusion problems [153] and for moment estimation in bimolecular
reactions [154]. However authors of [155] argued that the series of approximations in
EKF algorithm can lead to the nonlinear functions and associated probabilities being
poorly represented. Another problem is that large qualitative discrete variables can-
not be represented since the system is assumed to be jointly Gaussian [13]. For this
reason, the more efficient DBN model is preferred in this study.
3.4 Machine Learning in Bionformatics
Machine learning is a multidisciplinary field of study that involves computer science,
statistics, artificial intelligence and programming. Machine learning is the ability of
computer systems to gain or acquire knowledge about a task without further explicit
programming. Tom Mitchell [156] defined machine learning as ”A well-posed learn-
ing problem: A computer program is said to learn from experience E with respect to
some task T and some performance measure P, if its performance on T, as measured
by P, improves with experience E.” The field of machine learning seeks to answer the
question of how a computer system can be built to automatically learn from experience
and take actions based on what has been learned.
Machine learning algorithms are broadly divided into supervised learning, unsuper-
vised learning and reinforcement learning [157]. Supervised learning involves pre-
senting an algorithm with example inputs and desired outputs called training data.
The goal of the learning algorithm is to map inputs to outputs [158]. There are two
main supervised learning tasks —classification and regression.
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Classification problems involve identifying which label a set of training features be-
long to. An example is trying to determine whether an email is either spam or not
or whether a patient has cancer or not given gene expression profiles. Regression in-
volves predicting continuous valued outputs (rather than discrete as in classification).
The task is to estimate relationships between one or more independent variables and a
dependent variable.
In unsupervised learning, there are no labels given to the learning algorithm. The algo-
rithm is left to find and discover hidden patterns in the data. For example finding dif-
ferent groups and pattern in relationships given a gene expression data using methods
such as clustering and algorithms such as K-Means Clustering and Hierarchical Clus-
tering. Patterns such as co-expression in genes can be discovered in high-dimensional
data using clustering [159].
In reinforcement learning, an algorithm tries to find suitable actions to take in a given
situation in order to maximise reward. For example an algorithm tries to perform task
such as driving a car without being given examples of optimal outputs (as in the case
of supervised learning) but must through trial and error discover them [134]. Rein-
forcement learning has been used to model reward prediction errors for patients with
schizophrenia where the goal was to assess belief formation and belief perseveration
[160]. Zhu et al also used reinforcement learning in addition to text mining to construct
protein-protein interaction network for diagnosis of prostrate cancer [161]. Reinforce-
ment learning continues to grow as an active area of research but it is however beyond
the scope of this study.
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3.5 Application Domains of Machine Learning for Dis-
ease Prognosis
The core cellular molecules in bioinformatics include DNA, RNA, Proteins and metabo-
lites. The central dogma of molecular biology is the transcription of DNA into RNA
and the translation of RNA into proteins. Some proteins may act as catalysts for
production of metabolites. Studying these interactions is one of the main focus of re-
search in bioinformatics however faster and cheaper computing power have increased
the possibilities of discovering novel interactions among these molecules.
Machine Learning methods have been widely successful in bioinformatics. With cur-
rent high-throughput gene expression data of high volume, variety and velocity, ma-
chine learning algorithms have helped speed up analysis that would have had long
completion times. Understanding bioinformatics data such as proteomics, genomic,
transcriptomic and metabolomic data have widely presented research problem. The
problem of mining and understanding these complex data is even increased due to
there high dimension where the number of features is in thousands. This requires
complex learning algorithms and in many cases, a combination of algorithms and en-
semble methods.
Support Vector Machines (SVMs) are supervised learning techniques for classification
and regression analysis tasks [26]. They are used to analyse and recognise patterns in
data. For a given set of training data, the SVM builds a model by constructing a hy-
perplane (decision boundary) that is used to mark the data as belonging to one of two
categories. The SVM can also be used to perform non-linear classification by implic-
itly mapping data inputs into high-dimensional feature space using kernel dot product.
The SVM was especially made popular in systems biology when it was successfully
applied with the recursive feature elimination algorithm by Guyon et al [28] to se-
lect genes relevant for cancer classification achieving high accuracy of 98%. Kara et
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al [162] applied SVM for the prediction of protein-protein interactions in which the
authors developed a web server aimed at interfacing a sequence-based predictor for
predicting pairing of histidine kinase.
Owens et al [163] applied SVM for early detection of ovarian cancer. The SVM
achieved a diagnostic accuracy of 74% for Raman spectra of blood plasma and an ac-
curacy of 93% for the Attenuated Total Reflection Fourier Transform Infrared (ATR-
FTIR) spectra of blood samples. They concluded that with SVM and biospectroscopy,
spectral alterations associated with ovarian cancer could be identified. Wang et al
[164] used SVM to detect four genes which accurately differentiated between benign
and malignant thyroid nodules. The genes namely Fibronectin 1 (FN1), neuronal gua-
nine nucleotide exchange factor (NGEF), gamma-aminobutyric acid type A receptor
beta 2 subunit (GABRB2) and a high mobility group AT-hook 2 (HMGA2) all had
overall performance of 97% and 93.8% sensitivity and specificity respectively.
The problem of accurate feature selection have been generally known and widely stud-
ied since the early days of machine learning [165]. [28] believed that a criterion for
good feature ranking was not necessarily a criterion for good feature subset ranking
and went on to develop the now popular Recursive Feature Elimination (RFE) algo-
rithm. The algorithm works in three main steps:
• Train the classifier such as the SVM to optimise the weights.
• Compute the ranking criterion for all features
• Remove the feature with the smallest ranking criterion.
Application of the RFE algorithm using the weight magnitude of the SVM yields the
SVMRFE algorithm. The SVMRFE algorithm in more detail can be represented thus.
Inputs:
Training examples
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X0 = [x1,x2, ...,xn]T
Class labels
y = [y1,y2, ...,yn]T
Initialize:
Subset of surviving features s = [1,2, ...p]
Feature ranked list
r = []
Repeat until s= [] where n is the number of examples and p is the number of predictor
features.
Experimental results on two gene expression datasets (colon cancer and leukemia)
obtained from DNA micro-arrays [166] showed that when the SVMRFE is applied,
linear kernel performed best, followed by the radial kernel and lastly the polynomial
kernel. Higher order polynomials are computationally expensive and do not gener-
alise well especially in high-dimensions. A large value of SVM cost of constraint C
results in low bias and high variance while a small value of C results in high bias and
low variance. For the radial basis function (RBF) kernel, large σ2 which is inversely
related to γ results in higher bias and lower variance while a small value of σ2 results
in lower bias and higher variance. The linear kernel generally performs better for situ-
ations where p >> n due to less overfitting because of the small number of examples
and less complexity while for p<< n scenarios, the radial kernel with a more complex
decision boundary performs better.
Figure 3.6 shows the performance of the three SVMRFE kernels used in this study on
the colon cancer gene expression datasets as studied by [28]. It contained 62 tissues
and 2000 gene expression values. Out of the 62 tissues, there were 40 colon cancer
tissues and 20 normal ones. As shown from the figure, linear kernel was most accurate
in distinguishing cancerous from non-cancerous tissues followed by the RBF kernel
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and lastly the polynomial kernel. The accuracy of the feature subsets were measure in
powers of two until the total number of features. The best results for all kernels were
achieved at the selection of 16 subsets after which the accuracy of the polynomial
kernel begins to go down followed by the RBF kernel. The linear kernel maintained a
high accuracy of 100% and then started going down from 512 subsets as more subsets
were been selected. All of the kernels showed downward trends as the number of
features increased.
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FIGURE 3.6: Performance of various SVMRFE kernels on Colon Cancer Dataset
Figure 3.7 shows the performance of the SVMRFE on a larger leukemia dataset. The
problem here was classifying two different types of leukemia (ALL and AML). The
dataset consists of 72 samples and 7129 features. The 72 samples were made up of 47
ALL and 25 AML samples. The figure shows a similar trend with the results from the
colon cancer experiment. The linear kernel had the best performance followed by the
RBF and lastly the polynomial kernel. The kernels had their peak performance at 64
subsets when the polynomial reached its best performance of 98.61%. Even though
this was slightly better than the best performance of the RBF at 97.22%, the RBF had
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overall better performance than the polynomial kernel which saw its performance go
down to 75% when 2048 subsets were selected while the linear was still at 100%.
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FIGURE 3.7: Performance of various SVMRFE kernels on Leukemia Dataset
3.6 Conclusions
The chapter reviews relevant literature and current methods for reverse engineering of
gene regulatory networks from gene expression data. It discusses the generic reverse
engineering framework and present existing methods which include differential equa-
tion and knowledge-based methods. It explores relevant literature involving machine
learning in bioinformatics such as Support Vector Machine and its adaptation in the
diagnosis of cancer.
It describes Bayesian Network and uncertainty representation in time using Dynamic
Bayesian Network and alternative methods such as the Hidden Markov Models. It also
shows the three kinds of SVMRFE kernels used in this study: the linear, the RBF and
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the polynomial kernels and how their cores vary with the number of feature subsets in
a classification task. Results from two datasets from the study of [28] are shown. The
kernels all generally show a downward trend as the number of features increase with
the linear kernel being better for p >> n scenarios.
The gaps discovered are that DBN is more suitable for modelling and inferring rela-
tionships among variable at different time points that the use of KFMs and HMMs and
hence the choice of adoption in this thesis. While machine learning techniques such as
SVMs are good at selecting high quality features, ways of inferring the relationships
between these selected features if each observation is a time point have not yet been
studied.
The linear assumptions of the DBN representation of a vector autoregressive process
(VAR) process is too strong and may not capture the true representation of complex
biological systems known to be inherently nonlinear. Nonlinear methods have to be
developed for more efficient modelling and representation of DBNs. This may poten-
tially yield novel relationships and interactions that may help clinicians in understand-
ing the nature of disease metastasis and in discovery of new drugs. For new drugs to
be developed for various diseases, genomic, proteomic and metabolomic data about
them have to be analysed using computational methods. These kinds of data were
used in this thesis and chapter 4 seeks to describe them.
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Description of Datasets
4.1 Introduction
In chapter 3 relevant literature and current methods for reverse engineering of gene
regulatory networks from gene expression data were discussed. It explained the generic
reverse engineering framework and presented existing methods which include differ-
ential equation and knowledge-based methods. Bayesian Network was introduced and
representation of uncertainty in time using Dynamic Bayesian Network explored.
This chapter explains the different key biomedical data used in this thesis to show ro-
bustness of methods developed. It studies ovarian cancer metabolite data, hypertension
gene expression profiles data, colorectal cancer protein profiles data, ovarian cancer
time-course data. It introduces the Dialogue on Reverse Engineering Assessment and
Methods (DREAM) datasets, the Escherichia coli and the Drosophila Melanogaster
datasets. All data used in this thesis are anonymised and publicly available. Ethical
approval was granted on the 25th of April 2013 prior to the commencement of the
experiments.
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4.2 Ovarian Cancer Metabolite Dataset
The dataset was generated by the study conducted Guan et al [19]. Serum samples
were obtained from the Ovarian Cancer Institute (OCI) Atlanta, GA and consists of
two study groups, 37 patients with papillary serous ovarian cancer and 35 control
groups. The mean age of the patient group was 60 years with age range of 43-79 years
all having stages I-IV of the disease. The mean age of the control group was 54 years
with age range of 32-84 years.
The samples were obtained after approval by the Institutional Review Board. The can-
cer patients and control group were required to avoid food, medicine and alcohol for
12 hours before sample collection. 5ml of blood samples were subsequently collected
from each donor by venipuncture. The samples were centrifuged at a low temperature
of 4 degrees Celsius for 5 minutes at 5000 r.p.m and the serum obtained subsequently.
Due to the complex nature of the serum samples, adduct ion analysis was performed
to assign signals to the mass spectrum. Adducts that usually form in the positive
ion mode electrospray (ESI) include [M+H]+, [M+NH4]+, [M+Na]+, [M+K]+,
[M−H20+H]+ and [2M+H]+ species. For the negative ion mode ESI, they include
[M−H]−, [M+CH3COO]−, [M+Cl]−, [M+HCOO]− and [2M−H]−.
Support Vector Machine Recursive Feature Elimination (SVMRFE) methods were
used to select features. These are SVMRFE with linear and non-linear kernels, L1-
norm SVM and the Weston feature selection using SVM non linear kernel (SVMRW).
Further investigation was performed with MzMine software [19] using Liquid Chro-
matography Time-of-Flight Mass Spectrometry (LC/TOF MS) which showed that a
total of 576 positive ion mode and 280 negative ion mode features were extracted.
Stratified analysis of the highly complex data revealed presence of redundant species
such as dimers, adducts and isotopes which were removed. The final resulting dataset
comprise of 360 features in positive ion mode and 232 features in negative ion mode
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making a total of 592 metabolomic features from 72 observations (37 cancer patients
and 35 control volunteers) used in this study.
4.3 Hypertension Gene Expression Profile Dataset
The gene expression profile dataset of hypertensive patients used in this study was
generated from the works of Lynn et al [20]. It consists of expression profiles of
male young-onset hypertension. After approval by the Institutional Review Board
of Academia Sinica, the highest academic institution in Taiwan, participants were
recruited from MJ life enterprise company healthcare facility with informed consent.
The recruitment criteria for the participants included: (i) Body Mass Index (BMI) <
35; (ii) age range 20-50 years; (iii) at least 8 hours of fasting; (iv) fasting blood sugar <
126 mg/dl; (v) no prior history of cancer or other liver, heart, lung or kidney diseases;
(vi) not on any hypertension medication and (vii) without major symptoms of acute
hypertension in the previous two weeks.
Participants’ blood pressure were measured three times and the average of the last two
measurements was used for the diagnosis of the disease. Participants were classed as
hypertensive if their systolic and diastolic blood pressures were greater than 140mmHg
and 90mmHg respectively, and normotensive otherwise. A total of 77 male hyperten-
sive patients with median age of [37.6 +- 7.2] and 82 normotensive controls of median
age [ 36 +- 6.6 ] took part in the study resulting in 159 total participants.
10ml of blood was obtained from each patient and frozen immediately at 70 degrees
Celsius and total RNA was subsequently extracted from the blood using the Human
OneArray microarray platform by the Phalanx Biotech Group, Taiwan. Four copies of
data were generated for each participant. There were a total of 39200 polynucleotide
data in each microarray chip of which 22184 were eventually mapped to the human
genome.
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Various quality control parameters were used for the microarray data. These include
coefficient of variation, Pearson correlation coefficient, percentage of present calls
and array quality filter. Global data normalization using logarithm and z-score was
carried out and a total of 103 out of the 22184 genes were found to be differentially
expressed with p-values less than 0.01 for both hypertensive and normotensive groups.
In summary the dataset used had 22184 features and 159 observations (rows).
4.4 Colorectal Cancer Protein Profiles Dataset
Colorectal cancer dataset was generated by the study of De Noo et al [21]. Serum
samples of 66 colorectal patients were obtained a day before surgery. The patients
were at stage IV of the disease and the extent of the tumour spread was determined
by the Tumour Node Metastasis (TNM) classification. The median age of the patients
was 62.8 years with a range of 32.6-90.3 and male to female ratio of 31:35. The
control group was made up of 50 healthy volunteers with median age of 49.7 years
ranging from 25.9-76.6 and a male to female to ratio of 21:29.
After approval by the medical ethics committee, 10cc of blood samples were drawn
following informed consent of the participants while they were seated and non fasting.
Serum was obtained after centrifugation at 3000 r.p.m for 10 minutes and stored at -
70 degrees Celcius. Samples from the 116 participants were distributed randomly
across three plates in a randomized block design [167], [168] of roughly equal equal
proportions. Analysis was carried out for three consecutive days.
Isolation of the peptides from the protein was done using magnetic beads based hy-
drophobic interaction chromatography (MB-HIC) kit from Bruker Daltonics (Bremen,
Germany) following manufacturers instructions. α-cyano-4 hydroxicinnamic acid
(0.3g/l in ethanol:actone 2:1) was used as matrix. The preparation was done on an
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8-channel Hamilton STAR pipetting robot (Hamilton, Martinsried, Germany). Ma-
trix assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass spectrom-
etry was carried out using an UltraFlex TOF/TOF instrument from Bruker Daltonics.
Ion-formed N2 pulse laser beam were accelerated to 25kv. With this specifications,
peptide/protein peaks in the range of 960-11,169 Da were measured.
All unprocessed spectra were exported in binary ASCII format and they consisted of
approximately 65,400 mass-to-charge ratio (m/z) values. Further low level analysis
were performed by [169] using Bruker Daltonics ClinProTools software version 2.2.
Recalibration and top-hat baseline correction using default parameters was performed.
Outlier detection with data reduction factor of 4 was done and two additional outliers
were detected from the control group. MATLAB software was used for interpolation
of all cancer and control spectra which resulted in a dataset of 64 cancer and 48 control
observations with 16331 spectral features used in this study.
4.5 Time-Course Ovarian Cancer dataset
Time-course ovarian cancer dataset was generated from the works of Yseult et al [22]
using A2780 human ovarian carcinoma. IC90 concentrations of oxaplatin (32µm) or
cisplatin (25µm) was introduced to the samples for 2 hours and were then allowed to
grow in a drug-free environment during the time-course experiment. The cells were
processed in three stages; before treatment, immediately after treatment 0hrs, and at
2hrs, 6hrs, 16hrs and 24hrs after treatment. Similar experiments were done for the
control experiment but cells were however exposed to drug-free medium.
The quality of each RNA sample during each step of the process was evaluated us-
ing gel electrophoresis and spectrophotometry. The RNA samples were purified and
fragmented and each fragment sample was carefully assessed by hybridization to
Affymetrix HGU95Av2 chips. The expression summaries of the probe levels were
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obtained using Robust Multichip Average (RMA) method 43 which involved the use
of a linear model fitted to quantile normalized and log transformed probe intensities.
The RMA calculations were done using a Bioconductor function justRMA available
in affy1.4.32 of the Bioconductor project 1.4 package.
The expression levels of each gene was modelled as a function of time having an
initial state response followed by an exponential increase or decrease to an asymptotic
final response. Genes were selected from the dataset which initially included 12625
gene probesets. From these probesets 34 genes were finally selected based on three
selection criteria. The first criterion involved selection of genes whose expression
levels were increased or decreased by both cisplatin and oxaliplatin platinum drugs.
The second selection criterion involved selection of genes differentially affected by
both the cisplatin and oxaliplatin. Genes selected by the second criterion include 3
genes with no material changes in oxaliplatin versus control samples but with increase
in cisplatin versus control; 1 gene with no significant changes in oxaliplatin versus
control but with significant decrease in cisplatin versus control; 6 genes with no mate-
rial changes in cisplatin versus control but with increase in oxaliplatin versus control
and 10 genes with no material changes in cisplatin versus control but with decrease in
oxaliplatin versus control.
After the selection criteria of both the first and the second have been met, the third
and final criteria involved visual inspection of time-course and concentrated-effect
patterns. A total of 34 genes were selected as follows: 3 genes with no changes due
to oxaliplatin but increase due to cisplatin; 0 genes with changes due to oxaliplatin
but increase caused by cisplatin; 5 genes with no changes caused by cisplatin but with
significant increase by oxaliplatin; 9 genes with no changes due to cisplatin but with
decrease by oxaliplatin; 12 genes with increase caused by both drugs and 5 genes with
decrease caused by both drugs.
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4.6 Reverse Engineering Datasets
This section explains the both simulated and real world reverse engineering datasets
used in this study. These are benchmark datasets commonly used to validate developed
algorithms for reverse engineering of gene regulatory networks from time-course gene
expression data.
4.6.1 DREAM Datasets
The Dialogue on Reverse Engineering Assessment and Methods (DREAM) initia-
tive organises reverse engineering competitions annually with the goal of predicting
the connectivities of networks from both simulated (in silico) and real (in vivo) gene
expression datasets. Two DREAM datasets were used in chapter 7 of this thesis:
DREAM3 dataset comprising of three Yeast knock-out expression matrix of sizes 10,
50 and 100 nodes [67] and DREAM4 dataset comprising of five Yeast datasets each
of 10 nodes and 21 time points [68]. First 10 features of the 100 node network of
DREAM3 dataset are shown in Appendix A. The in silico networks of the DREAM
datasets are generated by differential equation. The networks were modelled as sub-
graphs of real sequenced S. cerevisiae (Yeast) and E. coli gene expression networks
[170]. The DREAM datasets are publicly available from the GeneNetWeaver website
[171].
4.6.2 Escherichia coli Dataset
Miroslav Radman [172] carried out the first experiment that supported the existence
of inducible DNA repair network in Escherichia coli popularly known as E.coli. He
used the term ”SOS response” to describe the network in which during regulation
of the network, two proteins play key roles. The first protein, LexA acts as a re-
pressor while the second protein, RecA, acts as an inducer. The repressor binds to
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specific sequence —the SOS box which is present in the promoter region of the SOS
genes during normal growth and prevents their expression. The amount of repres-
sion depends on the exact sequence of their SOS box. The amount of LexA repres-
sor after ultraviolet light irradiation decreases about 10 times in a few minutes how-
ever, the genes are not all induced at the same time. Genes uvrA, uvrB and uvrD
are the first to be induced. These together with endonuclease UvrC, catalyse nu-
cleotide excision repair (NER) which excises the damaged nucleotide from double-
stranded DNA [173]. The 9 square matrix time-course SOS DNA repair network
used in this thesis was published by [174] and is freely available from their website
https://github.com/xiangdiuxiu/NetworkDC/tree/master/data/SOS and also shown in
Appendix A.
4.6.3 Drosophila Melanogaster Dataset
Drosophila Melanogaster also known as fruit fly has been widely used in biological
research in the areas of genetic, microbial pathogenesis, physiology and life history
evolution. Authors and scientists of [175] determined the nucleotide sequence of ap-
proximately 120 megabase euchromatic portion of the Drosophila genome. They used
a whole-genome shotgun strategy supported by a high-quality bacterial artificial chro-
mosome physical map and extensive clone-based sequence. The genome encodes
approximately 13,600 genes. The dataset is publicly available at fly base database
http://flybase.org/. Appendix A shows the subset of 67 genes and 11 time points used
in this study to compare the efficiency of developed algorithm which is publicly avail-
able from the author’s website http://icube-bfo.unistra.fr/en/index.php/G1DBNpractice
[131].
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4.7 Conclusion
This chapter describes the datasets used in this thesis. All the data used are anonymised
and publicly available. Ethical approval for the research was granted on the 25th of
April 2013 before the commencement of the experiments. Datasets introduced and
explored are Ovarian Cancer Metabolite Dataset, Hypertension Gene Expression Pro-
file Dataset, Colorectal Cancer Protein Profiles Dataset, Time-Course Ovarian Cancer
dataset, The Dialogue on Reverse Engineering Assessment and Methods (DREAM)
Datasets, Escherichia coli Dataset and the Drosophila Melanogaster Dataset.
In summary the ovarian cancer metabolite data comprise of 592 metabolomic features
and a total of 72 observations made up of 37 cancer patients and 35 control volun-
teers. The hypertension dataset had a total of 22184 gene expression profiles and 159
observations made up of 77 hypertension and 82 control volunteers. The colorectal
cancer protein profiles had a total of 16331 spectral features and 112 observations
which comprise of 64 cancer patients and 48 control volunteers.
The time-course ovarian cancer dataset had a total of 12625 genes and two drug types:
the cisplatin and oxaliplatin. Out of these, 34 were selected for this study based on
three selection criteria described in section 4.5. Figure 4.1 shows the 34 ovarian can-
cer time-course genes genes modelled in this thesis. Reverse engineering datasets are
also presented. These include both simulated Dialogue on Reverse Engineering As-
sessment and Methods (DREAM) datasets and real Escherichia coli and Drosophila
Melanogaster datasets. All the datasets are publicly available and can be downloaded
from the authors’ references and url links provided.
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FIGURE 4.1: The 34 Ovarian cancer Genes Modelled in this study.
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Inferring Gene Regulatory Network
using a Two-Stage Approach
5.1 Introduction
Machine learning and other computational approaches have been applied in the pre-
diction of biomarkers. This chapter investigates ovarian cancer and hypertension
diseases. Algorithms such as Vector Machines (SVMs) [163] and Artificial Neural
Networks (ANN) [176] have been applied for automatic detection of ovarian cancer
biomarkers. Attempts have also been made in detecting potential biomarkers for hy-
pertension disease using algorithms such as C4.5 classification algorithm [177] and
Neuro-Fuzzy systems [178]. These methods demonstrate classification abilities of the
algorithms but are not do not consider possible temporal associations of the biomark-
ers. Efficient algorithms and techniques are needed to discover possible associa-
tions between potential biomarkers which may lead to possible discovery of treatment
drugs.
Figure 5.1 shows block diagram of the computational model representing the two-
stage approach adapted in this chapter. The model takes biomedical data as input and
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applies feature selection on the data to determine best performing features. In this
chapter, two case studies were analysed using their respective datasets. The first in-
volves ovarian cancer datasets and the second involves hypertension datasets. Feature
selection was carried out at the first stage using different methods, more specifically,
RFRFE, LASSO, and SVMRFE with linear and RBF kernels were used in the first
study involving ovarian cancer. In the second stage, two DBN models based G1DBN
and LASSO are applied on the best selected features, relationships inferred, compar-
ison made between the two methods and further exploration of inferred relationships
carried out from published literature.
In the second study involving hypertension, feature selection was carried out using
RFRFE, LASSO, and SVMRFE with linear, RBF and polynomial kernels in the first
stage and DBN applied in the second stage. The relationships between the features are
inferred and further exploration of inferred relationships carried out from published
literature. These case studies are discussed in section 5.3 and section 5.4 with their
corresponding results.
Input Biomedical Data Apply feature selection
Output best performing 
features
Apply DBN on best 
performing features
Infer relationships
Further explore inferred 
relationships from 
literature
FIGURE 5.1: Block diagram of Computational Model representing the Two-Stage
Bio-Network Discovery Approach adapted in this chapter
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5.2 Materials and Methods
In this section, a proposed two-stage bio-network discovery approach is applied in
two different case studies to prove its efficiency and robustness. The methods used
are described thus; at the first stage, different feature selection methods are applied
and the best performing features based on statistical significance are selected. At the
second stage, dynamic Bayesian network is used to infer the temporal relationships of
the best performing features.
5.2.1 Feature Selection using Random Forest Recursive Feature
Elimination
Random Forests are ensemble methods for feature classification where many trees are
generated using the idea of bagging proposed by [30]. Random Forest computes the
ensemble of trees
f (x) =
M
∑
m=1
1
M
f m(x) (5.1)
where fm is the mth tree and M represents different trees to be trained on different
subsets of the data. The feature best among a set of randomly selected features is the
feature to be split in each at each node. After a large number of trees have been gen-
erated, the features with the most popular class are selected and recursive elimination
of least important features is carried out based on decreased classification accuracy.
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5.2.2 Feature Selection using Least Absolute Shrinkage and Selec-
tion Operator (LASSO)
The lasso developed by Robert Tibshirani in 1996 [98] is a method of regression anal-
ysis that performs both regularization and variable selection. It improves prediction
performance and prevents over-fitting and for both linear and logistic regression and
performs both shrinkage and continuous subset selection via an L1-norm regularisa-
tion penalty. In the R programming environment, the LASSO is implemented by the
LiblineaR package [179].
5.3 Bio-Network Discovery Approach for Ovarian Can-
cer Metabolites
Different computational approaches have been used for ovarian cancer research such
as Support Vector Machine [163] and Artificial Neural Network [176]. These methods
only account for performance of selected features but do not consider relationships
among the features. Also, most biomarker discovery efforts for ovarian cancer focus
mainly on large biopolymers such as DNA and RNA but small metabolomic features
(below 1KDa) have received little research attention.
The aim of this study was to investigate temporal associations of ovarian cancer fea-
tures and discover potential time-dependent associations among feature subsets. The
experimental hypothesis is that the two-stage bio-network discovery approach involv-
ing feature selection and DBN modelling yields better biologically interpretable re-
sults with significant relationships than single stage. This means that at the first stage,
best performing features are selected and at the second stage, two DBN inference
methods will predict significant relationships with some relationships predicted in
common between the two DBN algorithms. To test the hypothesis, four different
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feature selection methods are used at the first stage to select be performing features.
These methods are Support Vector Machine Recursive Feature Elimination with lin-
ear kernel (SVMRFE-Linear), Support Vector Machine Recursive Feature Elimination
with radial kernel (SVMRFE-Radial), Least Absolute Shrinkage and Selection Opera-
tor (LASSO) and Random Forest Recursive Feature Elimination (RFRFE). Two DBN
algorithms are used at the second stage which are the LASSO DBN and the G1DBN
algorithms.
5.3.1 Results
The ovarian cancer dataset was obtained from [19] and consists of serum samples from
37 papillary serous ovarian cancer patients and 35 controls. Details about the dataset
and its description can be found in section 4.2. To determine the important features
to be included in the model, feature selection was carried out using four different
methods which are: Support Vector Machine Recursive Feature Elimination with lin-
ear kernel (SVMRFE-Linear), Support Vector Machine Recursive Feature Elimination
with radial kernel (SVMRFE-Radial), Least Absolute Shrinkage and Selection Opera-
tor (LASSO) and Random Forest Recursive Feature Elimination (RFRFE). For all four
algorithms, 12-fold cross validation was used. Performance criteria used to evaluate
the features include sensitivity, accuracy, specificity, type 1 error or the false positive
rate (FPR), and Matthews Correlation Coefficient (MCC).
Accuracy = (T P+T N)/(T P+T N+FP+FN) (5.2)
Sensitivity(recall) = T P/(T P+FN) (5.3)
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Precision = T P/(T P+FP) (5.4)
Speci f icity = T N/(T N+T P) (5.5)
Type1error(FPR) = FP/(FP+T N) (5.6)
MatthewsCorrelationCoe f f icient (MCC) =
(T P×T N)− (FP×FN)√
(T P+FP)× (T P+FN)× (T N+FP)× (T N+FN)
(5.7)
where TP, TN, FP and FN are the true positive, true negative, false positive and false
negative respectively.
The NaN values in the cross-validation tables stand for ’Not a Number’. This is how
the R programming language denotes occurrences in the computation of the perfor-
mance criteria where both the numerator and the denominator are both zeros. The
MCC is used as a measure of quality in binary classification that takes into account
true and false positive and negatives. It is the correlation coefficient between the ob-
served and predicted binary classification and returns a value between -1 and +1. A
coefficient of +1 indicates perfect prediction and -1 indicates total disagreement be-
tween prediction and observation.
Table 5.1 shows 12-fold cross-validation results of the 40 features selected by RFRFE.
The second fold had NaN values in both the Sensitivity and MCC values indicating
areas where the numerator and denominator of the equations 5.3 and 5.6 were both
zero. Worst performance was at the 11th fold where the accuracy was only 0.3333.
This was also reflected by the negative value of the MCC at that fold at -0.2500.
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Table 5.2 shows the 12-fold cross-validation Result of the 39 features selected by
LASSO. The algorithm performed well across multiple folds. Accuracy results across
folds 2 to 5, 7 and 10 to 12 were all 1.0000 or 100%. MCC values of 1 across them
also meant perfect prediction however results from other folds compensated for over-
fitting —one of the main advantages of using cross-validation. It also achieved high
sensitivity values of 1.0000 in 11 out of the 12 folds.
Table 5.3 and Table 5.4 show 12-Fold cross-validation results of the top 50 features
selected by the SVMRFE-Linear and SVMRFE-Radial. The first two folds of the
SVMRFE-Linear showing perfect predictions with sensitivity, specificity, accuracy
and MCC values at 1.0000 or 100%. The performance of the SVMRFE-Radial was
good with high accuracy value of 1 in the 6th and 7th fold. After the feature selection
using the various algorithms, 39 features were selected by the LASSO because they
had non-zero coefficients as other less important features are penalised to zero by the
LASSO algorithm.
Table 5.5 shows overall performances of all the feature selection algorithms. It showed
that the 39 features selected by the LASSO outperformed the others with an overall
accuracy of 0.9306. Appendix A.1 shows 8 of these 39 features. For the RFRFE, 40
best features were selected when 2000 trees were initialized for 1000 iterations. For
SVMRFE-Linear and SVMRFE-Radial, the performance of top 50 ranked features
were considered which had overall accuracies of 0.9167 and 0.6944 respectively.
The relationships of these best performing features were modelled using two dynamic
Bayesian Network methods and the resulting networks compared. The first method,
the G1DBN [1], [131] is based on vector autoregression while the second method is
based on LASSO [180]. The resulting G1DBN network showed the discovery of 65 di-
rected arcs which describe full order conditional dependencies. The range of the score
matrices was between 0.000 and 0.049 where lower values represent greater strength
and probability in the connection between the edges. Figure 5.2 shows DBN model
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of the Ovarian cancer metabolite showing the significant features and their temporal
relationships. A feedback loop between features 219 and 51 implies that the features
influence each other in time and may be of significant clinical importance. The choice
of colours in all the diagrams in this chapter are for distinction and clarity.
FIGURE 5.2: The Dynamic Bayesian Network Model of key Ovarian Cancer
Metabolite features showing time-course relationships across two time points. (It
is important to note that the purple spheres are features of the predicted parents at
time t-1 which inhibit the children shown in the white spheres at time t) [3]
The experiment was performed using the LASSO DBN algorithm. The inferred net-
work was compared with the network generated by the G1DBN model. The result
(shown in Figure 5.3) indicate that features 219 and 225, and features 219 and 543, had
consistent temporal relationships as inferred by the two algorithms. The mass/charge
(m/z) values of features 219, 225 and 543 were found from the original dataset to
be 478.3359, 443.3006 and 583.2555 respectively. The metabolites corresponding to
these values were found from the Metlin metabolite database [181]. Feature 225 is
parent to features 219 and 164 while feature 480 is parent to both feature 543 and 199.
Feature 62 is parent to features 225 and 29. The figure also shows that features 252,
556 and 198 have feature 358 as their parent and feature 62 has only feature 506 as its
parent. These inferred relationships may be of significant clinical importance and the
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consistent arcs inferred by two DBN algorithms should further be investigated in wet
laboratories.
FIGURE 5.3: Comparison of metabolic profiles of ovarian cancer obtained through
DBN models based on G1DBN and LASSO algorithms. (It is important to note that
the purple spheres are features of the predicted parents at time t-1 which inhibit the
children shown in the white spheres at time t and the yellow spheres are the common
features features in the two DBN prediction results)
Table 5.6 shows description of features 219, 225 and 543 and the corresponding
metabolites from the database. It shows that 309 metabolites correspond to feature
219, 733 metabolites correspond to feature 225 and 300 metabolites correspond to
feature 543. Both features 219 and 225 have negatively charged adduct ion while
feature 543 has positively charged adduct ion.
TABLE 5.6: Description of Key Ovarian Cancer Features
Feature
Subsets
Mode Adduct ion m/z(Da) Number of
Metabolites
V219 Negative [M−H]− 478.3359 309
V225 Negative [M−H]− 443.3006 733
V543 Positive [M+H]+ 583.2555 300
Table 5.7 describes some of the metabolites corresponding to feature 543. It fur-
ther shows two main isomers C28H34N6O8 and C28H38N6O8 with 60 repeats while
C29H42N8O5 had 48 repeats. The corresponding change in parts per million of these
repeats are 7, 74 and 136 respectively. Stratified analysis showed the isomers were
amino acid sequences that potentially make up key ovarian cancer metabolites [181].
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TABLE 5.7: Description of Metabolites for Feature 543
Change
in ppm
Number of Repeats Formula
0 1 C33H34N4O6
7 60 C28H34N6O8
17 24 C24H38N8O7S
24 24 C29H38N6O5S
29 2 C28H38O13
38 24 C28H34N6O6S
39 7 C35H34O8
42 1 C35H38N2O6
46 1 C30H34N2O10
54 24 C29H38N6O7
55 1 C26H47O12P
61 1 C34H38N4O5
73 1 C18H38N4O15S
74 60 C28H38N8O6
86 12 C22H38N12O7
91 1 C27H34O14
101 1 C34H30O9
121 1 C24H46O8
127 2 C30H30O12
136 48 C29H42N8O5
153 4 C26H30O15
5.4 Hypertension Diagnosis via Temporal inference of
Gene Expression Profiles
The proposed two-stage approach was further applied to gene expression profiles of
high quality hypertension datasets in order to determine temporal associations among
features which may be important in the diagnosis of the disease.
Hypertension or high blood pressure is a common disease with one in three adults in
the United States of America affected [182]. It is defined as the diastolic or systolic
blood pressure greater than or equal to 90mmhg and 140mmhg respectively. It is also
considered to be a silent killer and a major risk factor for developing heart disease and
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as many as seven million people in the UK currently are living with undiagnosed high
blood pressure [183].
Various computational approached had been applied in trying to effectively diagnose
the disease such as improved C4.5 classification algorithm [177] based on the use of
maximal information for the identification of important features. Other methods such
as fuzzy systems and neuro-fuzzy systems [178] have also been applied in an attempt
to better diagnose the disease.
To overcome the inability of these methods to incorporate and model the temporal
relationships among key hypertension features, the proposed two-stage bio-network
discovery approach was applied. In this study, five feature selection algorithms were
applied at the first stage. These are Random Forest Recursive Feature Elimination
(RFRFE), Least Absolute Selection and Shrinkage Operator (LASSO), Support Vector
Machine Recursive Feature Elimination with Linear Kernel (SVMRFE-Linear), Sup-
port Vector Machine Recursive Feature Elimination with Polynomial Kernel (SVMRFE-
Poly) and Support Vector Machine Recursive Feature Elimination with Radial Kernel
(SVMRFE-Radial). At the second stage, dynamic Bayesian network defining a vector
autoregression of order 1 VAR(1) was used to infer the relationships.
5.4.1 Results
The dataset was obtained from [20] and comprise of gene expression profile of male
young-onset hypertension of ages 20-50 years. Section 4.3 explains the details of the
data. To determine which features to model their relationships, feature selection using
the five different algorithms was carried out. This ensured features with best class
discriminatory information were selected. For all selection algorithms, 10-fold cross
validation was performed and average performance measures taken. Performance cri-
teria used include accuracy, sensitivity, specificity, balanced classification rate (BCR),
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Type 1 error or False Positive Rate (FPR), F1-score and Matthews Correlation Coeffi-
cient (MCC).
F1−Score = 2× ((Precision∗Recall)/(Precision+Recall)) (5.8)
Balanced Classi f ication Rate (BCR) =
1/2× (T P/(T P+FN))+(T N/(T N+FP))
(5.9)
where F1-Score means the harmonic mean between the precision (the positive pre-
dicted value) and the recall (sensitivity) and the Balanced Classification Rate indicates
a balanced measure between the values of the sensitivity and the True Negative Rate
(the proportion of actual negatives which are predicted negative).
Table 5.8 shows 10-Fold Cross-Validation result of the 320 features selected by RFRFE.
It showed highest accuracy value of 0.7333 at folds 2, 5 and 9. Fold 1 had the low-
est BCR of 0.4722, low specificity of 0.1667 and a negative MCC value of 0.0680.
Table 5.9, Table 5.10 and Table 5.11 show the performance of the SVM across the lin-
ear, polynomial and radial basis function kernels respectively. It indicates very good
performance by the linear kernel which outperformed both the radial and the polyno-
mial kernels. The performance of the linear kernel showed perfect predictions across
folds 1 to 3 and 5 to 9. However, the performance of the 101 features selected by
LASSO because they are the non-zero coefficients exceeded the good performance of
the SVMRFE with linear kernel. It showed perfect performance in 9 out of the 10
folds and had overall best result.
Table 5.13 shows the number of selected features by the algorithms and their per-
formance measures. For the SVMRFE methods, the cost of constraint parameter C
was varied between between 1 and 10 and C = 1 with best accuracy was used. Mod-
erate polynomial of degree 3 was used for the SVMRFE-Poly with a gamma value
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of 0.0000451 which corresponds to the inverse of the dataset’s dimension. With the
SVMRFE-Linear, the SVMRFE-Poly and SVMRFE Radial, 137, 45 and 49 best fea-
tures were selected respectively. Using the RFRFE, 1000, 2000 and 5000 forests were
randomly initialised and the experiment conducted for 200, 500 and 1000 iterations.
320 top features were selected by the random forest method based on backward elim-
ination. The experiment results showed that 101 features which were selected by the
LASSO had best performance followed by the 137 features selected by the SVMRFE
Linear. Both had 99% accuracy however the features selected by the LASSO had
higher specificity and lower false positive rate than those selected by the SVMRFE
Linear.
For modelling the temporal associations of selected genes, the 101 and 137 features
selected by the LASSO and the SVMRFE Linear were considered as they both had
much higher accuracies of 99% while the other features were disregarded. The DBN
inference was performed using the G1DBN algorithm [131] based on first order con-
ditional dependencies and vector autoregression. There are two main steps involved
in the inference algorithm. In step 1, a first order dependency score matrix (S1) is
inferred which contains the score of each edge of the DBN. The inference is done by
defining an edge selection threshold α1. At step 2, edge selection threshold α1 and
score matrix S1 are used to infer the score of the edges of a DBN defining full order
conditional dependencies between successive variables. The smallest score refers to
the most significant edge. To obtain optimised DBN, threshold values of α1 and α2
are found to be 0.5 and 0.05 respectively which are used to prune the edges of the
DBN [4].
The result of the inferred network showed the discovery of 351 directed arcs defining
full order conditional dependencies for the 101 features selected by the LASSO and
460 directed arcs for the 137 features selected by the SVMRFE Linear.
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FIGURE 5.4: This shows the DBN model of Hypertension genes showing temporal
relationships 13 strongest edges and their connecting genes. It is worth noting that the
predicted parents at time t-1 are shown by the green ellipses. These features inhibit
the children shown in the pink circles at time t [4]
Figure 5.4 shows the DBN inference of 13 strongest edges and their connecting fea-
tures selected by the LASSO. These have most significant edges with a score 0.000.
The meaning of the genes with symbols and genes represented only by their UniGene
IDs (starting with Hs.) were verified from Gene Expression Omnibus [184]. The fig-
ure shows that the human transcribed locus gene (Hs.649978) and cell regulation may
inhibit the expression of focusyltransferase-6 (FUT6).
Figure 5.5 shows DBN inference of the 15 genes with the most significant inferred
edges having scores of 0.0000. It shows that both NR2E3 nuclear receptor sub-family
2 and CGB2 Chromatin Gonadotrophin might play inhibitory role against ABCG1
ATP-binding cassette sub-family G. Further stratified analysis showed that 22 genes
were picked up in common by both the LASSO and the SVMRFE linear feature se-
lection methods.
Figure 5.6 shows temporal associations of 11 genes that have six most significant
edges of lowest scores. The result showed that CRABP2 cellular retinoic acid binding
protein 2 may play an inhibitory role and highly associated with DKK3 dickkopf WNT
signaling pathway inhibitor 3.
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FIGURE 5.5: DBN Model of Hypertension genes showing temporal relationship
among top genes selected by SVM-RFE Linear method. It is worth noting that the
predicted parents at time t-1 are shown by the green ellipses. These features inhibit
the children shown in the pink circles at time t
FIGURE 5.6: DBN of Hypertension genes showing temporal relationship among
key features selected by both the LASSO and SVM-RFE Linear methods (the green
spheres are features of predicted parents at time t-1 which inhibit features in red cir-
cles (children) at time t.
Four key genes were selected in common by the three SVMRFE methods and the
LASSO as shown in Table 5.14. These are Human transcribed locus with UniGene ID
Hs.666652, ribonuclease RNase A family 3 (eosinophil cationic protein) (RNASE3),
Human protein-coding gene (PLXNA2) and CDNA FLJ36210 fis, clone THYMU2000155
with UniGene ID Hs.656129. These genes selected in common across different selec-
tion methods may be highly associated with hypertension and should further be inves-
tigated. Appendix A.2 shows description of the 101 hypertension features selected by
the LASSO.
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TABLE 5.14: Key Hypertension Genes Commonly Selected by LASSO and SVM-
RFE Methods
UniGene
ID
Symbol Name
Hs.666652 null Human transcribed locus
Hs.73839 RNASE3 ribonuclease; RNase A family; 3
(eosinophil cationic protein)
Hs.497626 PLXNA2 Human protein-coding gene
PLXNA2
Hs.656129 null CDNA FLJ36210 fis, clone
THYMU2000155
5.5 Conclusion
In this study, a two-stage bio-network discovery approach was developed and applied
in two different real world case studies. The framework allowed for modelling the rela-
tionships across high quality selected features using a dynamic Bayesian network as an
inference algorithm. The experimental hypothesis is that two-stage bio-network dis-
covery approach involving feature selection and Dynamic Bayesian Network (DBN)
modelling yields better biologically interpretable results with significant relationships
than single stage. This means that at the first stage, best performing features are se-
lected and at the second stage, DBN inference methods will predict significant rela-
tionships. To test the hypothesis, four different feature selection methods are used at
the first stage to select be performing features. Two DBN methods are used in the
second stage and it was hypothesised that there would be similarities in the results of
the two DBN methods with some relationships predicted in common between the two
DBN algorithms.
Feature selection was carried out using 12-fold cross-validation. The cross-validation
tables show how the features performed across each fold by the different feature selec-
tion algorithms. Mean cross-validation results showed that the 39 features selected by
the least absolute shrinkage and selection operator (LASSO) had the highest accuracy
of 93.06%. The performance of these features was better than other the performance of
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the features selected by other algorithms which are the random forest recursive feature
elimination and the support vector machine recursive feature elimination with linear
and radial basis function kernels. The 39 features were selected by the (LASSO) be-
cause they had non-zero coefficients. 7 of these selected features are shown in section
1 of Appendix A.
Their performance were assess using criteria which include accuracy, sensitivity, speci-
ficity and Matthews Correlation Coefficient. Feature selection algorithms used in-
clude: Support Vector Machine Recursive Feature Elimination with linear kernel,
Support Vector Machine Recursive Feature Elimination with radial kernel (SVMRFE-
Radial), Least Absolute Shrinkage and Selection Operator (LASSO) and Random For-
est Recursive Feature Elimination (RFRFE). 39 features were selected by the LASSO
because they had non-zero coefficients as other less important features are penalised
to zero by the LASSO algorithm. These had best overall performance when compare
to the features selected by other methods.
The relationships of these best performing features were modelled using two dynamic
Bayesian Network methods and the resulting networks compared. These relationships
could reveal novel pathways in the metastasis of the disease and aid in further diagno-
sis and drug discovery. The study also shows comprehensive comparison of two DBN
inference algorithms, the G1DBN and the LASSO, and how similar result obtained by
the two may be helpful in insilico modelling of biological pathways.
The second case study used the proposed two-stage bio-network discovery approach to
analyse temporal associations of Hypertension gene expression profile dataset. Meth-
ods applied include Support Vector Machine Recursive Feature Elimination using
the linear, polynomial and radial basis function kernels of the Support Vector Ma-
chine, Random Forest Recursive Feature Elimination and Least Absolute Selection
and Shrinkage Operator (LASSO).
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10-fold cross-validation tables presented show performances of the selected features.
The tables indicate very good performance by the linear kernel which outperformed
both the radial and the polynomial kernels. The performance of the linear kernel
showed perfect predictions across folds 1 to 3 and 5 to 9. However, the performance
of the 101 features selected by LASSO because they are the non-zero coefficients
exceeded the good performance of the SVMRFE with linear kernel. It showed perfect
performance in 9 out of the 10 folds and had overall best result.
The findings of this chapter appear to suggest that further investigation into the features
which showed self loops, and those whose relationships showed the same results using
the two DBN modelling methods are required. One major challenge of the two-stage
approach approach explored in this chapter seems to be robust and automatic selection
of best set of parameters for the feature selection algorithms to be applied at the first
stage instead of performing multiple runs of the experiment using different manually
selected parameter values. Therefore, chapter 6 aims to address this problem.
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Chapter 6
Improved prediction of Gene
Regulatory Networks via Optimised
Two-Stage Approach for Cancer
Diagnosis
6.1 Introduction
In chapter 5, a two-stage bio-network discovery approach was proposed and devel-
oped. The efficiency of the proposed method was tested in two different real world
case studies. However, parameter values for the feature selection algorithms at the
first stage were manually fixed which required many runs of the experiment to achieve
good results based on values that yielded best accuracy.
This chapter introduces the development of a hybrid approach by adapting parameter
optimisation algorithms. Instead of trying out every possible combination of param-
eters using popular grid search method, combination of parameters that yield best
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results are evolved. This is more efficient and saves time when a wide range of pa-
rameter combinations are needed. This was successfully implemented for the study
of colorectal cancer metastasis and results showed improved performance when com-
pared with non-optimised approaches. The hypothesis is that optimised embedded
methods of feature selection are better than non-optimised filter methods of feature
selection in colorectal cancer diagnosis. Filter methods are selection methods that ig-
nore interaction with the classification algorithm. Embedded methods are selection
methods that interact with classification algorithm. This chapter also investigates bi-
ological interpretation of best colorectal protein features using two-stage bio-network
discovery approach developed in chapter 5. Introduction and motivation for the exper-
iments done in this chapter are described thus.
Colorectal cancer is a deadly disease and one of the most common cancer diagnosed in
the UK. It is also known as bowel cancer or rectal cancer depending on where it starts.
With around 40,000 new cases [185], and is estimated to cause 49,190 deaths in 2016
[186]. The diagnosis of the disease was traditionally being done using microscopic
analysis of histopathological cancer samples. This manual process has necessitated
the need for automatic detection and diagnosis using computational means. There are
five main detection methods studied [187]. These are object-oriented texture analysis,
serum analysis, texture analysis, gene analysis and spectral analysis. Serum analy-
sis in line with recent computational advances in the post-genome era, has received
significant attention.
Various methods for computationally diagnosis the disease were proposed. Hong et al
2011 [188] proposed the method based on empirical mode decomposition (EMD) with
least square support vector machine (LS-SVM). This involved using EMD for feature
selection and LS-SVM for classification of selected features and computation of per-
formance measures using accuracy metric. A feed-forward neural network model was
proposed by [189] involved the use of two feature selection methods one after an-
other. The selection methods used are chi-squared method and minimum redundancy
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maximum relevance (MRMR) method. A method based on discrete wavelength trans-
formation was also proposed by [169] in which features are selected as wavelength
coefficients and classification carried out using support vector machine.
These methods have a number of inadequacies. First, they implement filter method of
feature selection which ignore interaction with the classifier and has been known to
result in poorer features being selected [190]. Secondly, parameter optimization for
feature selection or classification algorithms was not implemented which may have
improved overall efficiency and accuracy. Finally, the methods used do not consider
interaction between features. This is important as various stages of cancer growth and
metastasis are linked to the various stages of molecular interactions of key features.
Capturing these interactions using the best optimised way is therefore important in the
diagnosis of the disease and further discovery of significant pathways that may be of
clinical importance.
This study aims to address these aforementioned problems using an improved two-
stage bio-network discovery approach via parameter optimisation. Two major evolu-
tionary algorithms are adopted in this study. These are the Differential Evolution (DE)
and Particle Swarm Optimisation (PSO) algorithms. This study extends previous opti-
mised two-stage studies in which only DE was applied using for liver cancer diagnosis
[16] and only PSO was applied for colorectal cancer diagnosis [191].
Figure 6.1 shows overall block diagram of the computational model adapted in this
chapter. It represents the optimised approach implemented specifically on the colon
cancer dataset which describes steps taken to generate and analyse the results. At the
first stage it takes cancer data as input and the optimization algorithm generates initial
population of optimisation parameters C and gamma for the SVM. The parameters are
varied by the optimisation algorithm until lowest error where the error is the objective
function to be minimised. Within the loop, recursive feature elimination is carried out
to select best features using best parameters. Features with smallest ranking criterion,
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in this case the weight magnitude of the SVM, are identified, removed and the best
performing features returned as output of the first stage.
At the second stage DBN is then applied on the selected best features, relationships
inferred and further exploration of inferred relationships carried out from published
literature. The rest of the chapter describes the details of how this model was adapted
with corresponding results. It is worth noting that the outcome of this chapter appeared
in IET Systems Biology Journal in December 2015 [15].
Input Cancer Data
Generate initial 
population of 
optimization 
parameters (C and 
gamma) 
Train SVM with features
Vary parameters until 
lowest error
With best parameters 
select features
Identify and remove 
features with smallest 
ranking criterion
Return remaining best 
performing features
Apply DBN of the 
best features
Infer 
relationships
Further explore 
inferred 
relationships 
from literature
FIGURE 6.1: Block diagram showing Computational Model of the Optimized Two-
Stage Approach adapted in this chapter
6.2 Materials and Methods
The colorectal cancer dataset was first presented in [21]. 66 colorectal cancer patients
and 50 healthy volunteers were involved in the study whose serum samples were ob-
tained a day before surgery. Further low level analysis which include recalibration,
top-hat base line correction and outlier detection were performed on the dataset [169].
Detailed description of the dataset are in section 4.4. The aim of the experiment is
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to select best features relevant to the disease and model relationships among features
using dynamic Bayesian network via the proposed two-stage approach.
6.2.0.1 Application of the Proposed two-stage approach
In this study, the proposed two stage approach is improved upon through parameter
optimisation. It combines optimised SVMRFE feature elimination whose parameters
have been fine-tuned using two evolutionary algorithms namely particle swarm op-
timisation (PSO) and differential evolution (DE). Evolutionary algorithms have been
chosen and preferred for the feature selection over grid search due to their exhaustive
search for candidate solutions and better overall performance [192] [193]. This will
aid the selection of high quality potential biomarkers and also make for better under-
standing the tumour metastasis which may provide new insight for discovery of new
drugs to clinicians and wet-lab scientists.
6.2.0.2 First Stage —Parameter Optimisation for SVMRFE
In the first stage, the C and γ parameters of SVMRFE feature selection algorithm are
fine-tuned for best selection performance using the Average Test Error (ATE). The
ATE is defined by
Accuracy = (T P+T N)/(T P+T N+FP+FN) (6.1)
AT E = 1−Accuracy (6.2)
where TP, TN, FP and FN are the true positive, true negative, false positive and false
negative respectively. The SVMRFE algorithm uses backward elimination based on
the weight magnitude of the classifier and performs more accurate selection because
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the algorithm interacts with the classifier [28]. This embedded method of feature
selection is preferred over the filter method used in previous studies because they have
been known to yield better selection results [190]. The SVMRFE procedure involves
• Training the classifier (i.e. optimising the weights wi for all features.
• Calculating the ranking criterion.
• Removing the features with the smallest ranking criterion.
Cross-validation was performed using the Leave-one-out cross-validation (LOOCV).
The SVMRFE uses the optimised parameters for accurate selection of the features.
Algorithm 6.1 describes the optimisation approach used in this study.
Algorithm 6.1: SVMRFE Optimisation Algorithm
1 Rank features with SVMRFE.
2 Split data with two-thirds for training and one third for testing.
3 Generate an initial population of SVM parameters using PSO and DE Algorithms.
4 With training data, evaluate the ATE as the optimisation objective of each solution
using LOOCV.
5 Obtain generalisation error at each generation.
6 Continue until the lowest possible error or no improvement is achieved.
7 Choose parameters with best average performance.
8 Obtain generalisation performance on the test set using optimised parameters.
9 Choose optimum number of features based on number of features with lowest test
error.
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The algorithm is a slightly modified version of earlier proposed methods [194], [195]
due to the implementation of population-based algorithms which are used on the train-
ing data to fine-tune the parameters of the SVMRFE. Feature selection using the op-
timised parameters is then carried out using LOOCV. The LOOCV was chosen over
the k-fold cross-validation because of the small sample size of 112.
6.2.0.3 Results from the first Stage
Three main kinds of SVM kernels, the linear, the polynomial and the radial basis func-
tion (RBF), were considered for feature selection using recursive feature elimination.
The five DE algorithm variants and the PSO algorithm were used and implementa-
tion was done using the R Language for Statistical Computing [17]. The aim was
minimisation of the ATE objective function. Each algorithm was executed for 40,000
fitness evaluations over 30 independent runs. Manually tuned parameter of the DE
were: scaling factor F=0.8 and crossover rate CR=0.9. For the PSO, c1=0.4, c2=0.8,
wmax=1.0, wmin=0.1.
The optimisation algorithms were applied on the three different SVMRFE methods.
Table 6.1 shows best cross-validation performance results and the optimum values of
SVM C and γ parameters. It shows that the PSO performance with the linear kernel
of the SVM had the lowest cross validation error of 0.038 followed by the perfor-
mance of the DE/rand/1 algorithm using the RBF kernel. The DE/rand-to-best/1 had
the worst performance on average when compared with the other algorithms. Its per-
formance on the polynomial and RBF kernels were 0.378 and 0.392 respectively with
the performance on the linear kernel being 0.486. DE/best/1 had good performance on
RBF kernel at 0.169 which was slightly better then the performance of DE/best/2 on
the RBF kernel at 0.189. Though the PSO achieved better results than the DE and its
variants in this study, the run time of DE was faster than the PSO however, run time
is only significant if the resulting solution is of good quality. In this study, the PSO
97
Chapter 6 Improved prediction of Gene Regulatory Networks via Optimised
Two-Stage Approach for Cancer Diagnosis
achieved better and more accurate result than the DE. For this reason the PSO and an-
other variant of PSO called the Comprehensive Learning Particle Swarm Optimisation
(CLPSO) were subsequently used in chapter 7 of this thesis.
The variation in performance results of the various SVM kernels was due to the dif-
ferent values of C and γ parameters that were selected after 40,000 fitness evaluations.
The γ parameter defines how far the influence of a single training example reaches the
decision boundary. Low values of γ means a far reach while higher values of γ indicate
a close reach to the decision boundary. The C cost of constraint parameter controls the
trade-off between smooth decision boundary and classifying training points correctly.
Hence for both linear and nonlinear kernels, the optimum values reached at the end of
each iteration of the optimisation algorithms determine the final performance of the
SVM kernel.
Table 6.2 shows the values of the optimised parameters. From the table, different algo-
rithms performed differently on the kernels. The PSO and DE/rand/1 achieved lowest
test error on the SVM linear and SVM radial kernels respectively. The performance
of the DE/rand/2 on the SVM radial kernel closely matches the previous result with a
low test error of 0.036. The DE/rand-to-best/1 has overall worst performance with the
performance on the linear kernel at 0.243 while the polynomial and RBF kernels were
0.162 and 0.108 respectively.
The area under the curve (AUC) of the receiver operating characteristics (ROC) gives a
clearer picture of the performances of the classifiers where a higher value of AUC will
indicate better performance of the classifier. The accuracy metric favours the dominant
class in feature selection tasks. This means that accuracy values may not always vary
with the values of the AUC and high values of the AUC such as 1 (or 100%) does not
necessarily indicate absence of misclassification errors which may still persist in the
computation depending on the dominant class. The curves of the ROC the values of
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AUC show trade-offs between false positive rate and true positive rate values which
has been shown to be a better measure than accuracy [196].
From Table 6.2, the AUC value of the linear SVM as optimised by the PSO has a value
of 1. This means that it has more probability of better classification performance than
the other SVM classifiers. This may have been due to the high-dimension of the
dataset and small sample size. The radial kernel however had values of 0.993 when
parameters were optimised by DE/rand/2 and 0.988 when optimised by DE/rand/1,
DE/best/1 and DE/best/2 respectively.
TABLE 6.1: Cross- Validation results showing best performance with lowest error
and best SVM parameters
Optimization
Algorithm
SVM-
kernel
C γ Cross-
Validation
Error
PSO Linear 3.0924 — 0.038
Poly 281.334 0.2321 0.319
RBF 635.783 0.0002 0.125
DE/rand/1 Linear 8.6754 — 0.262
Poly 75.6499 0.1632 0.165
RBF 332.3389 0.0003 0.042
DE/best/1 Linear 67.9443 — 0.219
Poly 175.6499 0.1642 0.349
RBF 7992.5412 0.1566 0.169
DE/rand-to-
best/1
Linear 463.9081 — 0.486
Poly 862.0241 0.3321 0.378
RBF 4.9882 0.0451 0.392
DE/best/2 Linear 51.5332 — 0.295
Poly 966.9021 0.0034 0.267
RBF 1214.9883 0.0043 0.189
DE/rand/2 Linear 20.6754 — 0.196
Poly 289.8233 0.0009 0.298
RBF 1279.3341 0.0022 0.049
The ROC curves indicating the performances of the optimisation algorithms on the
SVM methods is shown in Figure 6.2. It showed the varying performances of the
algorithms on the SVM kernels and on the top left, the linear SVM as optimised by
the PSO had the highest ROC value of 1. The number of features selected by the
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SVMRFE methods using the optimised parameter values are shown in Table 6.3. The
PSO optimised SVMRFE linear and the DE/rand/1 optimised SVMRFE radial both
had 18 and 25 feature selected respectively. They both achieved high accuracies of
0.973 each and sensitivity values of 1 and 0.952 respectively. 12 of the 18 Colorec-
tal Cancer Spectral Profiles selected by PSO SVMRFE Linear are show in Appendix
A.3. There were also 62 features selected by the SVMRFE radial kernel as optimised
by DE/rand/2 which achieved a total accuracy of 0.964 and a sensitivity of 1. Other
performance values computed are balanced classification rate (BCR), F1-score, speci-
ficity and Matthew’s Correlation Coefficient (MCC). The corresponding equations are
shown:
F1−Score = 2× ((Precision∗Recall)/(Precision+Recall)) (6.3)
TABLE 6.2: Optimised parameters of the PSO and DE algorithms for the three ker-
nels of the SVMRFE showing values of ATE, accuracy and AUC
Optimization
Algorithm
SVM-
kernel
C γ Testing
Error
Acc. AUC
PSO Linear 3.0924 — 0.027 0.973 1.000
Poly 281.334 0.2321 0.162 0.878 0.935
RBF 635.783 0.0002 0.081 0.919 0.935
DE/rand/1 Linear 8.6754 — 0.189 0.811 0.903
Poly 75.6499 0.1632 0.054 0.946 0.93
RBF 332.3389 0.0003 0.027 0.973 0.988
DE/best/1 Linear 67.9443 — 0.135 0.865 0.962
Poly 175.6499 0.1642 0.162 0.838 0.938
RBF 7992.5412 0.1566 0.081 0.919 0.988
DE/rand-to-
best/1
Linear 463.9081 — 0.243 0.957 0.835
Poly 862.0241 0.3321 0.162 0.838 0.955
RBF 4.9882 0.0451 0.108 0.892 0.962
DE/best/2 Linear 51.5332 — 0.108 0.892 0.942
Poly 966.9021 0.0034 0.054 0.946 0.93
RBF 1214.9883 0.0043 0.054 0.946 0.988
DE/rand/2 Linear 20.6754 — 0.054 0.946 0.971
Poly 289.8233 0.0009 0.162 0.838 0.9
RBF 1279.3341 0.0022 0.036 0.964 0.993
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FIGURE 6.2: ROC curves showing the performance of the SVM kernels as optimised
by the six optimisation algorithms.
Precision = T P/(T P+FP) (6.4)
Recall(Sensitivity) = T P/(T P+FN) (6.5)
Speci f icity = T N/(T N+T P) (6.6)
Balanced Classi f ication Rate (BCR) =
1/2× (T P/(T P+FN))+(T N/(T N+FP))
(6.7)
MatthewsCorrelationCoe f f icient (MCC) =
(T P×T N)− (FP×FN)√
(T P+FP)× (T P+FN)× (T N+FP)× (T N+FN)
(6.8)
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FIGURE 6.3: Overall performance of other performance measures for all SVM meth-
ods with all the optimisation algorithms. DE/r-to-b/1 is the DE/rand-to-best/1 algo-
rithm.
where TP is the True Positive, FP is the False Positive, TN is the True Negative and
FN is the False Negative. The F1-score is the harmonic mean of the precision and
recall. The recall (sensitivity) is the number of true positives divided by the sum of
true positive and false negatives and the precision or positive predicted value is the
number of true positives divided by the sum of the true positives and false positives
[142]
The 18 features selected by the PSO optimised Linear SVM and the 25 features se-
lected by the DE/rand/1 optimised SVM radial kernel chosen for the DBN modelling
and inference in the second stage because of their high accuracy and F1-score values.
Figure 6.3 shows the bar plot of the computed performance measures which indicates
how the various optimisation algorithms performed on the dataset using different SVM
kernels. From the figure it can be inferred that the PSO performed best overall on the
linear kernel of the SVM while DE/rand/1 performed best on the radial kernel. The
performance of the linear kernel over the radial was surprising in this study as the
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radial kernel appears to used by most researchers however the this study also shows
that datasets vary for different experiments and that various kernels of the SVM should
be implemented when working on classification and feature selection tasks.
6.2.1 Results from Second Stage
With the features selected from the first stage, the second stage seeks to predict the
relationship between the features by inferring the structure of a DBN. The DBN was
inferred using the G1DBN algorithm [1] [131]. The modelling was based on the es-
tablished assumption of this study that each patient (observation) represents a time
point, which had been successfully implemented for diagnosis involving hypertension
and cancer studies [3] [4]. The 64 cancer observations from the dataset and the se-
lected features were used to infer which features at a previous time point X it−1 predicts
a target feature at X jt at the current time point.
The G1DBN algorithm is implemented in two main steps. The first step involves the
inference of a first-order dependence score matrix S1 based on the Markov assumption
that only the past variable which is one step back in time X it−1 predicts the variable
at the current time point X jt by measuring the conditional dependence between the
variables and any other variable Xkt−1. Robust statistical estimators such as the M-
estimators which include the Least Square (LS) estimator, Huber estimator and Tukey
estimator are usually used [130]. In this study, the LS estimator was used to in the
algorithm for inference of the relationships.
The algorithm works by computing for each k 6= j, the estimates ai j|k according to
the LS estimator and the p-value pi j|k is derived from the standard significance test.
A score matrix S1(i, j) is assigned to each potential edge X it−1 → X jt under the null
assumption that H i jk0 : ai j|k = 0, which is equal to the maximum Maxk 6= j(pi j|k)
computed p-values [1][130]. The most significant edge is represented by the smallest
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score which contains the inferred directed acyclic graph DAG G(1) whose edge have a
score below a chosen threshold α1. The G1DBN algorithm [1] is shown in Figure 6.4.
At the second step of the algorithm, a reduction in the search space of the inferred
network is carried out. This is done using the score matrix S1 obtained from step 1
and an edge selection threshold α2 (from step 2) to infer the score S2 of each edge
FIGURE 6.4: The G1DBN Algorithm
FIGURE 6.5: DBN model of the 18 features selected by the PSO-SVM-linear model
showing significant interactions among high score edges. Red nodes are of key inter-
est in this study.
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of a DBN that describes full-order dependencies between successive variables. The
algorithm is implemented in the G1DBN R programming language package [131] and
is used to infer the temporal relationships of the top 18 and 25 features. The results of
the inference with the algorithm may reveal novel pathways and relationships that have
not been previously explored or studied. The inferred network shows arcs from parents
to children with parents having high probability of inhibiting the corresponding gene
depending on the strength of the arc. The network structure inferred shows predicted
features at a previous time point t − 1 pointing to a target feature at time t. More
laboratory experiments which are needed for further clinical validation are beyond the
scope of this thesis.
Figure 6.5 shows the DBN model of the 18 best features selected by the PSO lin-
ear. The network diagram made up of 36 edges was visualised using Cytoscape
[18]. The inferred network shows that Alpha-2-HS-glycoprotein FETUA_HUMAN and
tachykinin, precursor 1 TKN1_HUMAN, may be dominant hub genes. Also Alpha-2-
HS-glycoprotein may be associated with Prorelaxin H1 REL1-HUMAN and Fibrinogen
alpha chain FIBA_HUMAN. Research by [197] show that Alpha-2-HS-glycoprotein is a
key biomarker which is believed to be associated with colorectal cancer and may also
be aassocaited with early stages of breast cancer [198].
Studies by [199] also showed that Fibrinogen alpha chain may be a prognostic marker
for colorectal cancer while tachykinin, precursor was found to be to have a sensitivity
of 99% for non small cell lung cancer [200]. The result of this analysis also shows
that Prorelaxin H1 REL1_HUMAN which in breast cancer research, controls that the in-
vitro invasive potential [201] may be associated in time with Gonadotropin-releasing
hormone II GON2_HUMAN which is known for being a key breast cancer biomarker
[202] and in the prognosis of ovarian cancer [203], [204].
The inferred DBN of 24 out of the 25 features selected by DE/rand/1 optimised SVM-
RFE radial kernel is shown in figure 6.5. These are the features that also had 97.3%
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accuracy represented by 55 significant edges with one node pruned. Analysis revealed
that the minor histocompatibility protein HMSD variant form HMSDV_HUMAN was a
dominant hub in the network and had significant interactions with other features in-
cluding with Pro-opiomelanocortin COLI_HUMAN which is a biomarker for small cell
lung cancer [205]. Table 6.4 showed four features in common between the 18 and 25
selected features. Research shows that Proprotein convertase subtilisin/kexin type 1 is
possibly associated with liver cancer [206] while Histatin-3 was found to be associated
with oral candidiasis [207].
Molecular weight also plays a key role in colon cancer research as heavy kilo Dalton
(kDa) protein biomarkers have been known to be associated with the disease. This
includes metastasis associated in colon cancer-1 MACC1_HUMAN which has a molecu-
lar weight of 97kDa verified from UniProt [208] and was found to be highly associ-
ated with breast cancer and liver cancer (hepatocellular carcinoma) respectively [209],
[210]. The E2F transcription factor 4 E2F4_HUMAN, another heavy protein biomarker
FIGURE 6.6: DBN model of 24 of the 25 features selected by the DE/rand/1 SVM-
RFE with radial kernel showing key interactions among high score edges with one
edge pruned. Red nodes are of key interest in this study.
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with a molecular weight of 44 kDa, have also been linked to the metastasis of col-
orectal cancer [211].
6.3 Conclusion
This study aimed at selecting high quality colorectal cancer features using a more
robust optimised two-stage approach. The hypothesis for the experiment states that
optimised embedded methods of feature selection are better than non-optimised fil-
ter methods of feature selection in colorectal cancer diagnosis. The chapter also in-
vestigates biological interpretation of best colorectal protein features using two-stage
bio-network discovery approach developed in chapter 5.
Six optimisation algorithms were adapted for parameter optimisation of the SVMRFE
feature selection method which from literature is more accurate than other filter ap-
proaches used in previous studies. Three main kinds of SVM kernels, the linear, the
polynomial and the radial basis function (RBF), were considered for feature selection
using recursive feature elimination. The five DE algorithm variants and the PSO al-
gorithm were used and implementation was done using the R Language for Statistical
Computing.
The optimization algorithms were applied on the three different SVMRFE methods
following the steps described in the presented pseudo-code. Cross-validation results
show that the PSO’s performance with the linear kernel of the SVM had the lowest
cross validation error of 0.038 followed by the performance of the DE/rand/1 algo-
rithm using the RBF kernel. The DE/rand-to-best/1 had the worst performance on
average when compared with the other algorithms. Its performance on the polynomial
and RBF kernels were 0.378 and 0.392 respectively with the performance on the linear
kernel being 0.486. DE/best/1 had good performance on RBF kernel at 0.169 which
was slightly better then the performance of DE/best/2 on the RBF kernel at 0.189. In
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this study, even though the PSO achieved better results than the DE and its variants, the
run time of DE was faster than that of the PSO. However, run time is only significant
if the resulting solution is of good quality.
The optimised values of C and γ after cross-validation were used to selected best col-
orectal cancer features. The result showed that 18 and 25 features were respectively
selected by the PSO and DE/rand/1 optimised SVMRFE methods. The features had
the same highest average accuracy of 97.3% with F1-scores of 97.7 and 97.6 respec-
tively. The temporal relationships of the selected features were modelled using the
G1DBN algorithm where temporal interaction between a network predicted at a pre-
vious time point t−1 has a target feature at time t.
The 18 best features selected by the PSO linear were modelled using DBN. The re-
sulting network was made up of 36 edges. The inferred network shows that Alpha-
2-HS-glycoprotein FETUA_HUMAN and tachykinin, precursor 1 TKN1_HUMAN, may be
dominant hub genes. Also Alpha-2-HS-glycoprotein may be associated with Prore-
laxin H1 REL1-HUMAN and Fibrinogen alpha chain FIBA_HUMAN. Research by [197]
show that Alpha-2-HS-glycoprotein is a key biomarker which is believed to be asso-
ciated with colorectal cancer and may also be aassocaited with early stages of breast
cancer [198].
The two-stage approach will aid in obtaining high quality feature with predicted inter-
actions among features, however, one drawback is that the DBN algorithm adapted at
the second stage of assumes a linear dependency among variables and hence modelled
using a linear model which at the core of the algorithm with p-values as a measure of
edge strength. This strong assumption of linearity is not always true in real biological
systems which are inherently nonlinear. This leads to misrepresentation of actual dy-
namics of biological systems and chapter 7 aims to address this problem by proposing
and successfully adapting nonlinear algorithmic methods.
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TABLE 6.4: Four features selected in common between the 18 and 25 selected fea-
tures
Swiss-Prot entry Full name Related dis-
ease
Reference
FIBA_HUMAN Fibrinogen alpha chain colon cancer [199]
CCKN_HUMAN Cholecystokinin colon cancer [212]
HIS3 HUMAN Histatin-3 oral candidia-
sis
[207]
PCSK1_HUMAN Proprotein convertase sub-
tilisin/kexin type 1
liver cancer [206]
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Chapter 7
Inferring the Dynamics of Gene
Regulatory Networks via Optimised
Non-linear Predictors and DBN
7.1 Introduction
In chapter 6, ways to improve on the already developed two-stage DBN-based ap-
proach were proposed and implemented. In particular two major kinds of optimi-
sation algorithms, particle swarm optimization and differential evolution algorithms,
were adapted for parameter optimisation of the two-stage approach. The experimental
results showed improved feature selection accuracy and more relevant features being
selected. DBN-modelled relationships further revealed remarkable discovery of gene
associations that might be important in the diagnosis of colorectal cancer and investi-
gation of its metastasis. As noted however, the strong assumption of linearity of the
DBN second stage does not fully capture the true representation of biological systems
which are known to be nonlinear
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The hypothesis for this chapter is that nonlinear DBN-based algorithms are better than
linear DBN-bassed algorithms for the task of reverse engineering of gene expression
network from time-course gene expression data. To test the hypothesis, two nonlinear
DBN-based algorithms are developed and adapted to both simulated and real world
data to prove their robustness. In particular, the methods developed are applied to
inference of gene regulatory networks and ovarian cancer time course data. It is worth
noting that the developed methods have successfully been published.
Inferring GRNs from high-dimensional time course data is a key challenge in bioinfor-
matics. This is difficult because of the p n curse of dimensionality problem where
the number of predictors p is much greater than the number of observations n. Vari-
ous methods have been proposed in literature over the years for reverse engineering of
GRN such as methods based on state-space models [213], [214], dynamic Bayesian
network [1], [215], [125] and vector autoregressive models [216], [217], [218]. These
methods however assume linearity of relationships among the genes which is not al-
ways a true representation of actual biological systems which are known to be inher-
ently non-linear.
To address this problem, two dynamic Bayesian network-based algorithms based on
non-linear predictors are proposed. This first algorithm is the Recurrent Neural Net-
work Dynamic Bayesian Network (RNN-DBN) algorithm and the second is the Sup-
port Vector Regression Dynamic Bayesian Network (SVR-DBN) algorithm. These
two developed algorithms were found to be better than exiting linear DBN-based
G1DBN algorithm and were successfully published in IEEE conferences [5] [6]. The
two DBN-based algorithms improve on the second stage (DBN) of the proposed two-
stage optimisation approach introduced in chapter 5. The G1DBN algorithm was used
to model and infer a DBN at the second stage but the algorithm assumes linear inter-
action among genes which made it less practical as biological networks are not always
linearly related.
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7.1.1 RNN-DBN
The RNN-DBN algorithm was proposed to overcome the limitations of linearity as-
sumption in modelling GRNs which are inherently non-linear. The algorithm also
overcomes the analytical intractability of methods based on Ordinary Differential
Equation (ODE) such as the S-systems [219] and the non-linear dynamical system
(NDS) [220], [221].
Figure 7.1 shows overall block diagram of the computational model adapted in this
RNN-DBN subsection. It represents the RNN-DBN algorithm developed for infer-
ring the dynamics of gene regulatory networks. It takes (time-course) gene regulatory
network data as input. At the second step in the diagram, initial population of opti-
misation parameters are generated by the optimisation algorithm, in this study, both
the inertia weight PSO and CLPSO were used. The parameters are the hidden layers
and the learning parameters for the Elman RNN. The pseudo-code is also shown in
Figure 7.2.
Within the DBN, the weights of the RNN are computed as probabilities p for each
feature; this forms the score matrix M1. The maximum weight for each feature is
then selected such that it is less than α1 threshold. The edges between the predicted
M1 and the true matrix MT are set. The strength of these edges are determined by
the weights. The mean squared error (MSE) between M1 and MT is computed and
the optimisation algorithm varies the optimisation parameters until lowest MSE. The
output is the vector of best parameters with lowest MSE.
With the optimised parameters, the weights of the nonlinear Elman RNN are com-
puted as probabilities p within the DBN. The area under the precision-recall curve
(AUPR) is computed using matrices M1 and MT. This is compared with the results
from the standard G1DBN algorithm using Drosophila Melanogaster dataset and the
result shown in Figure 7.3.
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Input Gene Regulatory 
Network data
Generate initial 
population of 
optimization 
parameters
Within the DBN, compute 
the weights of the RNN as 
probabilities p. This forms 
score matrix M1
Select the maximum 
weight for each 
variable such that it is 
less than α1 threshold.
Set the edges between 
the predicted M1 and 
the true matrix MT
Compare M1 and MT 
and compute the MSE
Vary parameters until 
lowest MSE
Output best 
parameters with lowest 
MSE
FIGURE 7.1: Block diagram showing the Computational Model of the Optimised
RNN-DBN Algorithm [5]
FIGURE 7.2: Pseudo-code of The Optimised RNN-DBN Algorithm
The DBN’s learning approach is based on first-order conditional dependencies intro-
duced by [1]. The contribution of the algorithm is improved modelling accuracy using
optimized RNN. The Elman Recurrent Network was chosen because of it’s simplicity
and power [222], [223] in modelling non-linear feedback which are very common in
biological systems. The state-space characteristics of the Elman Recurrent Network
was another reason for its choice. It models non-linear relationships delayed by one
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step back in time and using parameter optimization allows for solving specific infer-
ence problems [37]. The precision-recall (PR) curve was used as measurement metric
and Figure 7.3 shows the RNN-DBN outperformed the G1DBN algorithm.
The inference of the algorithm is based on the Markov Assumption that only the past
variable which is one step back in time predicts a target variable at the current time
point by measuring the conditional dependence between the variables given any other
variable. This is computed using the weights of the RNN. A score matrix M1(i,j) is
assigned to each potential edge. The highest score indicates the most significant edge
and the inferred DAG G(1) contains the edges which have been assigned a chosen
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Drosophila Melanogaster Life Cycle
FIGURE 7.3: PR Curve Comparison of RNN-DBN and G1DBN on D. Melanogaster
Benchmark dataset.
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threshold al pha1.
7.1.2 Application Results of the RNN-DBN Algorithm
The algorithm was implemented using the R Statistical Language and the Elman
Recurrent Network was computed using the RSNNS package [224]. The algorithm
was demonstrated using real world time-course Drosophila Melanogaster benchmark
dataset and human ovarian carcinoma time-course dataset. PSO and CLPSO were
used to tune the parameters of the Elman Recurrent Network with the mean square
error as the objective function. Inertia weight variant of the PSO was implemented.
Parameters of the PSO and CLPSO used are: wmin=0.1, wmax=1, c1=0.4, c2=0.8,
number of population=30, number of iteration=1000 and number of dimension (D)=4.
The dimension is 4 because the parameters of the Elman Recurrent Network to be opti-
mized are two hidden layers sizes and two learning parameters α1 and α2. Additional
parameters of the CLPSO used are: PcMax=0.5 and PcMin=0.05.
7.1.2.1 Results based on Drosophila Melanogaster Dataset
The life cycle of the Drosophila Melanogaster dataset has been widely used in gene
regulatory network studies and systems biology as its entire genome has been se-
quenced. In this study, the RNN-DBN algorithm was compared with the G1DBN
developed by [1]. It has previously has been known to outperform other algorithms
for inference such LASSO shrinkage, [1], the CLR [225] and the ARACNE [218]
according to [213]. The RNN-DBN algorithm’s performance was examined using
11 genes (variables) and 67 time points of Drosophila Melanogaster dataset. The di-
mension of the dataset was chosen as it has previously been used with the G1DBN R
package [131]. Description of eight out of the 11 genes from the dataset used is shown
in Appendix A.
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The RNN was trained using the entire dataset to obtain optimum values for learning
parameters α1 and α2 and also optimum values for the sizes of the hidden layers 1
and 2. The PSO and CLPSO were optimisation algorithms used to determine these
optimum values and the better values were used. Table 7.2 shows the performance
of the PSO and CLPSO algorithms. The CLPSO outperformed the PSO with lower
MSE value of 0.0009 as compared to PSO’s 0.0012 after 1000 iterations. The reason
for using the entire dataset was that the resulting optimum parameters will be used by
RNN within DBN algorithm for reverse engineering of gene regulatory network and
not on a prediction test set.
This adaptation of RNN with a DBN is different from conventional training, validation
and testing of artificial neural networks. In this adaptation, instead of using a linear
model within DBN and computing the edge strength of the resulting network using p-
values, the nonlinear RNN is used and the strength of the edges is computed using the
weights of the RNN. The precision recall curve was used to compare the performance
of both RNN-DBN and G1DBN algorithms.
Precision = TP / (TP + FP) Recall (Sensitivity) = TP / (TP + FN) where TP is the true
positive, FP is the false positive, TN is the true negative and FN is the false negative.
Figure 7.3 shows that the RNN-DBN algorithm outperformed the G1DBN algorithm
in modelling non-linear time-course GRN using real world data. It was more sensitive
in modelling and representing non-linearities in biological systems such as GRN. The
green lines represent the RNN-DBN, the blue lines represent the second step of the
G1DBN and the red lines represent the first step of the G1DBN. The first step of the
G1DBN involves inference of first-order conditional dependencies and the second step
involves inference of full-order conditional dependencies.
At the first step and second step, the G1DBN attained maximum precisions of 0.2595
and 0.5214 respectively however the RNN-DBN outperformed it with a maximum
precision of 0.7562. Table 7.1 shows the values of the area under the precision recall
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curve (AUPR) which indicates the overall performance of the algorithms. It shows
overall performance of 0.2166 for the RNN-DBN, 0.1404 for the second step of the
G1DBN and 0.0881 for the first step of G1DBN algorithm. It can therefore be inferred
from the results that the nonlinear RNN-DBN is more sensitive in inferring the struc-
ture of Drosophila Melanogaster than the linear G1DBN and hence can better model
the network structure of time-course gene expression datasets in diagnosis of diseases
such as cancer.
TABLE 7.1: Performance Comparison of RNN-DBN and G1DBN
Algorithm AUPR
RNN-DBN 0.2166
G1DBN Step 2 0.1404
G1DBN Step 1 0.0881
7.1.2.2 Results based on Ovarian Carcinoma time-course dataset
The ovarian carcinoma time-course dataset GSE8057 [22] was downloaded analysed.
It comprised of 51 time series arrays of Affymetrix HGU95Av2 GeneChips and 12625
genes. Further details about the data and the selection criteria for the genes used in
this study can be found in section 4.5. The RNN-DBN algorithm was used to model
the temporal relationships of the 34 genes used and time dependencies between the
genes and connecting edges was visualised using Cytoscape [18]. Figure 7.7 shows
67 most significant edges above the α1 threshold with 30 genes realised from the
inferred network.
Five potential hub genes each with four outgoing edges were discovered. These are
These are flap structurespecific endonuclease 1, CDC6 cell division cycle 6 homolog
(S. cerevisiae), kinesin family member 11, H2bd, TRAF family member-associated
NFIB activator and histone 1. The hub genes discovered should be investigated fur-
ther as the may be potential ovarian cancer biomarkers. For instance in DNA repair,
the protein encoded by flap structure-specific endonuclease 1 removes 5 inches over
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hanging flaps; as a tumour suppressor, it plays essential role in tumorigenesis and
studies by [226] found it to be a key gene in human breast carcinogenesis.
kinesin family member 11 (KIF11), also known as Eg5 might be a significant biomarker
in pancreatic and lung cancer cells where dimethylenastron inhibits its function and
further prevents the growth of the cancer cells. Eg5 is a mitotic kinesin that plays a
crucial role in the formation of bipolar mitotic spindles by hydrolyzing ATP to push
apart anti-parallel microtubules [227]. Further more, abnormal expression of both cy-
clin D1 and CDC6 by YB-1 may significantly contribute to lung carcinoma because
CDC6 cell division cycle 6 homolog (S. cerevisiae) is essential for the initiation of
DNA replication [228]. The significant interactions of these genes with other hub and
non hub genes in the inferred network may reveal novel insights into the mechanism
of the disease.
Stratified analysis of the discovered potential hub genes further showed that the ex-
pression levels of histone 1 was raised by oxaliplatin but remained constant with cis-
platin while the expression level of TRAF family member-associated NFB activator
was raised by cisplatin but remained constant with oxaliplatin. Also the expression
levels of flap structure-specific endonuclease 1, kinesin family member 11 and CDC6
cell division cycle 6 homolog (S. cerevisiae) were decreased by oxaliplatin but re-
mained constant with cisplatin platinum drugs.
Further analysis from Figure 7.7 also showed that three genes were highly regulated
by other genes as shown in Table 7.3. This means that they had interactions coming to
them rather than from them (as seen in the hub genes). The highly regulated genes are
cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), prostate differentiation
factor (PLAB) and stratifin (SFN).
The five hub genes and three highly regulated genes may reveal novel insights into the
disease metastasis and further clinical experiments are required as they may be highly
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TABLE 7.3: Specific Hub Genes and Key Highly Regulated Genes
Probeset Gene Sym-
bol
Gene Title
Hub Genes
39742_at TANK TRAF family member-
associated NF-κB activator
38576_at HIST1H2 histone 1, H2bd
1536_at CDC6 CDC6 cell division cycle 6
homolog (S. cerevisiae)
40726_at KIF11 kinesin family member 11
1515_at FEN1 flap structure-specific en-
donuclease1
Regulated
Genes
2031_s_at CDKN1A cyclin-dependent kinase in-
hibitor 1A (p21, Cip1)
1890_at PLAB prostate differentiation factor
33322_i_at SFN stratifin
associated with ovarian cancer. The strongest edge in the inferred network was be-
tween cyclin-dependent kinase inhibitor 1A (p21, Cip1) and CDC6 cell division cycle
6 homolog (S. cerevisiae) (CDC6) followed by the edge between prostate differentia-
tion factor (PLAB) and replication factor C (activator 1) 3, 38 kDa (RFC3).
7.2 Ensemble SVR-DBN
The ensemble SVR-DBN algorithm was proposed to overcome the limitations of lin-
earity assumption in modelling GRNs. It involves the use of the non-linear radial basis
function (RBF) kernel of the support vector regression algorithm within a dynamic
Bayesian network framework. The DBN model is based on the first order conditional
dependencies introduced by [1].
Figure 7.4 shows overall block diagram of the computational model adapted in this
ensemble SVR-DBN section. The input is a time-course gene regulatory network
data. The initial population of optimisation parameters are generated using the CLPSO
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optimisation algorithm. Here the parameters to optimise are the C and γ of the SVR.
Within the DBN, the weights of the SVR are computed as probabilities p. This forms
the score matrix M1.
The maximum weight of the SVR for each feature is selected such that it is less than
α1. This weight determines the strength of the edges of the DBN. The score ma-
trix M2 based on α2 is evaluated as the full-order conditional dependencies of the
DBN. This M2 is compared with true matrix MT and the inverse of the area under
the precision-recall (1/AUPR) curve computed. The inverse is computed because it
is a minimisation problem. The CLPSO varies the parameters until lowest 1/AUPR.
The output is the inverse of the lowest (best) 1/AUPR. The contribution of the SVR-
DBN algorithm is the improved sensitivity of inferring non-linear GRNs using non-
linear RBF kernel of the SVR. The C and γ parameters of the SVR which represent a
2-Dimensional particle are also optimised using the comprehensive learning particle
swarm optimisation (CLPSO) which was chosen because it yielded better results than
the inertia weight PSO algorithm.
The G1DBN algorithm is implemented in two main steps. The first step involves the
Input Gene Regulatory 
Network data
Generate initial 
population of 
optimization 
parameters
Within the DBN, compute 
the weights of the SVR as 
probabilities p. This forms 
score matrix M1
Select the maximum 
weight for each 
variable such that it is 
less than α1 threshold.
Evaluate score matrix 
M2 based on α2 (DBN 
full order conditional 
dependencies) 
Compare M2 and MT 
and compute 1/AUPR 
(because it is a 
minimisation problem)
Vary parameters until 
lowest 1/AUPR
Output best AUPR as 
inverse of 1/AUPR
FIGURE 7.4: Block diagram showing the Computational Model of the Ensemble
SVR-DBN Algorithm
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inference of a first-order dependence score matrix S1 based on the Markov assumption
that only the past variable which is one step back in time X it−1 predicts the variable
at the current time point X jt by measuring the conditional dependence between the
variables and any other variable Xkt−1. Robust statistical estimators such as the M-
estimators which include the Least Square (LS) estimator, Huber estimator and Tukey
estimator are usually used [130]. In this study, the LS estimator was used to in the
algorithm for inference of the relationships.
The algorithm works by computing for each k 6= j, the estimates ai j|k according to
the LS estimator and the p-value pi j|k is derived from the standard significance test.
A score matrix S1(i, j) is assigned to each potential edge X it−1 → X jt under the null
assumption that H i jk0 : ai j|k = 0, which is equal to the maximum Maxk 6= j(pi j|k)
computed p-values [1][130]. The most significant edge is represented by the smallest
score which contains the inferred directed acyclic graph DAG G(1) whose edge have a
score below a chosen threshold α1.
At the second step of the algorithm, a reduction in the search space of the inferred
network is carried out. This is done using the score matrix S1 obtained from step 1
and an edge selection threshold α2 (from step 2) to infer the score S2 of each edge of
a DBN that describes full-order dependencies between successive variables.
The performance of the algorithm was proven on ten well-known benchmark datasets
comprising of eight insilico-generated and two real world datasets. The insilico-
generated datasets are made up of three Yeast knock-out gene expression square ma-
trix datasets of sizes 10, 50 and 100 nodes. These were from the popular Dialogue for
Reverse Engineering Assessments and Methods 3 (DREAM 3) datasets [67], and five
DREAM 4 datasets of ten nodes and 21 time points each [68].
The two real world datasets used are the 11 genes and 67 time points of the Drosophila
Melanogaster life cycle and the nine node network of the SOS DNA repair network of
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Escherichia coli (E.coli).Miroslav Radman introduced the term ”SOS response” to de-
scribe the network of the first experiment that supported the existence of an inducible
DNA repair network [172]. The CLPSO was used to optimise the C and γ param-
eters of the SVR using the inverse of the area under the precision-recall (AUPR) as
the objective function to be minimised. The parameters of the CLPSO were set at
wmin=0.1, wmax=1, c1=0.4, c2=0.8, PcMax=0.5, PcMin=0.05, number of popula-
tion=30, dimension (D) of population=2, number of iteration=1000.
As shown from the algorithm in Figure 7.5, the optimised ensemble SVR-DBN al-
gorithm starts by generating an initial solution of N particles. The CLPSO was used
in this study as it showed better performance however the PSO can also be used and
may perform differently on different datasets. While the desired number of iterations
is not yet met, particles of the CLPSO are constantly varied as the result of the DBN
inference matrix M2 is constantly compared with that of the true matrix MT using
the inverse of the Area under the precision recall curve as the objective function. The
particle here are the C and γ parameters of the support vector regression algorithm
which performs nonlinear inference within the DBN and the strength of the inferred
edges is the weight of the SVR. The higher the weight, the higher strength of the edges
between a predicted gene at time t−1 and a target gene at time t.
7.2.0.1 Results based on DREAM3 AND DREAM4 datasets
Table 7.4 shows the results obtained after 1000 iterations of the SVR-DBN algorithm
for each of the datasets. The area under the precision-recall curve (AUPR) and the area
under the receiver operating characteristics curves were computed for the SVR-DBN
and the G1DBN. The G1DBN algorithm has been known to outperform other dynamic
inference algorithms such as the LASSO, ARACNE, CLR and the VBSSM according
to [213] and [70]. The result clearly shows the new SVR-DBN outperformed the
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FIGURE 7.5: Pseudo-code of The Ensemble SVR-DBN Algorithm [6]
G1DBN consistently with 12% average increase in total accuracy based on AUROC
values over the 10 different datasets used in this study.
7.2.0.2 Results based on Real World Datasets
DREAM3 and DREAM4 are synthetically generated datasets and try to represent
expression characteristics of real world datasets however they are generated using
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TABLE 7.4: Comparison Results of SVR-DBN with G1DBN [6]
G1DBN Optimised SVR-DBN
Dataset AUPR AUROC AUPR AUROC
DREAM4-1 0.1648 0.5537 0.2287 0.4614
DREAM4-2 0.1760 0.5476 0.2303 0.6607
DREAM4-3 0.1402 0.5153 0.1663 0.5867
DREAM4-4 0.1431 0.5561 0.2607 0.7126
DREAM4-5 0.1333 0.5483 0.2175 0.6922
DREAM3-10 0.1955 0.4862 0.3323 0.6925
DREAM3-50 0.0555 0.4831 0.0856 0.5684
DREAM3-100 0.0355 0.5353 0.0402 0.5525
D.Melanogaster 0.1113 0.5287 0.1476 0.6282
E.Coli 0.5649 0.4564 0.7393 0.6931
mathematical models such as ordinary differential equations or stochastic differen-
tial equations and are rare in practical biological scenarios. For example a single time
series with 21 time points (sequence of 0-1000 by 50) used in DREAM4 are not very
common in practice. For this reason, the SVRDBN algorithm was also tested using
real world datasets. Two popular real world data commonly used are the Drosophila
Melanogaster and the Escherichia Coli. Table 7.4 also shows that the SVR-DBN
outperformed the G1DBN and is more sensitive and better in accuracy at capturing
non-linearities of biological systems.
Figure 7.6 shows the ROC curves which indicates the performance of the algorithms
on the two real world datasets used. The green line with open squares represents
performance of the SVR-DBN on Drosophila Melanogaster while the red line with
open squares represents performance of the G1DBN on Drosophila Melanogaster. It
shows that the total area covered by the SVR-DBN at is more than that of the G1DBN.
From Table 7.4, the area under the ROC curve is 0.5287 for the G1DBN and 0.6282
for the SVR-DBN. The area under the precision-recall curve (AUPR) is 0.1113 and
0.1476 for the G1DBN and the SVR-DBN.
The performance of the algorithms on Escherichia Coli dataset is also shown in Fig-
ure 7.6. The green line with closed circles represents the performance of the SVR-
DBN and the red line with closed circles represent the performance of the G1DBN
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algorithm. Again the area under the SVR-DBN ROC curve is more than that of the
G1DBN and from Table 7.4, the G1DBN had 0.4546 while the SVR-DBN had 0.6931.
Also the AUPR values of both the G1DBN and the SVR-DBN algorithms are 0.5649
and 0.7393 respectively. These results indicate clear out-performance of the nonlinear
SVR-DBN algorithm over the existing G1DBN. It means that the SVR-DBN is more
accurate in inferring regulatory network of time-course gene expression data and can
better infer the structure of time-course gene expression data of diseases such as ovar-
ian cancer. This can aid clinician in the development of new drug as the metastasis of
the disease can better understood during prognosis.
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7.3 Conclusion
Modelling and inferring temporal associations of gene expression profiles can aid bet-
ter understanding of molecular interactions which is important in drug discovery re-
search. The dynamic Bayesian network is a robust and powerful inference algorithm
preferred over static BN, the hidden Markov model and Kalman filters. The DBN
modelling was extended to include inference based on vector autoregression and out-
performs previous dynamic modelling algorithms. It was introduced and adapted as
part of the two-stage approach proposed in this study and successfully developed us-
ing different case studies. One downside however was its rather unreal representation
of biological networks as being linearly related to each other. The RNN-DBN and
the SVR-DBN algorithms were proposed to address this problem and successfully
developed and since published.
The two algorithms use nonlinear functions for nonlinear inference and allows for pa-
rameter optimisation for improved accuracy. In this study, the RNN-DBN was first
developed before SVR-DBN. The stated hypothesis is that nonlinear DBN-based al-
gorithms are better than linear DBN-based algorithms for the task of reverse engineer-
ing of gene expression network from time-course gene expression data. To test the
hypothesis, two nonlinear DBN-based algorithms are developed and their efficiency
tested using simulated and real world datasets.
The SVR-DBN was developed as an improvement to the RNN-DBN which was more
complex and took more time to run. On the Drosophila Melanogaster dataset how-
ever, the RNN-DBN achieved AUPR value of 0.2166 while the SVR-DBN achieved
a lower value of 0.1476. This was evident in this research; more runs of the RNN-
DBN needed a more powerful computation platform. The SVM needs to consider the
number of support vectors and the dimension of the dimension of the input space. The
neural network however needs to consider the dimensions, the number of iterations,
the number of hidden layers and the number of neurons in each hidden layer.
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The results in this chapter appear to suggest that for the task of reverse engineering
in gene regulatory networks, the more complex and more difficult RNN-DBN yields
better results than the SVR-DBN. It will take multiple runs of both algorithms on all
the ten datasets (and may be more) to conclude the better one. This is left as a further
study. In terms of speed however, the SVR-DBN was much faster and could run on all
the datasets easily.
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Chapter 8
Discussion and Conclusions
This thesis has been focused on covering research on using supervised learning meth-
ods and graphical models using dynamic Bayesian network for accurate feature se-
lection and inference of relationships of biomedical data. Feature selection methods
used include random forest recursive feature elimination, least absolute shrinkage and
subset operator (LASSO) and support vector machine recursive feature elimination
(SVMRFE) using the linear, the polynomial and radial basis function kernels. Various
methods for inferring gene regulatory networks were reviewed.
This research introduced three main new methods. First, a two-stage bio-network
discovery approach to identify and infer relationships between potential high quality
biomarkers that may be of importance in clinical trial and drug discovery. At the first
stage of the two-stage process, feature selection is carried using various feature selec-
tion methods mentioned and at the second stage, dynamic Bayesian network is used
to infer the relationships among these features. The two-stage method was further im-
proved by parameter optimisation using Particle Swarm Optimisation and Differential
Evolution algorithms. The second method introduced in this thesis is the use of the
RNN-DBN algorithm for reverse engineering of gene regulatory networks.
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The methods developed are important and relevant both computationally and biolog-
ically. Computationally, a new two-stage framework was successfully developed and
would help in better understanding temporal relationships between high quality se-
lected features. The adapted optimisation algorithms means increased speed in deliv-
ering the tasks as best parameter values are automatically selected instead of manually
trying out various values.
Biologically, the works done in the labs could be done faster using the proposed meth-
ods. They were tested on both real and simulated datasets and found to be more effi-
cient than previous algorithms. Novel pathways that have not been discovered before
in disease diagnosis can potentially be discovered by applying the proposed methods.
The nonlinear inference DBN-based algorithms developed are more representative of
actual dynamics of biological systems and would better capture the true picture for
instance of temporal relationships among potential biomarkers, and help in the under-
standing of tumour metastasis and drug discovery efforts.
8.1 Summary of the Research Study
This study focused on developing Dynamic Bayesian Network (DBN) for analysis
of high-dimensional biomedical data. This involved adapting various machine learn-
ing and computational optimisation methods. Machine learning methods adapted in-
clude random forest, the least absolute shrinkage and selection operator (LASSO) and
three kinds of support vector machine: the linear, the polynomial and the radial basis
function. The computational optimisation algorithms adapted are Particle Swarm Op-
timisation and its variant the Comprehensive Learning Particle Swarm Optimisation,
and five variants of Differential Evolution algorithm which are: DE/rand/1, DE/best/1,
DE/rand-to-best/1, DE/best/2 and DE/rand/2. The Differential Evolution and the Parti-
cle Swarm Optimisation algorithms were chosen because at the time of the PhD study,
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they were not much explored in the DBN domain for biomarker discovery and were
quite good at high dimension for parameter optimisation.
Dynamic Bayesian Network was chosen as the inference algorithm for time-course
gene expression data because other alternative methods such as the Kalman Filter
Model and the Hidden Markov Model (HMM) are not as suitable and efficient. For
example, the Kalman Filter Model are not suitable for representing data with large
qualitative discrete variables, and the Hidden Markov Model was more computation-
ally complex than the DBN. As explained in chapter 1, it will take the HMM O(T K2D)
time for exact inference, where as it will take the DBN O(T DKD+1) for exact infer-
ence for T sequence length with D chains and K number of states.
8.2 Overall achievements and contribution to literature
The main results and contribution of this thesis are summarised as follows:
• Development of a two-stage DBN-based bio-network discovery approach for
analysing and inferring temporal associations of biomedical data.
Accurate modelling of temporal relationships between biomarkers is important
in disease prognosis and drug discovery. Existing methods focused only on
classification performance of selected biomarkers but did not consider possible
temporal relationships among feature subsets. At the first stage of the approach,
feature selection is carried out using five different selection algorithms which
are Random Forest Recursive Feature Elimination (RF-RFE), Least Absolute
Shrinkage and Selection Operator (LASSO) and Linear, Polynomial and Radial
Basis Function kernels of the Support Vector Machine Recursive Feature Elim-
ination (SVMRFE) algorithm. Performance of the selected biomarkers were
evaluated using machine learning criteria such as Sensitivity, Specificity, Accu-
racy, False Positive Rate and Matthews Correlation Coefficient. At the second
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stage, the temporal relationships of features with the best overall performance
from the first stage are inferred using Dynamic Bayesian Network. The rel-
evance of the feature interactions and inferred network model is verified from
literature for each of the use cases studied. Two case studies that were developed
and published to address this objective are: ovarian cancer [3] and hypertension
[4]. This objective is also addressed in chapter 5.
• Development of optimised two-stage approach using swarm optimisation for
parameter optimisation
This study aimed to address the problem of inaccuracies in selection of key
biomarkers of potential relevance to drug discovery by using optimisation algo-
rithms to fine-tune the parameters of feature selection algorithms for improved
accuracy. Two key case studies were investigated:
A) Diagnosis of Colorectal Cancer. In this study, significant pathways in col-
orectal cancer metastasis were discovered using the proposed two-stage DBN-
based optimization approach. Previous modelling techniques from literature
adopted less accurate filter methods of feature selection and methods of param-
eter optimization for improved accuracy were not proposed nor implemented.
Furthermore, temporal relationships among potential biomarkers which might
reveal significant pathways in the spread of the disease were not considered.
This study aimed to address the aforementioned problems by adopting three
kinds of more efficient SVMRFE feature selection algorithm.
The algorithms were further optimised using particle swarm optimisation and
five differential optimisation algorithms. The best performing features from the
algorithm were modelled using DBN. The resulting inferred network, verified
from published literature, showed that Alpha-2-HS-glycoprotein was highly as-
sociated with Fibrinogen alpha chain which had been shown to be a possible
biomarker for colorectal cancer. This is addressed in chapter 6 and published in
IET Systems Biology [15]
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• Development and implementation of optimised Recurrent Neural Network Dy-
namic Bayesian Network (RNN-DBN) algorithm for accurate inference of Gene
Regulatory Networks (GRNs).
The study aimed to address the problem of linearity assumed by most tempo-
ral inference methods and inefficiencies of parametric methods such as the S-
systems model. After analytical reviews of different recurrent neural network
models, the Elman Recurrent Neural Network was chosen due to its simple
feedback connections which makes it powerful for nonlinear mapping. The pa-
rameters of the RNN were further optimized using particle swarm optimisation
(PSO) and comprehensive learning particle swarm optimization (CLPSO) algo-
rithms.
Results from the area under the precision recall (AUPR) curve using bench-
mark Drosophila Melanogaster dataset showed that the algorithm outperformed
existing G1DBN algorithm which had been know to outperform three other al-
gorithms: the LASSO, the ARACNE and the CLR algorithms. The developed
algorithm was further used to model time-course human ovarian carcinoma cell
dataset. Five key hub genes with four outgoing edges each were discovered.
These are flap structure-specific endonuclease 1, kinesin family member 11,
CDC6 cell division cycle 6 homolog (S. cerevisiae), histone 1, H2bd and TRAF
family member-associated NFIB activator. This study is presented in chapter 7
and published in IEEE [5].
• Development and implementation of optimised Support Vector Regression Dy-
namic Bayesian Network (SVR-DBN)
This study aims to further address the assumption of linearity by many gene reg-
ulatory network inference models proposed in literature. The study improves on
DBN for modelling GRNs by using a more efficient non-linear support vector re-
gression (SVR) algorithm. The SVR-DBN algorithm is further improved by the
use of particle swarm optimisation to fine-tune the parameters of the SVR. The
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robustness of the algorithm was tested on eight popular benchmark Dialogue
for Reverse Engineering Assessments and Methods (DREAM) datasets and two
real world datasets of Drosophila Melanogaster and Escherichia Coli. The re-
sults based on computed area under the precision recall curve (AUPR) and area
under the receiver operating characteristics curve (AUROC) showed that the al-
gorithm outperformed the existing G1DBN algorithm on all ten datasets. This
study is presented in chapter 7 and published in IEEE [6].
8.3 Limitations and Future Work
New horizons for future work are suggested by the developments made in this. These
are given below:
• The first order Markov assumption is used to simplify modelling efforts in time
series where the present depends only on the past variable. A second order
Markov process can be possible with many parameters to compute. The de-
velopment of such models may better capture better representation of system
dynamics.
• The methods developed can be applied to streaming analytics which is currently
trending with the emergence of big data techniques. How can the methods de-
veloped be robust enough to handle data streams and infer relationships using
real time that only from static data? This would be an interesting way to forward
this research beyond what has been done.
• This entire research was conducted using individual computer nodes. At other
times multiple computers in the laboratory were used to run experiments concur-
rently however with petabytes of data generated regularly, this work can be fur-
ther developed to run on big data platforms such as Apache Spark and Hadoop.
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Another criticism is that the algorithms developed were mainly single-threaded
and multi-threaded and faster methods could be developed.
• In terms of DBN-based inference algorithms and further developement, others
such as Modular networks [229] and James-Stein Shrinkage [230] can be fur-
ther developed and improved upon could be compared with the ones developed.
Other regression based DBN algorithms could also be developed and compared
with the SVR-DBN developed in this work. Code could be optimised for bet-
ter speed by adapting multi-threaded approaches using more recent developed
libraries in R language. More bespoke libraries could be developed also be de-
veloped.
• Web application interface of the algorithms developed could mean they can be
used more easily. The author was working on developing web front-end for ease
of use and a small prototype have been developed however more can be done.
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A.1 7 of the 39 Ovarian Cancer Metabolites selected
by the LASSO
V19 V29 V51 V62 V77 V89 V100
1 12339.00 597.42 10131.00 1938.10 3325.70 104930.00 3492.50
2 26461.00 1142.80 4249.50 30.65 2559.10 68223.00 6143.20
3 35497.00 954.73 12952.00 248.63 6276.00 52304.00 31985.00
4 17220.00 1188.90 12054.00 2677.40 7981.10 76646.00 19436.00
5 22673.00 1763.30 56387.00 5170.00 1369.70 35534.00 0.00
6 13378.00 1423.30 17851.00 4401.50 990.45 142440.00 0.00
7 21667.00 1049.20 13021.00 7066.40 1866.20 25610.00 0.00
8 33408.00 1399.20 15430.00 3383.70 1699.80 86068.00 0.00
9 30616.00 1369.80 10236.00 17.84 2656.80 525.68 22.93
10 15621.00 1478.30 3690.90 2753.00 6638.40 3112.40 310.12
11 31453.00 2294.70 1756.00 0.00 3953.60 82864.00 0.00
12 18323.00 564.89 13201.00 3479.10 6458.80 14294.00 13197.00
13 22373.00 1890.90 15662.00 259.25 7525.10 31238.00 0.00
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14 25198.00 1142.10 4475.60 0.00 3809.80 2711.80 0.00
15 29950.00 209.07 130.00 171.67 3479.40 1511.80 0.00
16 20961.00 1882.90 41224.00 623.93 8497.60 54820.00 0.00
17 32192.00 1161.40 141.76 298.26 9910.10 33788.00 1176.00
18 3334.70 1992.00 10026.00 277.65 7569.20 28327.00 45.37
19 24928.00 607.97 12941.00 1162.40 4063.50 18947.00 12439.00
20 21854.00 1730.50 3161.50 3484.50 4844.10 31903.00 0.00
21 31383.00 761.19 0.00 190.33 354.14 23748.00 384.66
22 26699.00 2112.20 4336.80 110.02 4690.60 12522.00 0.00
23 27353.00 1487.30 582.59 2611.60 2646.00 19525.00 11250.00
24 20053.00 331.89 10404.00 0.00 1072.30 5908.40 0.00
25 18481.00 965.67 15780.00 1436.30 4097.10 3120.00 0.00
26 344.78 398.58 46630.00 1457.50 4087.70 63779.00 0.00
27 24695.00 693.14 0.00 789.52 4216.10 60746.00 17330.00
28 21175.00 831.90 0.00 1335.20 1744.90 1664.50 3085.40
29 32273.00 1613.70 2739.10 0.00 5091.80 54049.00 10466.00
30 36174.00 1380.80 1051.10 2252.60 2408.40 52448.00 16376.00
31 19350.00 1071.70 402.89 6681.60 8343.90 49141.00 4776.40
32 27248.00 798.76 4422.60 0.00 6838.40 102290.00 137.32
33 26190.00 360.48 11194.00 4737.20 4805.80 9780.60 20030.00
34 27279.00 327.95 1251.20 351.29 6432.20 176690.00 26444.00
35 17547.00 728.91 68.89 7470.20 3144.70 330.64 24255.00
36 29456.00 1094.20 3909.70 1147.00 10987.00 77960.00 0.00
37 18056.00 370.59 29967.00 1939.80 5467.10 36427.00 14301.00
38 29085.00 1221.80 15119.00 2404.10 7208.80 40024.00 15082.00
39 16914.00 1062.10 9473.70 19693.00 3866.80 31193.00 3786.10
40 12298.00 699.89 18994.00 8539.00 3894.30 58057.00 6796.60
41 15496.00 2010.90 11265.00 55.77 4097.50 66400.00 1366.70
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42 15153.00 1611.80 104290.00 1346.50 3035.10 29605.00 0.00
43 7760.70 912.15 116060.00 493.62 3884.80 5993.10 3913.40
44 35724.00 1333.10 55740.00 637.00 5834.40 71639.00 0.00
45 29448.00 2494.60 1120.60 6058.70 4179.30 1441.20 28.81
46 25976.00 507.17 0.00 6275.20 5019.10 63593.00 17725.00
47 30633.00 1074.60 29.26 66.71 4385.10 30650.00 0.00
48 15997.00 827.78 0.00 91.77 12069.00 13763.00 3578.60
49 31394.00 2042.90 0.00 0.00 3077.60 185.00 0.00
50 25879.00 1380.10 675.77 11705.00 4098.90 15688.00 1705.30
51 13456.00 1025.40 30075.00 0.00 4118.80 5400.50 2305.50
52 8430.80 942.92 27.64 2375.70 12002.00 2818.20 16.69
53 242.63 729.48 52593.00 1780.90 7151.50 26045.00 25.37
54 667.56 2471.50 10339.00 2844.70 4209.70 9502.70 0.00
55 41134.00 2499.10 8114.80 0.00 4802.90 25239.00 0.00
56 28190.00 1687.40 8366.80 8464.40 4418.10 7764.60 0.00
57 33193.00 2048.20 0.00 0.00 3119.00 92.99 0.00
58 62810.00 1407.40 8769.80 2372.60 2053.90 6068.20 3418.50
59 3361.50 1818.80 39793.00 1276.50 11490.00 2757.20 0.00
60 30532.00 2994.80 31243.00 46.78 6201.00 7323.10 0.00
61 43399.00 1099.90 76487.00 1430.70 5492.40 51411.00 0.00
62 11552.00 560.78 8397.70 0.00 1726.60 4172.20 0.00
63 45942.00 1149.50 543.03 532.40 6822.40 19558.00 0.00
64 32153.00 1832.40 1505.20 0.00 5337.60 49991.00 0.00
65 13368.00 2142.70 38670.00 696.13 10499.00 37959.00 0.00
66 25612.00 2938.50 26077.00 712.14 8895.50 7677.20 0.00
67 36443.00 398.84 42883.00 181.29 6354.70 146230.00 0.00
68 34762.00 895.55 12074.00 3573.40 5431.20 32242.00 0.00
69 47203.00 173.52 464.00 1472.70 5266.10 20677.00 2575.00
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70 38923.00 1900.70 10237.00 725.90 8635.60 36822.00 0.00
71 27836.00 1612.50 499.16 15923.00 3519.10 10411.00 0.00
72 35487.00 369.60 1124.90 279.09 5559.50 1995.30 2222.40
A.2 DESCRIPTION OF THE 101 hypertension fea-
tures selected by the LASSO
Row Col ProbeName Gene.Symbol Unigene.ID.v163. Locus.ID p.value
315 7 15 probe 687 null Hs.440731 352046 0.01
358 7 85 probe 757 SATB2 Hs.412327 23314 0.03
386 8 32 probe 816 CRABP2 Hs.183650 1382 0.00
1039 19 55 probe 2071 SCRG1 Hs.7122 11341 0.01
1183 21 76 probe 2316 PEPP-2 Hs.370012 84528 0.01
1503 26 61 probe 2861 CSS3 Hs.165050 337876 0.05
1711 29 91 probe 3227 SEC61A2 Hs.368481 55176 0.00
1902 32 67 probe 3539 null Hs.283271 -1 0.01
2192 37 21 probe 4053 null Hs.371800 -1 0.01
2226 37 70 probe 4102 null Hs.171885 -1 0.04
2298 38 106 probe 4250 null Hs.198671 -1 0.02
2299 38 111 probe 4255 null Hs.72307 -1 0.01
2505 41 101 probe 4581 null Hs.370546 -1 0.11
2782 46 70 probe 5110 null Hs.35090 -1 0.00
3499 58 44 probe 6428 MNAB Hs.112227 54542 0.04
3506 58 55 probe 6439 null Hs.79856 -1 0.00
3734 62 2 probe 6834 MPP4 Hs.63085 58538 0.00
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3884 64 12 probe 7068 null Hs.290255 -1 0.02
4075 66 110 probe 7390 null Hs.346735 346850 0.02
4154 68 8 probe 7512 null Hs.207092 -1 0.01
4232 69 2 probe 7618 null Hs.116153 -1 0.01
4998 80 28 probe 8876 null Hs.282862 -1 0.03
5109 82 6 probe 9078 MGC20781 Hs.237536 115024 0.00
5127 82 38 probe 9110 null Hs.242822 -1 0.01
5179 83 6 probe 9190 null Hs.378505 -1 0.01
5458 87 41 probe 9673 null Hs.444491 -1 0.11
5545 88 53 probe 9797 null Hs.306968 -1 0.03
5667 90 39 probe 10007 null Hs.130465 -1 0.00
5771 91 89 probe 10169 null Hs.26026 -1 0.02
5938 94 7 probe 10423 ADAM29 Hs.126838 11086 0.04
5959 94 43 probe 10459 null Hs.437554 -1 0.06
6208 97 103 probe 10855 LDOC1 Hs.45231 23641 0.00
6428 101 29 probe 11229 FLJ38705 Hs.149740 286128 0.00
7009 109 104 probe 12200 null Hs.133900 -1 0.06
7706 120 55 probe 13383 PANX3 Hs.99235 116337 0.03
7732 120 108 probe 13436 null Hs.385784 -1 0.00
7923 124 18 probe 13794 CAST Hs.434457 26059 0.08
8136 127 96 probe 14208 null Hs.143715 -1 0.00
8451 132 66 probe 14738 KCNK7 Hs.175218 10089 0.00
8583 134 44 probe 14940 null Hs.201184 -1 0.06
9113 142 39 probe 15831 FOXG1B Hs.525266 2290 0.19
9254 144 39 probe 16055 FUT6 Hs.32956 2528 0.05
9407 146 100 probe 16340 null Hs.62697 -1 0.03
9450 147 50 probe 16402 CEACAM3 Hs.11 1084 0.10
9735 151 108 probe 16908 RIG Hs.278503 10530 0.00
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9856 153 74 probe 17098 LZTFL1 Hs.30824 54585 0.00
9984 155 95 probe 17343 KIAA1202 Hs.380697 57477 0.00
10568 164 51 probe 18307 VTS58635 Hs.437035 91608 0.02
10621 165 31 probe 18399 null Hs.100636 -1 0.00
10883 169 10 probe 18826 DRP2 Hs.159291 1821 0.03
11249 174 84 probe 19460 MIST Hs.381351 116449 0.00
11368 176 65 probe 19665 RNASE3 Hs.73839 6037 0.05
11631 180 109 probe 20157 SDOS Hs.6949 84309 0.01
11710 182 31 probe 20303 RBMY1A3P Hs.449529 286557 0.08
11965 186 102 probe 20822 null Hs.255678 -1 0.01
12002 187 61 probe 20893 null Hs.255496 -1 0.08
12267 191 38 probe 21318 FLJ23129 Hs.49421 79819 0.02
12313 191 101 probe 21381 FLJ33207 Hs.146083 339855 0.04
12376 193 17 probe 21521 RFX2 Hs.100007 5990 0.00
12602 196 105 probe 21945 ADAM21 Hs.178748 8747 0.05
12786 199 103 probe 22279 null Hs.443145 341460 0.01
13024 203 60 probe 22684 null Hs.97553 -1 0.02
13467 210 40 probe 23448 ATP1A4 Hs.367953 480 0.01
13790 215 41 probe 24009 null Hs.372092 -1 0.01
13903 217 3 probe 24195 PRLR Hs.212892 5618 0.00
14618 228 50 probe 25474 APOBEC3F Hs.337667 200316 0.01
14786 231 6 probe 25766 null Hs.363495 -1 0.05
14801 231 30 probe 25790 STAR Hs.440760 6770 0.02
14977 233 90 probe 26074 FOXQ1 Hs.297452 94234 0.04
15131 236 60 probe 26380 KIAA0645 Hs.435022 9681 0.04
15380 240 75 probe 26843 BNIP1 Hs.145726 662 0.01
15764 246 43 probe 27483 null Hs.188836 -1 0.01
15958 249 54 probe 27830 null Hs.97300 145788 0.06
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16114 251 112 probe 28112 GCGR Hs.208 2642 0.01
16298 255 30 probe 28478 FLJ30634 Hs.350065 148697 0.01
16375 256 45 probe 28605 STEAP2 Hs.408200 261729 0.02
16500 258 98 probe 28882 null Hs.381151 79944 0.00
16870 265 25 probe 29593 null Hs.319565 -1 0.01
16926 266 19 probe 29699 null Hs.280357 -1 0.00
17146 269 75 probe 30091 FLJ31393 Hs.350816 219445 0.00
17392 273 66 probe 30530 ARPP-21 Hs.412268 10777 0.00
18340 288 24 probe 32168 MYO7B Hs.154578 4648 0.02
18495 290 25 probe 32393 KCNC2 Hs.345757 3747 0.09
18591 291 74 probe 32554 CNN1 Hs.21223 1264 0.00
18629 292 34 probe 32626 null Hs.332123 -1 0.02
18712 293 50 probe 32754 ZNF37A Hs.446382 7587 0.04
19134 300 5 probe 33493 null Hs.195391 -1 0.03
19165 300 58 probe 33546 null Hs.279596 -1 0.00
19366 303 49 probe 33873 SLC4A5 Hs.321127 57835 0.01
19730 308 82 probe 34466 MGC45404 Hs.371135 257397 0.04
20013 313 41 probe 34985 null Hs.372738 -1 0.01
20024 313 64 probe 35008 MEP1A Hs.179704 4224 0.06
20209 316 58 probe 35338 null Hs.199882 -1 0.01
20475 320 78 probe 35806 null Hs.208550 -1 0.10
20562 322 27 probe 35979 FLJ23356 Hs.277431 84197 0.05
20899 327 97 probe 36609 null Hs.372172 -1 0.01
20915 328 25 probe 36649 CKLFSF1 Hs.513657 113540 0.01
20976 328 109 probe 36733 FLJ12687 Hs.417062 79979 0.01
21056 330 40 probe 36888 null Hs.429904 338987 0.05
21581 339 49 probe 37905 ALDH1A2 Hs.435689 8854 0.04
21614 339 97 probe 37953 null Hs.432395 -1 0.09
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A.3 12 of the 18 Colorectal Cancer Spectral Profiles se-
lected by PSO SVMRFE Linear
1 2 3 4 5 6 7 8 9 10 11 12
V1 1.08 2.49 3.29 1.14 2.46 3.25 4.05 1.19 2.45 50.46 5.40 2.58
V2 1.48 1.25 2.99 1.34 1.27 3.72 6.67 0.94 1.21 21.44 7.64 1.15
V3 0.56 0.70 1.96 0.31 0.80 1.91 8.49 0.15 0.58 22.64 6.57 1.50
V4 2.07 1.68 4.81 1.97 1.66 2.70 6.87 1.90 1.66 28.88 9.15 1.26
V5 4.62 1.45 11.02 4.57 1.37 4.65 6.47 4.30 1.42 34.91 7.53 2.28
V6 1.99 1.59 5.26 1.94 1.48 5.89 7.15 1.91 1.53 49.83 6.99 5.09
V7 1.92 1.39 5.34 2.09 1.35 3.65 4.77 2.17 1.39 76.22 6.49 2.91
V8 2.61 2.49 3.49 2.69 2.41 5.86 7.24 2.75 2.43 25.04 9.08 2.80
V9 1.07 1.62 3.81 1.18 1.58 2.70 7.30 1.16 1.62 61.28 12.52 1.23
V10 1.19 1.68 5.91 1.27 1.75 5.25 5.85 1.35 1.60 33.82 6.41 1.42
V11 0.83 1.41 3.75 1.02 1.31 3.03 3.53 0.93 1.42 27.83 4.29 1.75
V12 2.16 0.73 6.39 2.32 0.67 2.33 2.36 2.34 0.77 44.55 6.06 1.91
V13 2.57 0.37 5.79 2.53 0.32 0.83 3.00 2.79 0.41 37.43 9.52 1.88
V14 2.03 0.77 8.78 1.87 0.75 2.84 4.59 1.65 0.79 11.98 10.19 1.64
V15 3.78 1.13 14.36 3.55 1.12 4.05 5.05 3.52 1.10 27.94 7.10 2.26
V16 0.73 0.46 2.35 0.72 0.50 2.23 3.99 0.72 0.53 57.47 5.55 0.31
V17 2.01 1.20 6.96 2.03 1.18 5.92 4.07 1.97 1.13 43.33 5.44 2.25
V18 2.98 1.46 9.71 2.98 1.37 5.89 9.53 3.04 1.50 34.34 8.03 2.40
V19 4.67 1.09 7.72 5.06 1.11 9.04 3.92 5.21 1.02 25.73 6.17 3.44
V20 2.05 0.81 10.89 2.02 0.85 9.49 5.64 1.93 0.72 66.05 7.29 4.07
V21 4.64 1.33 15.33 4.77 1.27 4.46 2.03 4.82 1.40 2.89 9.02 2.34
V22 2.86 1.27 6.51 3.09 1.25 6.15 4.87 3.08 1.33 13.12 2.77 3.32
V23 1.89 0.49 7.04 1.70 0.51 4.84 4.84 1.50 0.51 30.45 7.30 2.26
V24 3.70 0.92 9.33 3.99 0.94 5.82 7.62 4.45 0.90 11.65 11.81 3.20
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V25 3.74 3.49 10.46 4.10 3.54 5.11 7.33 4.12 3.36 50.54 9.10 2.43
V26 3.51 1.06 15.11 3.65 1.06 3.14 3.33 3.71 1.07 80.25 7.60 4.04
V27 1.96 3.32 7.16 2.37 3.36 4.88 4.76 2.75 3.24 42.74 2.77 1.81
V28 0.61 2.87 6.68 0.88 2.85 2.19 7.64 1.13 2.80 27.97 4.06 5.62
V29 1.44 2.52 5.94 1.60 2.36 4.01 5.10 1.48 2.48 57.71 6.20 3.92
V30 1.47 3.94 10.83 1.72 3.94 5.82 3.53 1.77 3.80 87.27 6.64 3.81
V31 1.12 5.04 11.29 1.08 4.97 5.81 3.09 1.14 4.94 56.08 5.44 3.44
V32 1.67 2.71 4.51 1.68 2.65 4.33 3.78 1.84 2.70 52.61 10.43 2.39
V33 1.38 5.08 6.85 1.91 4.95 2.46 2.51 2.11 5.05 67.04 3.33 4.71
V34 2.80 5.01 24.74 2.94 4.79 2.55 4.64 3.03 4.93 15.41 9.36 1.93
V35 0.61 1.40 7.99 0.62 1.42 3.89 10.29 0.73 1.34 31.62 6.04 3.77
V36 0.31 3.08 5.20 0.45 3.12 1.60 5.45 0.78 3.05 37.53 7.78 1.51
V37 2.30 2.41 11.03 2.65 2.29 4.81 3.37 2.73 2.40 33.82 10.86 2.64
V38 2.69 3.07 14.72 3.13 2.96 7.93 4.07 3.49 3.15 19.35 13.28 2.17
V39 2.65 5.87 14.74 2.64 5.79 6.08 4.32 2.57 5.89 12.37 11.60 2.39
V40 2.11 4.34 13.97 2.34 4.07 4.14 3.25 2.60 4.42 19.98 7.38 2.32
V41 3.35 2.58 14.62 3.68 2.54 6.23 3.54 4.09 2.58 19.23 8.81 4.41
V42 1.50 6.43 5.77 1.59 6.42 8.51 5.94 1.70 6.42 15.75 5.36 4.18
V43 2.07 2.38 6.66 1.99 2.32 7.03 4.19 2.17 2.50 28.45 7.05 2.85
V44 1.56 2.42 7.60 1.75 2.28 5.12 4.83 1.73 2.49 39.53 3.06 2.29
V45 0.73 0.83 7.54 0.98 0.94 4.42 4.60 1.06 0.78 36.56 2.99 3.81
V46 2.26 1.00 7.91 2.29 0.92 2.25 3.59 2.38 1.04 71.69 8.73 3.06
V47 2.08 1.49 9.03 2.26 1.50 3.26 3.06 2.43 1.51 60.25 4.33 2.38
V48 2.59 2.03 12.81 2.59 2.01 2.21 4.29 2.55 2.01 64.54 1.44 3.37
V49 1.76 3.00 9.50 2.03 2.87 5.47 3.33 1.81 2.97 15.57 5.31 2.50
V50 1.28 4.32 3.69 1.33 4.26 5.40 4.27 1.21 4.27 28.58 5.42 1.66
V51 1.97 2.23 8.15 2.07 2.13 5.57 4.91 2.01 2.43 14.54 6.71 1.46
V52 2.36 1.28 8.53 2.36 1.24 6.28 4.80 2.34 1.26 9.03 6.46 2.30
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V53 1.81 2.66 11.61 1.49 2.69 5.79 3.71 1.64 2.59 19.63 4.08 2.84
V54 2.20 5.76 11.80 2.22 5.72 7.27 4.10 2.14 5.70 9.16 5.55 3.58
V55 2.61 3.83 8.14 2.72 3.67 11.69 5.69 2.75 3.82 8.89 9.06 3.43
V56 2.72 2.94 7.80 2.98 3.03 9.82 6.31 3.13 2.84 19.78 6.72 2.80
V57 2.73 3.50 9.46 2.86 3.50 6.14 7.41 2.98 3.58 8.82 5.28 1.47
V58 4.53 2.62 16.68 4.68 2.56 3.82 3.54 4.94 2.62 22.11 3.81 1.63
V59 2.86 5.00 11.50 2.78 4.93 4.00 4.07 2.68 4.96 5.77 6.33 2.00
V60 0.57 1.61 4.69 0.49 1.52 9.36 10.34 0.53 1.53 33.00 4.77 1.20
V61 3.41 4.38 5.68 3.69 4.28 6.40 29.20 3.76 4.22 13.27 10.50 4.43
V62 5.18 3.16 12.26 5.35 3.11 6.69 14.71 5.22 3.02 10.90 9.17 2.16
V63 4.59 2.87 18.77 4.71 2.97 7.09 3.70 4.89 2.81 14.17 7.35 1.35
V64 4.65 1.21 10.82 4.89 1.22 7.91 6.74 4.77 1.21 28.09 5.79 4.29
A.4 Description of the Drosophila Melanogaster Dataset
eve gfl.lmd twi mlc1 sls mhc prm actn
E01hunfertilized -1.94 -0.31 -0.89 -2.47 -0.30 -2.96 -1.80 0.25
E01h -0.56 0.62 -0.94 -2.38 -0.64 -4.27 -3.12 -0.08
E0515h -0.06 0.59 -0.50 -3.78 -0.25 -4.39 -3.28 -0.06
E012h -0.29 0.62 -0.82 -4.47 -0.73 -3.79 -2.89 -0.03
E01525h 0.93 0.25 0.17 -3.14 -0.39 -4.02 -2.70 0.02
E023h 1.46 0.51 1.00 -3.51 -0.36 -3.54 -2.83 -1.30
E02535h 1.89 0.73 1.74 -3.78 -0.53 -3.39 -2.55 -1.26
E034h 2.10 0.16 1.78 -3.90 -0.38 -3.34 -2.60 -1.23
E03545h 2.23 -0.15 1.66 -3.93 -0.25 -3.55 -2.29 -1.44
E045h 1.94 -0.50 2.01 -3.59 -0.66 -3.60 -2.46 -1.43
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E04555h 1.26 0.23 1.82 -3.79 -0.39 -3.43 -2.45 -1.16
E056h 1.21 0.22 1.73 -3.84 -0.72 -3.51 -2.46 -1.40
E05565h -0.13 0.78 0.53 -3.89 -0.74 -3.27 -2.06 -1.63
E067h -0.38 0.72 0.21 -3.93 -0.60 -2.75 -2.00 -1.78
E078h -0.26 0.62 -0.12 -3.82 -0.71 -3.01 -2.23 -1.52
E089h -0.01 1.10 0.22 -1.53 0.18 -2.63 -2.10 -1.57
E0910h 0.16 0.99 -0.67 -3.22 -0.11 -3.20 -2.13 -0.65
E1011h -0.02 0.69 -0.09 -2.74 -0.41 -1.59 -1.35 -0.80
E1112h 0.00 0.03 -0.73 -1.36 -0.09 -0.44 -0.98 -0.03
E1213h -0.14 0.13 -0.31 1.20 -0.01 1.83 0.48 -0.09
E1314h 0.03 0.15 -0.57 0.64 -0.00 1.24 -0.38 -0.60
E1415h -0.14 0.23 -0.43 1.02 0.22 1.83 0.09 -0.26
E1516h 0.03 -0.13 -0.59 1.64 0.27 2.33 0.46 -0.31
E1617h 0.06 -0.20 -0.28 1.86 0.06 2.67 1.63 -0.13
E1718h -0.42 -0.48 -0.38 2.27 0.23 2.80 1.99 -0.35
E1819h -0.30 -0.53 -0.41 2.82 0.07 3.23 1.79 -0.39
E1920h -0.10 -0.86 -0.55 3.13 0.48 3.27 2.26 0.39
E2021h -0.01 -0.34 -0.40 3.29 0.20 3.47 2.50 0.33
E2122h -0.08 -0.31 -0.78 3.22 0.23 3.40 2.44 0.26
E2223h 0.02 -0.79 -0.59 2.89 0.15 3.22 2.37 0.19
E2324h -0.03 -0.89 -0.36 2.84 0.35 3.72 2.38 -0.09
L24h -0.26 -0.28 -1.17 2.90 -0.26 2.06 0.01 0.77
L33h 0.08 -0.22 -1.01 3.33 -0.06 2.24 0.38 1.24
L43h -0.08 0.70 -1.43 3.76 -0.11 2.78 0.76 0.24
L49h -0.24 -0.51 -0.72 2.53 -0.21 1.96 0.11 1.45
L57h 0.03 0.14 -1.48 3.21 -0.01 2.88 1.12 0.07
L67h 0.31 0.02 -0.82 3.26 -0.06 2.43 0.09 0.81
L72h -0.40 0.27 -1.23 3.96 -0.15 4.07 1.37 -0.81
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L84h 0.42 0.55 -1.53 4.04 0.11 3.13 1.12 -0.44
L96h 0.01 0.28 -0.85 3.37 0.55 3.60 2.09 -0.28
L105h -1.01 0.82 -0.66 2.11 0.26 -0.40 -0.31 -0.17
M0h -0.55 0.62 -1.05 -1.31 -0.18 -1.67 -0.51 -1.88
M02h -1.10 1.46 -0.44 -4.04 0.10 -4.13 -1.68 -0.83
M04h -0.86 1.13 -0.21 -3.30 0.26 -4.06 -1.31 -0.07
M06h -1.12 0.80 -0.28 -2.90 0.25 -3.96 -0.75 -0.55
M08h -0.63 1.77 -0.31 -2.12 -0.22 -3.23 -0.66 -0.12
M10h -0.56 0.95 -0.34 -1.75 0.26 -3.44 -1.59 -0.10
M12h 0.14 0.81 0.29 -1.49 -0.43 -3.10 -1.94 -0.23
M16h -1.17 0.67 -0.06 -4.51 -0.08 -4.24 -1.99 0.24
M20h -1.24 0.72 -0.16 -3.85 -0.03 -4.45 -2.30 0.38
M24h -1.20 0.67 -0.06 -2.65 -0.14 -2.74 -2.16 0.85
M30h -1.01 0.51 -0.39 -4.70 -0.12 -4.02 -2.36 1.43
M36h -1.24 0.91 -0.61 0.97 0.25 0.17 0.10 0.55
M42h -1.05 0.22 -0.37 0.98 0.17 -0.57 -0.99 1.63
M48h -0.95 0.21 -0.87 1.18 0.33 0.84 0.11 1.55
M60h -0.71 0.86 -0.76 3.06 0.62 2.78 0.92 1.35
M72h -0.85 0.88 -0.99 4.95 0.72 4.19 2.65 1.11
M80h -0.94 0.57 -0.87 4.70 0.89 3.99 2.30 1.24
M96h -2.02 -1.05 -1.11 4.45 1.46 4.83 3.05 1.65
Am024h -1.04 0.05 -1.25 4.14 -0.05 3.42 1.19 0.60
Am03d -0.39 -0.03 -1.03 1.44 0.11 1.17 0.09 0.82
Am05d -0.54 -0.66 -1.33 0.06 0.20 0.68 -0.08 0.86
Am10d -0.49 -0.49 -1.43 -0.49 0.22 0.07 -0.38 0.62
Am15d -0.96 -0.31 -1.37 -0.61 0.31 -0.04 -0.47 0.79
Am20d -0.81 -0.54 -0.95 -0.91 0.27 0.41 -0.49 0.51
Am25d -1.02 -0.62 -1.08 -0.62 0.08 0.29 -0.25 1.18
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Am30d -1.24 -0.61 -1.27 -0.78 0.21 0.02 -0.32 0.33
A.5 Nine node network of the SOS DNA repair net-
work of Escherichia coli
V1 V2 V3 V4 V5 V6 V7 V8 V9
1 0.91 -0.13 -0.14 0.19 0.29 -0.06 -0.08 -0.02 -0.03
2 0.21 0.38 -0.12 0.06 0.17 -0.09 0.04 0.12 0.08
3 0.02 -0.11 10.52 0.06 0.08 0.01 0.06 0.09 -0.07
4 0.10 -0.05 -0.27 0.14 0.18 0.15 0.07 -0.00 0.28
5 0.12 -0.10 0.06 0.32 2.15 0.14 -0.07 0.14 0.11
6 0.08 -0.19 -0.12 0.25 0.35 2.02 -0.07 -0.17 -0.02
7 -0.12 -0.05 -0.10 -0.11 -0.01 0.10 3.07 0.36 0.22
8 0.18 -0.18 0.04 -0.07 -0.03 -0.15 0.01 26.63 0.09
9 0.07 -0.13 0.07 0.08 0.30 0.05 -0.06 0.27 0.67
A.6 10 features of the 100 DREAM3-100 simulated
dataset used in chapter 7
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10
1 0.88 0.73 0.51 0.76 0.46 0.55 0.39 0.36 0.46 0.08
2 0.06 0.05 0.41 0.09 0.28 0.33 0.40 0.24 0.45 0.02
3 0.93 0.06 0.43 0.12 0.28 0.34 0.44 0.28 0.40 0.02
4 0.86 0.81 0.00 0.81 0.41 0.52 0.43 0.41 0.43 0.07
150
Appendix A Appendices
5 0.80 0.88 0.01 0.01 0.36 0.56 0.46 0.34 0.49 0.07
6 0.82 0.81 0.48 0.77 0.01 0.09 0.36 0.11 0.47 0.03
7 0.86 0.83 0.52 0.87 0.44 0.00 0.44 0.39 0.40 0.00
8 0.94 0.81 0.54 0.83 0.29 0.36 0.00 0.27 0.38 0.02
9 0.86 0.87 0.58 0.79 0.45 0.54 0.39 0.03 0.41 0.05
10 0.85 0.78 0.51 0.80 0.15 0.25 0.42 0.47 0.02 0.81
11 0.83 0.78 0.57 0.79 0.49 0.44 0.49 0.35 0.42 0.00
12 0.74 0.88 0.49 0.79 0.52 0.52 0.46 0.35 0.47 0.05
13 0.89 0.74 0.46 0.82 0.44 0.49 0.46 0.43 0.40 0.00
14 0.84 0.87 0.54 0.85 0.38 0.44 0.37 0.44 0.37 0.00
15 0.86 0.85 0.52 0.85 0.39 0.47 0.44 0.43 0.41 0.05
16 0.86 0.82 0.48 0.87 0.46 0.43 0.44 0.37 0.36 0.00
17 0.84 0.77 0.53 0.82 0.42 0.49 0.38 0.46 0.39 0.09
18 0.86 0.85 0.58 0.88 0.46 0.49 0.40 0.41 0.42 0.04
19 0.88 0.84 0.57 0.81 0.43 0.48 0.39 0.35 0.47 0.00
20 0.87 0.82 0.53 0.77 0.45 0.50 0.43 0.44 0.40 0.01
21 0.87 0.79 0.41 0.82 0.46 0.54 0.42 0.38 0.88 0.00
22 0.85 0.87 0.54 0.80 0.47 0.49 0.38 0.38 0.41 0.05
23 0.80 0.91 0.50 0.86 0.44 0.48 0.41 0.37 0.44 0.05
24 0.86 0.85 0.52 0.82 0.51 0.49 0.46 0.44 0.48 0.08
25 0.85 0.89 0.52 0.86 0.45 0.45 0.43 0.42 0.42 0.01
26 0.82 0.80 0.55 0.85 0.52 0.44 0.48 0.32 0.42 0.00
27 0.87 0.88 0.56 0.80 0.45 0.45 0.47 0.41 0.45 0.00
28 0.86 0.82 0.56 0.85 0.50 0.53 0.38 0.40 0.40 0.00
29 0.77 0.77 0.51 0.84 0.38 0.49 0.44 0.36 0.41 0.10
30 0.85 0.82 0.47 0.88 0.47 0.49 0.43 0.40 0.53 0.05
31 0.85 0.88 0.53 0.83 0.40 0.44 0.37 0.30 0.47 0.00
32 0.84 0.83 0.50 0.80 0.39 0.41 0.45 0.40 0.39 0.08
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33 0.86 0.83 0.52 0.87 0.44 0.41 0.41 0.38 0.45 0.09
34 0.91 0.84 0.57 0.83 0.44 0.52 0.42 0.36 0.41 0.09
35 0.87 0.85 0.52 0.85 0.44 0.47 0.34 0.40 0.50 0.11
36 0.85 0.82 0.55 0.81 0.52 0.43 0.44 0.42 0.50 0.02
37 0.80 0.79 0.57 0.83 0.43 0.42 0.46 0.45 0.39 0.05
38 0.86 0.89 0.53 0.78 0.43 0.47 0.41 0.42 0.50 0.11
39 0.84 0.86 0.56 0.85 0.46 0.46 0.45 0.38 0.50 0.07
40 0.76 0.81 0.54 0.84 0.46 0.48 0.34 0.40 0.46 0.00
41 0.89 0.84 0.52 0.80 0.44 0.49 0.48 0.38 0.46 0.10
42 0.88 0.84 0.54 0.82 0.44 0.49 0.43 0.39 0.47 0.04
43 0.88 0.82 0.63 0.82 0.49 0.43 0.49 0.40 0.50 0.00
44 0.78 0.84 0.62 0.80 0.40 0.43 0.39 0.34 0.36 0.05
45 0.90 0.84 0.51 0.78 0.47 0.44 0.42 0.36 0.47 0.00
46 0.84 0.78 0.50 0.83 0.45 0.36 0.39 0.41 0.50 0.05
47 0.80 0.77 0.52 0.77 0.48 0.48 0.35 0.43 0.40 0.05
48 0.90 0.87 0.53 0.84 0.49 0.45 0.36 0.39 0.43 0.00
49 0.83 0.73 0.48 0.79 0.41 0.46 0.50 0.33 0.41 0.01
50 0.84 0.85 0.58 0.87 0.45 0.46 0.41 0.35 0.49 0.02
51 0.89 0.79 0.54 0.75 0.40 0.47 0.43 0.33 0.48 0.04
52 0.89 0.81 0.47 0.83 0.44 0.48 0.93 0.38 0.35 0.02
53 0.82 0.81 0.53 0.80 0.49 0.43 0.50 0.34 0.36 0.00
54 0.92 0.76 0.54 0.80 0.50 0.49 0.39 0.33 0.41 0.10
55 0.81 0.86 0.53 0.83 0.44 0.47 0.42 0.31 0.38 0.00
56 0.86 0.89 0.52 0.86 0.48 0.52 0.78 0.38 0.56 0.13
57 0.78 0.77 0.43 0.82 0.50 0.48 0.44 0.37 0.44 0.08
58 0.92 0.87 0.51 0.84 0.42 0.48 0.45 0.42 0.40 0.11
59 0.85 0.89 0.59 0.84 0.47 0.45 0.42 0.39 0.36 0.00
60 0.88 0.84 0.54 0.78 0.43 0.55 0.44 0.42 0.52 0.00
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61 0.82 0.85 0.57 0.90 0.45 0.46 0.43 0.37 0.44 0.02
62 0.84 0.89 0.53 0.82 0.50 0.49 0.60 0.45 0.46 0.05
63 0.87 0.83 0.52 0.86 0.40 0.49 0.43 0.32 0.38 0.00
64 0.83 0.83 0.56 0.90 0.46 0.44 0.41 0.51 0.42 0.00
65 0.88 0.78 0.53 0.79 0.41 0.46 0.42 0.32 0.44 0.05
66 0.80 0.82 0.49 0.88 0.43 0.48 0.49 0.31 0.52 0.07
67 0.83 0.84 0.51 0.80 0.41 0.48 0.44 0.38 0.42 0.02
68 0.82 0.91 0.44 0.84 0.46 0.49 0.39 0.33 0.47 0.01
69 0.91 0.82 0.52 0.87 0.45 0.43 0.41 0.33 0.37 0.09
70 0.86 0.81 0.56 0.92 0.38 0.43 0.39 0.36 0.44 0.00
71 0.82 0.86 0.56 0.89 0.45 0.54 0.41 0.45 0.48 0.01
72 0.84 0.89 0.50 0.82 0.47 0.52 0.39 0.32 0.43 0.07
73 0.89 0.83 0.53 0.80 0.44 0.55 0.42 0.36 0.52 0.00
74 0.87 0.85 0.52 0.83 0.46 0.53 0.38 0.42 0.42 0.00
75 0.83 0.84 0.50 0.79 0.36 0.44 0.48 0.38 0.40 0.05
76 0.83 0.85 0.59 0.78 0.48 0.51 0.40 0.44 0.45 0.00
77 0.86 0.80 0.52 0.81 0.44 0.52 0.45 0.41 0.42 0.05
78 0.90 0.77 0.49 0.82 0.49 0.49 0.42 0.35 0.40 0.05
79 0.80 0.84 0.48 0.78 0.42 0.49 0.44 0.42 0.44 0.04
80 0.90 0.89 0.45 0.84 0.40 0.46 0.47 0.41 0.34 0.07
81 0.89 0.77 0.50 0.86 0.46 0.55 0.40 0.37 0.46 0.00
82 0.89 0.88 0.48 0.91 0.47 0.47 0.40 0.41 0.46 0.01
83 0.91 0.84 0.60 0.83 0.48 0.40 0.38 0.41 0.38 0.02
84 0.91 0.77 0.49 0.89 0.40 0.48 0.41 0.37 0.50 0.04
85 0.92 0.91 0.53 0.86 0.36 0.43 0.49 0.39 0.40 0.03
86 0.82 0.82 0.51 0.83 0.48 0.47 0.44 0.31 0.46 0.03
87 0.93 0.76 0.57 0.82 0.42 0.45 0.44 0.36 0.44 0.06
88 0.82 0.78 0.57 0.80 0.38 0.46 0.44 0.38 0.41 0.06
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89 0.87 0.89 0.52 0.78 0.44 0.47 0.47 0.31 0.40 0.01
90 0.93 0.80 0.58 0.86 0.46 0.44 0.35 0.43 0.43 0.00
91 0.85 0.83 0.55 0.88 0.39 0.42 0.45 0.37 0.44 0.08
92 0.87 0.82 0.59 0.87 0.40 0.44 0.39 0.41 0.42 0.00
93 0.89 0.76 0.54 0.83 0.43 0.47 0.38 0.34 0.43 0.00
94 0.85 0.81 0.54 0.82 0.47 0.45 0.43 0.33 0.44 0.15
95 0.85 0.76 0.56 0.82 0.43 0.43 0.42 0.41 0.41 0.00
96 0.79 0.74 0.46 0.90 0.41 0.46 0.43 0.38 0.43 0.01
97 0.93 0.77 0.61 0.86 0.44 0.49 0.42 0.46 0.44 0.03
98 0.89 0.75 0.54 0.85 0.50 0.49 0.43 0.40 0.39 0.00
99 0.82 0.80 0.53 0.80 0.47 0.42 0.38 0.45 0.48 0.00
100 0.83 0.67 0.47 0.85 0.40 0.50 0.37 0.41 0.43 0.06
101 0.78 0.73 0.53 0.82 0.42 0.52 0.41 0.36 0.44 0.02
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